Datasets:
ChatDOC
/
OCRFlux-pubtabnet-single

Dataset card Data Studio Files Community
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
d13cf3efb50d1060b40d467275bd352b3359f89fe89ac2c0c2c740979310104b.png
simple
<table><tr><td>Line item category</td><td>Uganda per district (US$)</td><td>Kenya per district (US$)</td><td>% Uganda</td><td>% Kenya</td></tr><tr><td>Equipment</td><td>3,947</td><td>4,015</td><td>27.3</td><td>25.9</td></tr><tr><td>Consumables</td><td>502</td><td>91</td><td>3.5</td><td>0.6</td></tr><tr><td> Salaries</td><td>5,860</td><td>8,753</td><td>40.6</td><td>56.4</td></tr><tr><td> Per diems</td><td>20</td><td>84</td><td>0.1</td><td>0.5</td></tr><tr><td>Total personnel</td><td>5,880</td><td>8,837</td><td>40.7</td><td>57.0</td></tr><tr><td> Fuel</td><td>1,426</td><td>316</td><td>9.9</td><td>2.0</td></tr><tr><td> Maintenance</td><td>274</td><td>155</td><td>1.9</td><td>1.0</td></tr><tr><td>Total transport (excl. training)</td><td>1,700</td><td>472</td><td>11.8</td><td>3.0</td></tr><tr><td>Travel &amp; accommodation (for training)</td><td>590</td><td>64</td><td>4.1</td><td>0.4</td></tr><tr><td>Utilities</td><td>623</td><td>797</td><td>4.3</td><td>5.1</td></tr><tr><td>Room rental</td><td>521</td><td>816</td><td>3.6</td><td>5.3</td></tr><tr><td>Fees</td><td>93</td><td>19</td><td>0.6</td><td>0.1</td></tr><tr><td>Other</td><td>585</td><td>401</td><td>4.1</td><td>2.6</td></tr><tr><td>TOTAL</td><td>14,439</td><td>15,512</td><td>100.0</td><td>100.0</td></tr></table>
a4f9099064478e79dedbbfc15822886be74600ca7a9425b44932777974866842.png
simple
<table><tr><td>Ref.</td><td>Age</td><td>Sex</td><td>Implementation period</td><td>Admission to hospital</td><td>Location</td><td>Type of plant</td><td>Approach to lesions</td><td>Healing time</td></tr><tr><td>2</td><td>64</td><td>M</td><td>12 h</td><td>Immediately</td><td>Left distal thigh</td><td><i>R. arvensis</i></td><td>Debridement, topical nitrofurantoin</td><td>3 weeks</td></tr><tr><td>3</td><td>17</td><td>M</td><td>48 h</td><td>2 days</td><td>Back, scrotum, penis, chest</td><td><i>R. arvensis</i></td><td>Wet dressing, silver sulfadiazine, collogenase</td><td>4 weeks</td></tr><tr><td>4</td><td>42</td><td>M</td><td>8 h</td><td>1 week</td><td>Left foot dorsum and ankle</td><td><i>C. testiculatus</i></td><td>Clorhexidine scrub + split thickness skin graft</td><td>7 days</td></tr><tr><td></td><td>40</td><td>F</td><td>4 h</td><td>3 weeks</td><td>Right foot dorsum and ankle</td><td><i>C. testiculatus</i></td><td>Clorhexidine scrub + paraffin gauze</td><td>10 days</td></tr><tr><td></td><td>60</td><td>F</td><td>2 h</td><td>10 days</td><td>Right foot dosrum and left knee</td><td><i>C. testiculatus</i></td><td>Clorhexidine scrub + paraffin gauze</td><td>7 days</td></tr><tr><td></td><td>65</td><td>F</td><td>2 h</td><td>1 week</td><td>Left knee</td><td><i>C. testiculatus</i></td><td>Clorhexidine scrub+ paraffin gauze</td><td>15 days</td></tr><tr><td></td><td>48</td><td>F</td><td>4 h</td><td>14 days</td><td>Right leg</td><td><i>C. falcatus</i></td><td>Clorhexidine scrub + paraffin gauze</td><td>2 weeks</td></tr><tr><td>5</td><td>52-76</td><td>F:6 M:3</td><td>12 h</td><td>NA</td><td>Both knees: 7 One knee: 2</td><td><i>R. constantinopolitanus</i></td><td>Topical antibacterial treatment</td><td>10 d</td></tr><tr><td>6</td><td>55</td><td>F</td><td>1 day</td><td>2 days</td><td>Right knee</td><td>R. illyricus</td><td>Wet dressing and topical antibiotics</td><td>4 days</td></tr><tr><td>7</td><td>58</td><td>F</td><td>2 days</td><td>5 days</td><td>Left knee</td><td><i>R. illyricus</i></td><td>Topical antibacterial cream</td><td>A few days</td></tr><tr><td></td><td>54</td><td>F</td><td>1 days</td><td>3 days</td><td>Right knee</td><td><i>R. illyricus</i></td><td>Wet dressing and topical antibiotic</td><td>1 week</td></tr><tr><td>8</td><td>69</td><td>M</td><td>2.5 h</td><td>2 days</td><td>Left knee</td><td><i>C. falcatus</i></td><td>Wet dressing and topical fusidic acid</td><td>2 weeks</td></tr><tr><td></td><td>33</td><td>F</td><td>1.5 h</td><td>2 days</td><td>Right distal leg, ankle, dorsal foot</td><td>C. falcatus</td><td>Wet dressing and topical antibiotic</td><td>3 weeks</td></tr><tr><td></td><td>18</td><td>F</td><td>1 h</td><td>1 week</td><td>Left ankle, dorsal foot</td><td><i>C. falcatus</i></td><td>Wet dressing and topical antibiotic</td><td>2 weeks</td></tr><tr><td>9</td><td>47</td><td>F</td><td>25 min</td><td>NA</td><td>Right knee</td><td><i>C. falcatus</i></td><td>Wet dressing and topical mometasone cream</td><td>10 days</td></tr><tr><td>10</td><td>45</td><td>F</td><td>Overnight</td><td>2 days</td><td>Abdomen, right leg</td><td><i>R. damascenus</i></td><td>Wet dressing and topical fusidic acid</td><td>10 days</td></tr><tr><td>11</td><td>NA</td><td>F</td><td>NA</td><td>NA</td><td>Right ankle</td><td><i>C. falcatus</i></td><td>Wet dressing</td><td>2 weeks</td></tr><tr><td>Current</td><td>48</td><td>M</td><td>1 h</td><td>1 days</td><td>Right thumb</td><td><i>R. arvensis</i></td><td>Dressing with fusidic acid</td><td>3 weeks</td></tr><tr><td></td><td>59</td><td>F</td><td>Overnight</td><td>3 days</td><td>Bilateral knee</td><td><i>R. arvensis</i></td><td>Clorhexidine scrub + silver sulfadiazine cream</td><td>2 weeks</td></tr><tr><td></td><td>70</td><td>F</td><td>2 days</td><td>Immediately</td><td>Bilateral knee</td><td><i>R. arvensis</i></td><td>Clorhexidine scrub + silver sulfadiazine cream</td><td>10 days</td></tr></table>
c881098b4cfd4e7528e6218a94227ca3d77d5c5f028bbccacf3e6950c95b90ca.png
complex
<table><tr><td>Baseline characteristics</td><td>Overall no. of patients (%)</td><td>Arm A (%)</td><td>Arm B (%)</td><td>Arm C (%)</td></tr><tr><td>Total</td><td>19</td><td>5</td><td>8</td><td>6</td></tr><tr><td>Age</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Median</td><td>60</td><td>51</td><td>57.5</td><td>61.5</td></tr><tr><td> Range</td><td>27&#8211;86</td><td>27&#8211;71</td><td>50&#8211;86</td><td>47&#8211;77</td></tr><tr><td>Sex</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Male</td><td>6 (32)</td><td>1 (20)</td><td>4 (50)</td><td>1 (17)</td></tr><tr><td> Female</td><td>13 (68)</td><td>4 (80)</td><td>4 (50)</td><td>5 (83)</td></tr><tr><td>ECOG Performance Status</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> 0</td><td>10</td><td>2</td><td>4</td><td>4</td></tr><tr><td> 1</td><td>9</td><td>3</td><td>4</td><td>2</td></tr><tr><td>Stage at Trial Entry</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> No evidence of disease</td><td>4 (21)</td><td>2 (40)</td><td>0 (0)</td><td>2 (33)</td></tr><tr><td> Locally advanced</td><td>1 (5)</td><td>0 (0)</td><td>0 (0)</td><td>1 (17)</td></tr><tr><td> Metastatic*</td><td>14 (74)</td><td>3 (60)</td><td>8 (100)</td><td>3 (50)</td></tr><tr><td>Prior Therapy</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Chemotherapy alone</td><td>5</td><td>1</td><td>3</td><td>1</td></tr><tr><td> Chemotherapy/RT alone</td><td>2</td><td>0</td><td>1</td><td>1</td></tr><tr><td> Surgery total</td><td>12</td><td>4</td><td>4</td><td>4</td></tr><tr><td rowspan="2">Surgery followed by chemotherapy</td><td>7</td><td>3</td><td>2</td><td>2</td></tr><tr><td rowspan="2">5</td><td rowspan="2">1</td><td rowspan="2">2</td><td rowspan="2">2</td></tr><tr><td>Surgery followed by chemo/RT</td></tr><tr><td>Prior surgical resection</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Yes</td><td>12 (63)</td><td>4 (80)</td><td>4 (50)</td><td>4 (67)</td></tr><tr><td> No</td><td>7 (37)</td><td>1 (20)</td><td>4 (50)</td><td>2 (33)</td></tr><tr><td>Serum CEA at trial initiation (ng/mL)</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Median</td><td>4.8</td><td>5.3</td><td>4.65</td><td>7.95</td></tr><tr><td> Range</td><td>1&#8211;246.7</td><td>1.1&#8211;34.2</td><td>2.1&#8211;246.7</td><td>1&#8211;18.1</td></tr><tr><td>Serum CA-19-9 at trial initiation (ng/mL)</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Median</td><td>532</td><td>22</td><td>1067</td><td>27</td></tr><tr><td> Range</td><td>3&#8211;96,900</td><td>3&#8211;2,710</td><td>3&#8211;96,900</td><td>3&#8211;30,300</td></tr></table>
bed9b4658b7ed04707d85c291b4f9ef38a687f5c9ef9bdc0bdf47f18042507b5.png
simple
<table><tr><td> Method </td><td> Precision </td><td> Recall </td><td><i>F</i><sub>1</sub></td></tr><tr><td> SVM only </td><td> 0.6 </td><td> 0.12 </td><td> 0.2</td></tr><tr><td> With del+WkNN </td><td> 0.7879 </td><td> 0.26 </td><td> 0.391 </td></tr><tr><td> With add+WkNN </td><td> 0.66 </td><td> 0.33 </td><td> 0.44</td></tr><tr><td> With del+SoftSL </td><td> 0.2140 </td><td> 0.64 </td><td> 0.3208</td></tr><tr><td> With add+SoftSL </td><td> 0.4653 </td><td> 0.47 </td><td> 0.4677</td></tr></table>
7a2b0902e50b49f5265e4ca442b394ca98566b7d2adfaea206909150593f763f.png
simple
<table><tr><td></td><td>without hot compress</td><td>with hot compress</td></tr><tr><td>ICG-half-life [min]</td><td>5.88 &#177; 0.49</td><td>5.35 &#177; 0.5</td></tr><tr><td>k-value (%/min)</td><td>11.8 &#177; 1.0</td><td>13.0 &#177; 1.2</td></tr><tr><td>Room temperature [&#176;C]</td><td>21.2 &#177; 0.8</td><td>22.1 &#177; 0.6</td></tr><tr><td>Skin temperature right upper abdomen [&#176;C]</td><td>32.8 &#177; 0.9</td><td>40.6 &#177; 1.6</td></tr><tr><td>Heart rate [1/min]</td><td>68.0 &#177; 8.4</td><td>68.0 &#177; 11.0</td></tr><tr><td>Systolic blood pressure [mmHg]</td><td>132 &#177; 18</td><td>132 &#177; 21</td></tr><tr><td>Diastolic blood pressure [mmHg]</td><td>86 &#177; 11</td><td>87 &#177; 16</td></tr></table>
9e49429f41ad0ca1ba8ed983e753d673869da629260617d7691ca9cc77858b96.png
complex
<table><tr><td>Management</td><td>All patients(<i>n</i> = 1,903)</td><td>Age &#8805; 65 years(<i>n</i> = 975)</td><td>Age &lt; 65 years(<i>n</i> = 928)</td></tr><tr><td colspan="4">Initial method (%)</td></tr><tr><td> Sedation without paralysis</td><td>682 (36)</td><td>360 (37)</td><td>322 (35)</td></tr><tr><td> Oral without medication</td><td>546 (29)</td><td>298 (31)</td><td>248 (27)</td></tr><tr><td> Rapid sequence intubation</td><td>542 (28)</td><td>269 (28)</td><td>273 (29)</td></tr><tr><td> Other*</td><td>133 (7)</td><td>48 (5)</td><td>85 (9)</td></tr><tr><td colspan="4">Initial device (%)</td></tr><tr><td> Direct laryngoscope</td><td>1,810 (95)</td><td>933 (96)</td><td>877 (95)</td></tr><tr><td> Video laryngoscope</td><td>44 (2)</td><td>17 (2)</td><td>27 (3)</td></tr><tr><td> Other&#8224;</td><td>49 (3)</td><td>25 (3)</td><td>24 (2)</td></tr><tr><td colspan="4">Sedative (%)</td></tr><tr><td> No sedatives</td><td>724 (38)</td><td>372 (38)</td><td>352 (38)</td></tr><tr><td> Benzodiazepine</td><td>630 (22)</td><td>343 (35)</td><td>287 (31)</td></tr><tr><td> Propofol</td><td>447 (23)</td><td>205 (21)</td><td>242 (26)</td></tr><tr><td> Ketamine</td><td>66 (3)</td><td>42 (4)</td><td>24 (3)</td></tr><tr><td> Other&#8225;</td><td>36 (2)</td><td>13 (1)</td><td>23 (2)</td></tr><tr><td colspan="4">Paralytic (%)</td></tr><tr><td> No paralytics</td><td>1,291 (68)</td><td>689 (71)</td><td>602 (65)</td></tr><tr><td> Rocuronium</td><td>402 (21)</td><td>177 (18)</td><td>225 (24)</td></tr><tr><td> Vecuronium</td><td>150 (8)</td><td>75 (8)</td><td>75 (8)</td></tr><tr><td> Succinylcholine</td><td>60 (3)</td><td>34 (3)</td><td>26 (3)</td></tr><tr><td colspan="4">Specialty of first intubator (%)</td></tr><tr><td> Transitional year resident&#167;</td><td>703 (37)</td><td>384 (39)</td><td>319 (34)</td></tr><tr><td> Emergency medicine resident</td><td>648 (34)</td><td>298 (31)</td><td>350 (39)</td></tr><tr><td> Emergency physician</td><td>348 (18)</td><td>180 (18)</td><td>168 (18)</td></tr><tr><td> Other specialties&#182;</td><td>202 (11)</td><td>113 (12)</td><td>89 (10)</td></tr><tr><td> Number of intubation attempts, median (IQR)</td><td>1(1&#8211;2)</td><td>1(1&#8211;2)</td><td>1 (1&#8211;2)</td></tr><tr><td>&gt; 3 intubation attempts (%)</td><td>255 (13)</td><td>128 (13)</td><td>127 (14)</td></tr><tr><td> Ultimate intubation success (%)</td><td>5 (&lt; 1)</td><td>3 (&lt; 1)</td><td>2 (&lt; 1)</td></tr></table>
f6094e208fcc92ef90185c4ff86b49ddd0888142e66c659167bc4b03d5aed85e.png
simple
<table><tr><td>siRNA name</td><td>sequence</td></tr><tr><td>A2-3UTR 1</td><td>5&#8242;-UUAAUUCUCUCCGUAGCUCCCCC-3&#8242;</td></tr><tr><td>A2-3UTR 2</td><td>5&#8242;-UCUUACUGUUCCAUUGGCCCCC-3&#8242;</td></tr><tr><td>A2-3UTR 3</td><td>5&#8242;-AUUAUCCUUAAGAACCUAGCCCCC-3&#8242;</td></tr><tr><td>A2-3UTR 4</td><td>5&#8242;-UUCUUACUGUUCCAUUGGCCCCC-3&#8242;</td></tr><tr><td>scrambled siRNA</td><td>5&#8242;-UAAGCACGAAGCUCAGAGUCCCCC-3&#8242;</td></tr></table>
a9f4f2fcc3be91c40c6b3762e5c483d4f87873b1b85adb125a7797dfcef8a942.png
complex
<table><tr><td></td><td>Number of patients (%)</td><td>Return of spontaneous circulation (<i>n</i>)</td><td><i>P </i>value</td><td colspan="2">Initial survival</td><td colspan="2">Final survival</td></tr><tr><td></td><td></td><td></td><td></td><td><i>n</i></td><td><i>P </i>value</td><td><i>n</i></td><td><i>P </i>value</td></tr><tr><td>Age</td><td></td><td></td><td>0.027</td><td></td><td>0.149</td><td></td><td>0.390</td></tr><tr><td> &lt;1 month</td><td>2 (4.5%)</td><td>1</td><td></td><td>0</td><td></td><td>0</td><td></td></tr><tr><td> 1&#8211;12 months</td><td>9 (20.4%)</td><td>2</td><td></td><td>2</td><td></td><td>0</td><td></td></tr><tr><td> 1&#8211;8 years</td><td>13 (29.5%)</td><td>10</td><td></td><td>5</td><td></td><td>0</td><td></td></tr><tr><td> &gt;8 years</td><td>20 (45.4%)</td><td>15</td><td></td><td>12</td><td></td><td>3</td><td></td></tr><tr><td>Gender</td><td></td><td></td><td>1</td><td></td><td>0.753</td><td></td><td>0.290</td></tr><tr><td> Female</td><td>16 (36.3%)</td><td>18</td><td></td><td>6</td><td></td><td>0</td><td></td></tr><tr><td> Male</td><td>28 (63.6%)</td><td>10</td><td></td><td>13</td><td></td><td>3</td><td></td></tr><tr><td>Site of arrest</td><td></td><td></td><td>0.827</td><td></td><td>1</td><td></td><td>0.693</td></tr><tr><td> Home</td><td>6 (13.6%)</td><td>5</td><td></td><td>3</td><td></td><td>0</td><td></td></tr><tr><td> Public place</td><td>13 (29.5%)</td><td>7</td><td></td><td>5</td><td></td><td>1</td><td></td></tr><tr><td> Emergency Department</td><td>3 (6.8%)</td><td>2</td><td></td><td>1</td><td></td><td>0</td><td></td></tr><tr><td> Pediatric intensive care unit</td><td>18 (40.9%)</td><td>11</td><td></td><td>8</td><td></td><td>1</td><td></td></tr><tr><td> Other hospital areas</td><td>4 (9%)</td><td>3</td><td></td><td>2</td><td></td><td>1</td><td></td></tr><tr><td>Inhospital versus out-of hospital</td><td></td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td></tr><tr><td> Inhospital</td><td>22 (50%)</td><td>14</td><td></td><td>10</td><td></td><td>2</td><td></td></tr><tr><td> Out-of-hospital</td><td>22 (50%)</td><td>14</td><td></td><td>9</td><td></td><td>1</td><td></td></tr><tr><td>Diagnosis</td><td></td><td></td><td>0.256</td><td></td><td>0.484</td><td></td><td>.06</td></tr><tr><td> Heart disease or arrhythmia</td><td>18 (40.9%)</td><td>13</td><td></td><td>9</td><td></td><td>2</td><td></td></tr><tr><td> Respiratory disease</td><td>1 (2.2%)</td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td></tr><tr><td> Neurological disease</td><td>8 (18.1%)</td><td>5</td><td></td><td>3</td><td></td><td>0</td><td></td></tr><tr><td> Infectious disease</td><td>3 (6.8%)</td><td>2</td><td></td><td>1</td><td></td><td>0</td><td></td></tr><tr><td> Drowning</td><td>4 (9%)</td><td>3</td><td></td><td>2</td><td></td><td>0</td><td></td></tr><tr><td> Sudden infant death syndrome</td><td>4 (9%)</td><td>0</td><td></td><td>0</td><td></td><td>0</td><td></td></tr><tr><td> Trauma<sup>a</sup></td><td>1 (2.2%)</td><td>1</td><td></td><td>0</td><td></td><td>0</td><td></td></tr><tr><td> Other</td><td>2 (4.5%)</td><td>1</td><td></td><td>1</td><td></td><td>0</td><td></td></tr><tr><td> Unknown</td><td>3 (6.8%)</td><td>2</td><td></td><td>2</td><td></td><td>0</td><td></td></tr></table>
8e0c23efe880343acd8618f8716ab697e46e7d20bbd3896ce061470495e40c75.png
complex
<table><tr><td>Comorbidity</td><td>Classification by severity</td><td colspan="3">PCs</td></tr><tr><td></td><td></td><td>n</td><td>n (%)</td><td>p</td></tr><tr><td>Heart disease</td><td>surgical or interventional</td><td>19</td><td>5 (26)</td><td>0.26</td></tr><tr><td></td><td>only medication</td><td>31</td><td>13 (42)</td><td></td></tr><tr><td>COPD</td><td>stage 3 or 4*</td><td>8</td><td>0 (0)</td><td>0.60</td></tr><tr><td></td><td>stage 1 or 2</td><td>104</td><td>17 (16)</td><td></td></tr><tr><td>CNS disease</td><td>paralysis</td><td>8</td><td>2 (25)</td><td>0.69</td></tr><tr><td></td><td>no paralysis</td><td>31</td><td>11 (35)</td><td></td></tr><tr><td>Liver disease</td><td>cirrhosis</td><td>8</td><td>5 (63)</td><td>0.16</td></tr><tr><td></td><td>hepatitis</td><td>13</td><td>3 (23)</td><td></td></tr><tr><td>Renal dysfunction</td><td>dialysis</td><td>5</td><td>2 (40)</td><td>0.65</td></tr><tr><td></td><td>no dialysis</td><td>49</td><td>15 (31)</td><td></td></tr><tr><td>Diabetes mellitus</td><td>regular use of insulin</td><td>16</td><td>4 (25)</td><td>0.46</td></tr><tr><td></td><td>oral medication</td><td>51</td><td>8 (16)</td><td></td></tr></table>
5a0a3cb936d404f9ecb27716304b8eb8a3c96fc317c1271f32ffdf20bb75e9fd.png
simple
<table><tr><td>1. Of three influenza reference strains provided to WHO (A/California/7/2009, A/California/4/2009 and A/Texas/5/2009) by NHRC and USAFSAM, the A/California/7/2009 was selected as the seed strain.</td></tr><tr><td>2. Two biosafety-level 3 (BSL-3) laboratories were commissioned in 2009 at NHRC in San Diego, Calif., and AFRIMS in Bangkok, Thailand; and two BSL-2 laboratories were commissioned, one at the University of Buea, Cameroon, and one on the campus of the Cameroonian Army installation in Yaounde&#769;, Cameroon, under supervision of the Global Viral Forecasting Initiative.</td></tr><tr><td>3. NAMRU-3 partners reported the first definitive evidence of human cutaneous leishmaniasis from <i>Leishmania major</i> infections in Ghana.</td></tr><tr><td>4. AFRIMS published the first report of clinically significant <i>Plasmodium falciparum</i> malaria resistance to the potent artemisinin antimalarial drug class, spurring WHO, Bill &amp; Melinda Gates Foundation and host national malaria control officials to institute aggressive measures to contain and eliminate artemisinin-resistant malaria in Southeast Asia.</td></tr><tr><td>5. The first documented cases of Venezuelan equine encephalitis, brucellosis, dengue and Q fever in Ecuador were reported by NMRCD-Lima, and the first laboratory-confirmed cases of leptospirosis in the border areas of Thailand and Myanmar were reported by AFRIMS.</td></tr><tr><td>6. AFRIMS provided timely outbreak response services to the Nepali National Public Health laboratory, ultimately characterizing (by pulse-field gel electrophoresis) nearly 6,000 cases of multidrug-resistant typhoid fever originating from a single point source, and uniformly quinolone-resistant.</td></tr><tr><td>7. NAMRU-3 worked closely with WHO to conduct novel A/H1N1 laboratory diagnostic training for 73 participants representing 32 different countries in a strategic and timely two-week period in May 2009.</td></tr><tr><td>8. NEPMU-2, NAMRU-3, and AFHSC collaboratively supported CENTCOM efforts in establishing in-theatre novel A/H1N1 testing and isolation of servicemembers deployed or deploying to sites around the world.</td></tr><tr><td>9. The WRAIR/USAMRU-K Malaria Diagnostics and Control Center of Excellence, established in 2003, having trained more than 600 malaria microscopists, established new malaria diagnostics training capabilities in Nigeria and Tanzania, leading to a visit by the president of Tanzania to WRAIR to establish new collaborations between the U.S. Army and Tanzania.</td></tr><tr><td>10. NMRCD, as part of its expansive febrile-disease surveillance network in the Amazon basin, published the first comprehensive study of the etiologies of undifferentiated febrile illness in Ecuador, documenting the first laboratory-confirmed cases of Venezualan equine encephalitis, brucellosis, dengue and Q fever in Ecuador.</td></tr></table>
600c7f4e14ad9424df5c868ec144bf6035a4116c10218204c6f159cccf3d364c.png
simple
<table><tr><td>Protein</td><td>Description</td><td>Other Aliases</td></tr><tr><td>BOD1</td><td>biorientation of chromosomes in cell division 1</td><td>FAM44B</td></tr><tr><td>CENPW</td><td>centromere protein W</td><td>CUG2</td></tr><tr><td>CENPN</td><td>centromere protein N</td><td>CENP-N</td></tr><tr><td>CCNB2</td><td>cyclin B2</td><td>HsT17299</td></tr><tr><td>CDKN3</td><td>cyclin-dependent kinase inhibitor 3</td><td>KAP</td></tr><tr><td>CKS1B</td><td>CDC28 protein kinase regulatory subunit 1B</td><td>CKS1</td></tr><tr><td>CKS2</td><td>CDC28 protein kinase regulatory subunit 2</td><td>CKSHS2</td></tr><tr><td>ERH</td><td>enhancer of rudimentary homolog (Drosophila)</td><td>DROER</td></tr><tr><td>GMNN</td><td>geminin, DNA replication inhibitor</td><td>Gem</td></tr><tr><td>HAUS1</td><td>HAUS augmin-like complex, subunit 1</td><td>CCDC5</td></tr><tr><td>ITGB3BP</td><td>integrin beta 3 binding protein (beta3-endonexin)</td><td>CENPR</td></tr><tr><td>MAD2L1</td><td>MAD2 mitotic arrest deficient-like 1 (yeast)</td><td>MAD2</td></tr><tr><td>MAD2L2</td><td>MAD2 mitotic arrest deficient-like 2 (yeast)</td><td>MAD2B</td></tr><tr><td>MITD1</td><td>microtubule interacting and trafficking domain containing 1</td><td>_</td></tr><tr><td>NUP37</td><td>nucleoporin 37 kDa</td><td>p37</td></tr><tr><td>RAN</td><td>RAN, member RAS oncogene family</td><td>Gsp1</td></tr><tr><td>SPC25</td><td>SPC25, NDC80 kinetochore complex component, homolog (S. cerevisiae)</td><td>SPBC25</td></tr><tr><td>OIP5</td><td>Opa interacting protein 5</td><td>MIS18B</td></tr></table>
23390013446a3cd1fd01283ddc4750855451780939bd2027d5da98a5ac8f87f7.png
simple
<table><tr><td>Tool</td><td>Method</td><td>Symbol</td><td>Ref.</td><td>Time/Gbase</td></tr><tr><td>FragGeneScan</td><td>Hidden Markov Model</td><td>FGS3,FGS5</td><td>[11]</td><td>6 hours</td></tr><tr><td>MetaGeneAnnotator</td><td>Codon usage + start site heuristics</td><td>MGA</td><td>[9]</td><td>15 min</td></tr><tr><td>MetaGeneMark</td><td>Codon usage + gc-content heuristics</td><td>MGM</td><td>[8]</td><td>20 min</td></tr><tr><td>Orphelia</td><td>Neural network</td><td>OPH</td><td>[10]</td><td>13 hours</td></tr><tr><td>Prodigal</td><td>Codon usage + dynamic programming</td><td>PRD</td><td>[12]</td><td>30 min</td></tr></table>
43e03ef2516c572053fc56e756338d19a416e84655f7e5b870f6cfecabcb08ad.png
complex
<table><tr><td rowspan="2">Parameters</td><td>AM</td><td>PM</td><td>ABS Diff</td><td>% Error</td><td></td></tr><tr><td>Mean &#177; SD (max)</td><td>Mean &#177; SD (max)</td><td>Mean &#177; SD (max)</td><td>Mean &#177; SD (max)</td><td><i>P</i> Value</td></tr><tr><td>SS Angle</td><td>38.26 &#177; 9.16(53.8)</td><td>37.82 &#177; 10.15(56.3)</td><td>37.82 &#177; 10.15(56.3)</td><td>16.17 &#177; 20.28(99.02)</td><td>0.72</td></tr><tr><td>AOD 500</td><td>0.42 &#177; 0.14(0.69)</td><td>0.41 &#177; 0.15(0.75)</td><td>0.07 &#177; 0.06(0.27)</td><td>20.39 &#177; 22.07(105.7)</td><td>0.68</td></tr><tr><td>AOD 750</td><td>0.59 &#177; 0.18(0.94)</td><td>0.6 &#177; 0.22(1.15)</td><td>0.09 &#177; 0.09(0.4)</td><td>15.39 &#177; 14.35(51.32)</td><td>0.68</td></tr><tr><td>TISA 500</td><td>0.18 &#177; 0.12(0.62)</td><td>0.14 &#177; 0.06(0.25)</td><td>0.06 &#177; 0.11(0.46)</td><td>26.5 &#177; 33.69(123.03)</td><td>0.13</td></tr><tr><td>TISA 750</td><td>0.27 &#177; 0.09(0.46)</td><td>0.27 &#177; 0.1(0.46)</td><td>0.05 &#177; 0.04(0.18)</td><td>17.56 &#177; 18.75(71.61)</td><td>0.93</td></tr></table>
1917f1135e0ec2e1c2bc0f3469dc2000652650e19498ddeb16e2490bf081f12d.png
complex
<table><tr><td></td><td></td><td>N =236</td><td>MV<sup>1</sup></td><td>Validation Sample S-QoL 18 matched by age and gender N=236</td></tr><tr><td>1. Sociodemographics</td><td></td><td>N (%)</td><td>%</td><td>N (%)</td></tr><tr><td>Gender</td><td>Men</td><td>205 (86.9)</td><td>0.0</td><td>205 (86.9)</td></tr><tr><td>Age (years)</td><td>M (SD)2</td><td>37.9 (10.8)</td><td>0.0</td><td>37.9 (10.7)</td></tr><tr><td>Marital status</td><td>Single</td><td>218 (94.0)</td><td>1.7</td><td>NA6</td></tr><tr><td colspan="2">2. Clinical characteristics</td><td>M(SD)<sup>2</sup></td><td>%</td><td></td></tr><tr><td>MCSI3</td><td>Total score</td><td>21.6 (12.4)</td><td>18.6</td><td>NA</td></tr><tr><td>RAS4</td><td>Personal confidence and hope</td><td>31.7 (6.5)</td><td>20.8</td><td>NA</td></tr><tr><td></td><td>Willingness to ask for help</td><td>10.0 (2.7)</td><td>8.9</td><td></td></tr><tr><td></td><td>Goal and success orientation</td><td>19.4 (3.8)</td><td>7.2</td><td></td></tr><tr><td></td><td>Reliance on others</td><td>13.6 (4.1)</td><td>12.3</td><td></td></tr><tr><td></td><td>No domination by symptoms</td><td>8.9 (3.2)</td><td>11.0</td><td></td></tr><tr><td>SF-365</td><td>Physical Functioning</td><td>82.7 (26.4)</td><td>0.04</td><td>79.1 (22.1)</td></tr><tr><td></td><td>Social Functioning</td><td>52.7 (33.5)</td><td>0.12</td><td>54.4 (29.0)</td></tr><tr><td></td><td>Role&#8212;Physical Problems</td><td>74.6 (30.2)</td><td>0.12</td><td>43.9 (35.6)</td></tr><tr><td></td><td>Role&#8212;Emotional Problems </td><td>55.8 (33.4)</td><td>0.12</td><td>39.6 (41.7)</td></tr><tr><td></td><td>Mental Health</td><td>48.2 (22.0)</td><td>0.12</td><td>57.2 (20.1)</td></tr><tr><td></td><td>Vitality</td><td>44.0 (20.1)</td><td>0.12</td><td>48.4 (19.0)</td></tr><tr><td></td><td>Bodily Pain</td><td>65.6 (32.6)</td><td>0.12</td><td>64.7 (27.0)</td></tr><tr><td></td><td>General Health</td><td>54.4 (21.0)</td><td>0.12</td><td>54.8 (20.1)</td></tr><tr><td></td><td>Mental composite score</td><td>34.7 (12.5)</td><td>0.12</td><td>37.3 (11.1)</td></tr><tr><td></td><td>Physical composite score</td><td>51.4 (11.1)</td><td>0.12</td><td>46.9 (7.9)</td></tr></table>
9281ed724a72223ae0f88bfad647ad58d04972a98a462acf19e3edf66189742d.png
simple
<table><tr><td>Medium/Organism</td><td><i>Staphylococcus aureus</i></td><td><i>Staphylococcus epidermidis</i></td><td><i>Escherichia coli</i></td><td><i>Candida albicans</i></td></tr><tr><td>Mueller-Hinton agar</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>Blood agar</td><td>x</td><td>x</td><td>x</td><td></td></tr><tr><td>Blood agar-NaCl</td><td>x</td><td>x</td><td></td><td></td></tr><tr><td>CHROMagar Candida</td><td></td><td></td><td></td><td>x</td></tr><tr><td>Roosvelt-Park Institute Medium 1640 with L-glutamine</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>Sabouraud agar</td><td></td><td></td><td></td><td>x</td></tr><tr><td>Endo agar</td><td></td><td></td><td>x</td><td></td></tr></table>
9129227e725f3a83db71382c92a36eaa7e9aa020144511739721a1e1632697a5.png
simple
<table><tr><td>Proposed legislation changes</td><td><underline>Utilitarian</underline></td><td><underline>++</underline></td><td><underline>+</underline></td><td><underline>0</underline></td><td><underline>-</underline></td><td><underline>--</underline></td><td><underline>Rights-focused</underline></td></tr><tr><td>Community supervision</td><td></td><td><underline>x</underline></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Broad definition of mental disorder</td><td></td><td><underline>x</underline></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Detention of DSPD</td><td></td><td><underline>x</underline></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>More general tribunal members</td><td></td><td></td><td></td><td><underline>x</underline></td><td></td><td></td><td></td></tr><tr><td>Communication amongst services</td><td></td><td><underline>x</underline></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Overall assessment</td><td></td><td></td><td><underline>x</underline></td><td></td><td></td><td></td><td></td></tr></table>
25fbe92c674a843fe10c9b20685fee92340a46baadd483fbd7ce467a60b651fe.png
simple
<table><tr><td>Variable</td><td>Percent (%)</td></tr><tr><td>Fitzpatrick skin score grades 4 and 5 </td><td>79</td></tr><tr><td>Using sunscreen</td><td>24.2</td></tr><tr><td>Exposure to direct sunlight &lt;15 min/day</td><td>71</td></tr><tr><td>Milk and milk product (servings/day)</td><td> </td></tr><tr><td> None</td><td>23</td></tr><tr><td> 1 to 2</td><td>64</td></tr><tr><td> 3 to 4</td><td>9</td></tr><tr><td> &gt;4</td><td>4</td></tr><tr><td>Fortified breakfast cereal (servings/week) </td><td> </td></tr><tr><td> None</td><td>73.6</td></tr><tr><td> 1 to 2</td><td>12.8</td></tr><tr><td> 3 to 4</td><td>12</td></tr><tr><td> &gt;4</td><td>1.6</td></tr><tr><td>Fish (servings/week)</td><td> </td></tr><tr><td> None</td><td>23</td></tr><tr><td> 1 to 2</td><td>46.2</td></tr><tr><td> 3 to 4</td><td>25.3</td></tr><tr><td> &gt;4</td><td>5.5</td></tr><tr><td>Cod liver oil </td><td>17.6</td></tr><tr><td>Vitamin D supplement </td><td>24.2</td></tr></table>
632246e5a41fd0c5034966b5fcf9e47fa72623695257831d9117f873387462b0.png
complex
<table><tr><td>Patient</td><td>Age</td><td>Clinical signs</td><td>Metal ions in peripheral blood</td><td>CRP (&gt;5 mg/L)</td><td>White cell count (&gt;10/nl)</td><td rowspan="2">Duration of implantation (years)</td><td>Articulating material</td></tr><tr><td colspan="3"> </td><td>a) Chrome (&gt;7 &#956;g/L)</td><td colspan="4"> </td></tr><tr><td colspan="3"> </td><td>b) Cobalt (&gt;7 &#956;g/L)</td><td colspan="4"> </td></tr><tr><td>Metallosis</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>1</td><td>62</td><td>Pain, osteolysis around cup on x-ray</td><td>a) 21.3 &#956;g/L</td><td>2.3 mg/L</td><td>4.55/nl</td><td>8</td><td>Metal on metal</td></tr><tr><td colspan="3"> </td><td>b) 37.6 &#956;g/L</td><td colspan="4"> </td></tr><tr><td>2</td><td>47</td><td>Pain</td><td>a) 17.7 &#956;g/L</td><td>16.6 mg/L</td><td>8.96/nl</td><td>5</td><td>Metal on metal</td></tr><tr><td colspan="3"> </td><td>b) 38.90 &#956;g/L</td><td colspan="4"> </td></tr><tr><td>3</td><td>42</td><td>Pain</td><td>a) 4.06 &#956;g/L</td><td>3.6 mg/L</td><td>9.39/nl</td><td>6</td><td>Metal on metal</td></tr><tr><td colspan="3"> </td><td>b) 5.49 &#956;g/L</td><td colspan="4"> </td></tr><tr><td>4</td><td>71</td><td>Pain</td><td>a) 15.0ug/L</td><td>6.9 mg/L</td><td>5.89/nl</td><td>6</td><td>Metal on metal</td></tr><tr><td colspan="3"> </td><td>b) 30.0ug/L</td><td colspan="4"> </td></tr><tr><td>5</td><td>60</td><td>Non</td><td>a) 43.0 &#956;g/L</td><td>2.0 mg/L</td><td>5.70/nl</td><td>8</td><td>Metal on metal</td></tr><tr><td colspan="3"> </td><td>b) 64.0 &#956;g/L</td><td colspan="4"> </td></tr><tr><td>Patient</td><td>Age</td><td colspan="2">Clinical signs</td><td>CRP (&gt;5 mg/l)</td><td>White cell count (&gt;10/nl)</td><td>Duration of implantation (years)</td><td>Articulating material</td></tr><tr><td colspan="4">Aseptic loosening</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>1</td><td>70</td><td colspan="2">Pain, osteolysis around cup and stem on x-ray</td><td>17.3 mg/l</td><td>4.91/nl</td><td>19</td><td>Ceramic on polyethylene</td></tr><tr><td>2</td><td>71</td><td colspan="2">Pain, osteolysis around stem on x-ray</td><td>10.0 mg/l</td><td>8.17/nl</td><td>3</td><td>Ceramic on polyethylene</td></tr><tr><td>3</td><td>75</td><td colspan="2">Pain, osteolysis around cup on x-ray</td><td>2.0 mg/l</td><td>5.74/nl</td><td>15</td><td>Metal on polyethylene</td></tr><tr><td>4</td><td>59</td><td colspan="2">Pain, osteolysis around stem on x-ray</td><td>2.0 mg/l</td><td>3.53/nl</td><td>2</td><td>Ceramic on polyethylene</td></tr><tr><td>5</td><td>81</td><td colspan="2">Pain, osteolysis around stem on x-ray</td><td>2.0 mg/l</td><td>6.92/nl</td><td>12</td><td>Metal on polyethylene</td></tr><tr><td>6</td><td>84</td><td colspan="2">Pain, osteolysis around stem on x-ray</td><td>2.0 mg/l</td><td>6.1/nl</td><td>6</td><td>Metal on polyethylene</td></tr></table>
5d5f61477355e21fc9be88a1975190b928b4de1f6247de17b0c5e94419ff8cbe.png
simple
<table><tr><td>Antigen</td><td>Species</td><td>Source</td><td>Number</td><td>Dilution (Western)</td><td>Dilution (IHC)</td><td>Pepsin (IHC)</td></tr><tr><td>&#947;-2</td><td>Guinea pig</td><td>M. Watanabe</td><td>&#8212;</td><td>1:500</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>&#947;-2<i><sup>b</sup></i></td><td>Rabbit</td><td>Cell Signaling Technology</td><td>8511</td><td>&#8212;</td><td>1:200</td><td>Yes<i><sup>c</sup></i></td></tr><tr><td>&#947;-3</td><td>Guinea pig</td><td>M. Watanabe</td><td>&#8212;</td><td>1:500</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>&#947;-4</td><td>Rabbit</td><td>Abcam</td><td>ab81107</td><td>1:500</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>&#947;-5</td><td>Rabbit</td><td>M. Watanabe</td><td>&#8212;</td><td>1:500</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>&#947;-7</td><td>Rabbit</td><td>Frontiers Institute</td><td>Af720</td><td>1:500</td><td>1:500</td><td>No</td></tr><tr><td>&#947;-8</td><td>Rabbit</td><td>Frontiers Institute</td><td>Af1000</td><td>1:2000</td><td>1:1000</td><td>No</td></tr><tr><td>GluA1</td><td>Rabbit</td><td>Abcam</td><td>ab31232</td><td>&#8212;</td><td>1:500</td><td>Yes</td></tr><tr><td>GluA2</td><td>Mouse</td><td>Millipore</td><td>MAB397</td><td>1:500</td><td>1:500</td><td>Yes</td></tr><tr><td>c-Fos</td><td>Goat</td><td>Santa Cruz Biotechnology</td><td>sc-52-G</td><td>&#8212;</td><td>1:100</td><td>No</td></tr><tr><td>Actin</td><td>Mouse</td><td>Abcam</td><td>ab3280</td><td>1:5000</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>GFP</td><td>Chicken</td><td>Abcam</td><td>Ab13970</td><td>&#8212;</td><td>1:500</td><td>No</td></tr><tr><td>CGRP<i><sup>b</sup></i></td><td>Mouse</td><td>Sigma</td><td>C7113</td><td>&#8212;</td><td>1:400</td><td>No</td></tr><tr><td>vGluT1<i><sup>b</sup></i></td><td>Guinea pig</td><td>Synaptic Systems</td><td>135 304</td><td>&#8212;</td><td>1:400</td><td>No</td></tr><tr><td>vGluT2<i><sup>b</sup></i></td><td>Guinea pig</td><td>Millipore</td><td>AB2251</td><td>&#8212;</td><td>1:4000</td><td>No</td></tr></table>
50560d7161377c35de3d6b6d42fbb2110081890fccdafc309c83be32f75e9a72.png
simple
<table><tr><td></td><td>PEmb-QoL questions</td><td>Number of items</td><td>Cronbach&#8217;s alpha</td><td>Average inter-item correlation (r)</td></tr><tr><td>Frequency of complaints</td><td>Q1</td><td>8</td><td>0.90</td><td>0.52</td></tr><tr><td>Activities of daily living limitations</td><td>Q4</td><td>13</td><td>0.95</td><td>0.60</td></tr><tr><td>Work-related problems</td><td>Q5</td><td>4</td><td>0.91</td><td>0.72</td></tr><tr><td>Social limitations</td><td>Q6</td><td>1</td><td>-</td><td>-</td></tr><tr><td>Intensity of complaints</td><td>Q7, Q8</td><td>2</td><td>0.70</td><td>0.54</td></tr><tr><td>Emotional complaints</td><td>Q9</td><td>10</td><td>0.92</td><td>0.52</td></tr><tr><td>PEmb-QoL summary score</td><td>Q1, Q4, Q5, Q6, Q7, Q8, Q9</td><td>38</td><td>0.92</td><td>0.44</td></tr></table>
7869ccfc0760929422abaa91f4d279b12570d54b6714f05e9c0a90ce789f5b5c.png
simple
<table><tr><td>Patient no.</td><td>Diagnosis</td><td>Source</td><td>PB-blast%</td><td>BM-blast%</td><td>WBC</td><td>FAB</td><td>Cytogenetics</td><td>Status</td></tr><tr><td>1</td><td>AML</td><td>PB</td><td>92</td><td> </td><td> </td><td>M1</td><td>OD</td><td>New</td></tr><tr><td>2</td><td>AML</td><td>PB</td><td> </td><td> </td><td>331.08</td><td>M1</td><td>CD34-ANLL</td><td>New</td></tr><tr><td>3</td><td>AML</td><td>PB</td><td>82</td><td>4.8</td><td>81.5</td><td>M2b</td><td>FLT-ITD</td><td>New</td></tr><tr><td>4</td><td>AML</td><td>PB</td><td>88</td><td> </td><td>29.5</td><td>M1</td><td>CEBPA mutation; BCR-ABL(9;22)(+)</td><td>New</td></tr><tr><td>5</td><td>AML</td><td>PB</td><td> </td><td>87.5</td><td>43.36</td><td>M5a</td><td>CBF<i>&#946;</i>/MYH11(+);BCR/ABL(-)</td><td>New</td></tr><tr><td>6</td><td>AML</td><td>PB</td><td> </td><td> </td><td>219.79</td><td>M1</td><td>BCR-ABL(9;22)(+), Ph (+)</td><td>New</td></tr><tr><td>7</td><td>AML</td><td>PB</td><td>52</td><td> </td><td>4.64</td><td>M1</td><td>OD</td><td>New</td></tr><tr><td>8</td><td>AML</td><td>PB</td><td>92</td><td> </td><td>53.48</td><td>M1</td><td>46XX[20] CD34-ANLL</td><td>Relapsed</td></tr><tr><td>9</td><td>AML</td><td>PB</td><td>98</td><td> </td><td>156.9</td><td>M1</td><td>OD</td><td>New</td></tr><tr><td>10</td><td>AML</td><td>PB</td><td>96</td><td> </td><td>143</td><td>M1</td><td>BCR/ABL</td><td>New</td></tr><tr><td>11</td><td>AML</td><td>PB</td><td> </td><td> </td><td>12.68</td><td>M2</td><td>OD</td><td>New</td></tr><tr><td>12</td><td>AML</td><td>PB</td><td> </td><td> </td><td>229</td><td>M1</td><td>OD</td><td>New</td></tr><tr><td>13</td><td>AML</td><td>PB</td><td>55</td><td>15.3</td><td>14.3</td><td>M1</td><td>OD</td><td>Relapsed</td></tr><tr><td>14</td><td>AML</td><td>PB</td><td>96</td><td> </td><td>102.5</td><td>M1</td><td>OD</td><td>New</td></tr><tr><td>15</td><td>AML</td><td>PB</td><td> </td><td> </td><td>31.0</td><td>M1</td><td>OD</td><td>New</td></tr><tr><td>16</td><td>AML</td><td>PB</td><td>63.5</td><td> </td><td>181.2</td><td>M0</td><td>TEL/AML1(+);C-Kit, NPM1, CEBPA, FLT3/ITD(-)</td><td>New</td></tr><tr><td>17</td><td>AML</td><td>PB</td><td> </td><td> </td><td>3.88</td><td>M3</td><td>PML-RARa(+)</td><td>Relapsed</td></tr><tr><td>18</td><td>AML</td><td>PB</td><td> </td><td>&gt;20</td><td>1.94</td><td>M6</td><td>OD</td><td>New</td></tr><tr><td>19</td><td>AML</td><td>PB</td><td>8</td><td> </td><td>19.1</td><td>M5b</td><td>WT1(+)</td><td>New</td></tr><tr><td>20</td><td>AML</td><td>PB</td><td> </td><td>&lt;10</td><td>14.7</td><td>M5</td><td>FISH-t (15;17) PML-RARa (bcr3)</td><td>New</td></tr><tr><td>21</td><td>AML</td><td>PB</td><td>28</td><td> </td><td>51.2</td><td>M2a</td><td>t(9;22) Bcr/abl (+); JAK2V617F(+) MLL/EVI1; MLL+</td><td>New</td></tr><tr><td>22</td><td>AML</td><td>PB</td><td> </td><td>42</td><td>116.3</td><td>M4a</td><td>WT1 (+); FLT3-ILD (+)</td><td>Relapsed</td></tr><tr><td>23</td><td>AML</td><td>PB</td><td> </td><td>24.5</td><td>77.4</td><td>M2b</td><td>FISH-AML/ETO (-); FLT3-ILD (+)</td><td>New</td></tr></table>
82222f50756cc95397fe5a3efc20812f338880fb7687de1883bbee7eb5389de7.png
complex
<table><tr><td colspan="2">Statement regarding condition</td><td></td><td></td><td colspan="2"></td></tr><tr><td colspan="2">With a typical asthmatic patient, how often do you actually talk about exercise?</td><td>Never or rarely: 12 (4.4)</td><td>Sometimes: 85 (31.1)</td><td colspan="2">Usually or always: 176 (64.5)</td></tr><tr><td colspan="2">How relevant do you think talking to asthmatic patients about exercise will be in your intended practice?</td><td>Not at all: 8 (3.0)</td><td>Somewhat: 95 (35.3)</td><td colspan="2">Highly: 166 (61.7)</td></tr><tr><td colspan="2">How much training have you had on talking to asthmatic patients about exercise?</td><td>None: 90 (33.2)</td><td>Some: 116 (42.8)</td><td colspan="2">Extensive: 65 (24.0)</td></tr><tr><td colspan="2">Data presented as n (%)</td><td></td><td></td><td colspan="2"></td></tr><tr><td>Statement regarding condition</td><td>Strongly agree</td><td>Agree</td><td>Neither agree nor disagree</td><td>Disagree</td><td>Strongly disagree</td></tr><tr><td></td><td>n (%)</td><td>n (%)</td><td>n (%)</td><td>n (%)</td><td>n (%)</td></tr><tr><td>Doctors need more training in preventive care</td><td>151 (55.1)</td><td>111 (39.6)</td><td>9 (3.2)</td><td>2 (0.7)</td><td>1 (0.4)</td></tr><tr><td>I will be able to provide more credible and effective counseling if I eat a healthy diet</td><td>103 (36.8)</td><td>128 (45.7)</td><td>29 (10.4)</td><td>13 (4.6)</td><td>3 (1.1)</td></tr><tr><td>I will be able to provide more credible and effective counseling if I exercise and stay fit</td><td>116 (42.2)</td><td>129 (46.9)</td><td>21 (7.6)</td><td>8 (2.9)</td><td>1 (0.4)</td></tr><tr><td>I will be able to provide more credible and effective counseling if I maintain a healthy weight</td><td>117 (42.4)</td><td>135 (48.9)</td><td>19 (6.9)</td><td>5 (1.8)</td><td>0 (0)</td></tr></table>
320d8c30ccb7a3fb0864ded9c78e89789b7122943539887565e93f41bd89ab79.png
complex
<table><tr><td rowspan="2">Locus</td><td colspan="5"><i>P</i> Value</td></tr><tr><td>All HSR</td><td>SJS/TEN</td><td>DILI</td><td>NIR</td><td>HSS</td></tr><tr><td><i>HLA-A</i></td><td>894</td><td>.015</td><td>.429</td><td>.672</td><td>.135</td></tr><tr><td><i>HLA-B</i></td><td>111</td><td>.160</td><td>.068</td><td>.478</td><td>.066</td></tr><tr><td><i>HLA-C</i></td><td>036</td><td>.014</td><td>.179</td><td>.489</td><td>.564</td></tr><tr><td><i>HLA-DQB1</i></td><td>002*</td><td>.003*</td><td>.006</td><td>.148</td><td>.030</td></tr><tr><td><i>HLA-DRB1</i></td><td>137</td><td>.123</td><td>.018</td><td>.455</td><td>.477</td></tr></table>
1d89cc235849edd2457a148cf6bf5e0616b409ddf112b2d257555aaacee17ae8.png
simple
<table><tr><td>Damage Case</td><td>I</td><td>D1</td><td>D2</td><td>D3</td><td>D4</td><td>D5</td><td>D6</td><td>D7</td><td>D8</td></tr><tr><td>Damage quantity of E<sub>3</sub> (%)</td><td>0</td><td>3 </td><td>5 </td><td>15 </td><td>18 </td><td>18 </td><td>18 </td><td>18 </td><td>18 </td></tr><tr><td>Damage quantity of E<sub>7</sub> (%)</td><td>0</td><td>0 </td><td>0 </td><td>0 </td><td>0 </td><td>3 </td><td>5 </td><td>15 </td><td>18 </td></tr></table>
70c7902d8a7501e653c9e169b9b5fccd686a9ddd135d423153bd925dd7b0bfa5.png
simple
<table><tr><td>Steps</td><td>Selected questions and issues raised by the example case study &#8220;Maria Morales&#8221;</td></tr><tr><td>1. <i>Identify and frame in own words</i>: What is the underlying moral conflict?</td><td>Can a parents&#8217; right to not have an intervention done with their child be overridden by the state (for someone else&#8217;s good)? Furthermore: Can parents exercise their will on behalf of their children?</td></tr><tr><td>2. <i>Identify and frame in ethical words</i>: Which ethical principles are relevant, how can they be specified and might they be in conflict to each other?</td><td>Overall, the principles respect for autonomy and health maximisation seem to be affected and seem to mutually exclude each other. But one also has to ask whose autonomy is at stake. Parents&#8217; autonomy &#8211; but what about the future autonomy of children? Furthermore, the immunising doctor might be indecisive whether to advocate for autonomy, health maximisation or non-maleficence.</td></tr><tr><td>3. <i>Zoom further in</i>: Do I have all relevant information? Can I get more background information to understand all particularities?</td><td>What are the potential side effects of measles immunisation? How severe are measles for children? About how many persons (to be vaccinated against their parents&#8217; will) can be protected, which effect would such an immunisation programme have on the incidence of measles and which side-effects could actually be prevented?</td></tr><tr><td>4. Are <i>alternative solutions</i> feasible with less moral issues/costs?</td><td>Can there be alternative approaches to mandatory measles immunisation? Can one raise immunisation rates by informing, advertising, setting incentives for parents?</td></tr><tr><td>5. <i>Further Specification</i>: Do the specifications change with more information?</td><td>If there are alternative ways that are less infringing on the respect for autonomy but rather support the health maximisation and the protection of those who cannot be immunised (ensuring non-maleficence), then these alternatives have a higher moral value.</td></tr><tr><td>6. <i>Weighing</i>: Are all conflicting principles and their specifications still of equal value?</td><td>If other measures (incentive setting, education campaigns for immunisation) can be successfully implemented elsewhere, mandatory immunisation seems less necessary. Yet, autonomy of the parents (who are safeguarding the autonomy of their children) attains even more weight.</td></tr><tr><td>7. What do I <i>conclude</i> from the specification and weighing? What would be my <i>solution</i> to the problem?</td><td>Mandatory measles immunisation would &#8211; in this very particular situation &#8211; not be necessary in order to achieve best health and given that it would infringe autonomy of parents (and allegedly of children), it should not be applied.</td></tr><tr><td>8. <i>Integrity</i>: Can I personally accept the conclusion drawn?</td><td>It seems to be a suitable solution to &#8211; at least first &#8211; try other measures, rather than being in charge of forcing parents and children to have children&#8217;s bodies &#8216;invaded&#8217; against their &#8216;guards&#8217; will.</td></tr><tr><td>9. <i>Act and convince:</i> I act according to my judgment and convince colleagues and others also based on ethical reasoning.</td><td>I try to find resources within my professional budget and start action to promote immunisation with other means.</td></tr></table>
c63a812f5e6feed784d0287db8dc147beabb6f4abdc8ad0b1e49fd09e2bcc6a7.png
simple
<table><tr><td>GenBank Accession Number</td><td>Previous name</td><td>New name</td></tr><tr><td>CAA78718</td><td><i>X. laevis </i>Apx</td><td>xShroom1</td></tr><tr><td>NP_597713</td><td><i>H. sapiens </i>APXL2</td><td>hShroom1</td></tr><tr><td>CAA58534</td><td><i>H. sapiens </i>APXL</td><td>hShroom2</td></tr><tr><td>ABD19518</td><td><i>M. musculus </i>Apxl</td><td>mShroom2</td></tr><tr><td>AAF13269</td><td><i>M. musculus </i>ShroomL</td><td>mShroom3a</td></tr><tr><td>AAF13270</td><td><i>M. musculus </i>ShroomS</td><td>mShroom3b</td></tr><tr><td>NP_065910</td><td><i>H. sapiens </i>Shroom</td><td>hShroom3</td></tr><tr><td>ABD59319</td><td><i>X. laevis </i>Shroom-like</td><td>xShroom3</td></tr><tr><td>NP_065768</td><td><i>H. sapiens </i>KIAA1202</td><td>hShroom4a</td></tr><tr><td>AAK95579</td><td><i>H. sapiens </i>SHAP-A</td><td>hShroom4b</td></tr><tr><td>DQ435686</td><td><i>M. musculus </i>KIAA1202</td><td>mShroom4</td></tr><tr><td>ABA81834</td><td><i>D. melanogaster </i>Shroom</td><td>dmShroom</td></tr><tr><td>EAA12598</td><td><i>A. gambiae </i>Shroom</td><td>agShroom</td></tr><tr><td>XP_392427</td><td><i>A. mellifera </i>Shroom</td><td>amShroom</td></tr><tr><td>XP_783573</td><td><i>S. purpuratus </i>Shroom</td><td>spShroom</td></tr></table>
15a022d26cefe9f752da56975ebcff96c8a7f64725342e2489aef48e40388eaf.png
complex
<table><tr><td>Family</td><td>Plant species</td><td>Plant part</td><td>Extraction</td><td colspan="3">Repellency%</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="3">(minutes post application)</td></tr><tr><td></td><td></td><td></td><td></td><td>60</td><td>120</td><td>180</td></tr><tr><td>Asteraceae</td><td><i>Litogyne gariepina</i></td><td>Roots</td><td>DCM</td><td>75</td><td>52</td><td>57</td></tr><tr><td>Buddlejaceae</td><td><i>Nuxia floribunda</i></td><td>Leaves</td><td>DCM/MeOH(1:1)</td><td>43</td><td>42</td><td>35</td></tr><tr><td>Chenopodiaceae</td><td><i>Chenopodium opulifolium</i></td><td>Roots</td><td>Water</td><td>97</td><td>17</td><td>30</td></tr><tr><td>Lamiaceae</td><td><i>Leucas martinicensis</i></td><td>Leaves</td><td>DCM</td><td>60</td><td>57</td><td>49</td></tr><tr><td>Malvaceae</td><td><i>Sida cordifolia</i></td><td>Whole Plant</td><td>DCM/MeOH(1:1)</td><td>40</td><td>23</td><td>10</td></tr><tr><td>Negative control</td><td></td><td></td><td>Distilled water</td><td>10</td><td>20</td><td>20</td></tr><tr><td>Negative control</td><td></td><td></td><td>Acetone</td><td>17</td><td>20</td><td>33</td></tr><tr><td>Positive control</td><td></td><td></td><td>DEET</td><td>100</td><td>100</td><td>100</td></tr></table>
a49590db7b9ccc0a06682512f77d11f5da5323a333fd584713c90d14e523087a.png
complex
<table><tr><td>Gender</td><td> </td><td> </td><td colspan="2">Age range (percentage)</td><td> </td><td> </td><td>Total</td></tr><tr><td> </td><td>0-6</td><td>7-13</td><td>14-21</td><td>22-29</td><td>30-40</td><td>&gt; 40</td><td></td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Female</td><td>56 (24.1)</td><td>82 (35.3)</td><td>35 (15.1)</td><td>34 (14.7)</td><td>19 (8.2)</td><td>6 (2.6)</td><td>232 (100)</td></tr><tr><td>Male</td><td>62 (14.9)</td><td>121 (29.2)</td><td>118 (28.4)</td><td>62 (14.9)</td><td>37 (8.9)</td><td>15 (3.6)</td><td>415 (100)</td></tr><tr><td>Total</td><td>118 (18.2)</td><td>203 (31.4)</td><td>153 (23.6)</td><td>96 (14.8)</td><td>56 (8.7)</td><td>21 (3.2)</td><td>647 (100)</td></tr></table>
e209586cecafff55c0a0ef0abdc3f9382d2659cfa2d566b5d81812453b33588b.png
simple
<table><tr><td></td><td>Area</td><td>Layer</td><td>Area * Layer</td></tr><tr><td>Squirrel monkey</td><td><i>F</i><sub>(3, 6)</sub> = 34.15, <i>p</i> &lt; 0.01<sup>*</sup></td><td><i>F</i><sub>(1, 6)</sub> = 21.43, <i>p</i> = 0.04<sup>*</sup></td><td><i>F</i><sub>(3, 6)</sub> = 3.59, <i>p</i> = 0.09</td></tr><tr><td>Capuchin</td><td><i>F</i><sub>(3, 9)</sub> = 5.58, <i>p</i> = 0.02<sup>*</sup></td><td><i>F</i><sub>(1, 9)</sub> = 20.01, <i>p</i> = 0.02<sup>*</sup></td><td><i>F</i><sub>(3, 9)</sub> = 14.17, <i>p</i> &lt; 0.01<sup>*</sup></td></tr><tr><td>Moor macaque</td><td><i>F</i><sub>(3, 9)</sub> = 6.29, <i>p</i> = 0.01<sup>*</sup></td><td><i>F</i><sub>(1, 9)</sub> = 79.83, <i>p</i> &lt; 0.01<sup>*</sup></td><td><i>F</i><sub>(3, 9)</sub> = 6.40, <i>p</i> = 0.01<sup>*</sup></td></tr><tr><td>Pigtailed macaque</td><td><i>F</i><sub>(3, 12)</sub> = 4.01, <i>p</i> = 0.03<sup>*</sup></td><td><i>F</i><sub>(1, 12)</sub> = 66.76, <i>p</i> &lt; 0.01<sup>*</sup></td><td><i>F</i><sub>(3, 12)</sub> = 0.54, <i>p</i> = 0.66</td></tr><tr><td>Baboon</td><td><i>F</i><sub>(3, 9)</sub> = 7.43, <i>p</i> = 0.01<sup>*</sup></td><td><i>F</i><sub>(1, 9)</sub> = 23.98, <i>p</i> = 0.02<sup>*</sup></td><td><i>F</i><sub>(3, 9)</sub> = 2.26, <i>p</i> = 0.15</td></tr><tr><td>Gorilla</td><td><i>F</i><sub>(3, 6)</sub> = 0.34, <i>p</i> = 0.80</td><td><i>F</i><sub>(1, 6)</sub> = 23.38, <i>p</i> = 0.04<sup>*</sup></td><td><i>F</i><sub>(3, 6)</sub> = 0.95, <i>p</i> = 0.47</td></tr><tr><td>Chimpanzee</td><td><i>F</i><sub>(3, 9)</sub> = 0.10, <i>p</i> = 0.96</td><td><i>F</i><sub>(1, 9)</sub> = 1.52, <i>p</i> = 0.31</td><td><i>F</i><sub>(3, 9)</sub> = 1.58, <i>p</i> = 0.26</td></tr><tr><td>Human</td><td><i>F</i><sub>(3, 9)</sub> = 3.98, <i>p</i> = 0.07</td><td><i>F</i><sub>(1, 9)</sub> = 0.71, <i>p</i> = 0.49</td><td><i>F</i><sub>(3, 9)</sub> = 0.68, <i>p</i> = 0.60</td></tr></table>
9f27fdeba510f5735e90824277ad7f5fa88b1ce25fc3443b60891adcd3e1f035.png
complex
<table><tr><td rowspan="3">HD score grade</td><td colspan="9">Breed</td><td rowspan="3">Total</td></tr><tr><td>Boxer</td><td>Doberman</td><td>Great Dane</td><td>Golden Retriever</td><td>German Shepherd</td><td>Hungarian Vizla</td><td>Labrador Retriever</td><td>Rottweiler</td><td>Rhodesian Ridgeback</td></tr><tr><td>&gt;18</td><td>-</td><td>1</td><td>-</td><td>-</td><td>77</td><td></td><td>10</td><td>10</td><td>-</td><td>98</td></tr><tr><td>13-18</td><td>-</td><td>-</td><td>1</td><td>1</td><td>139</td><td>1</td><td>26</td><td>22</td><td>3</td><td>193</td></tr><tr><td>9-12</td><td>3</td><td>5</td><td>2</td><td>-</td><td>147</td><td>-</td><td>30</td><td>30</td><td>6</td><td>223</td></tr><tr><td>7-8</td><td>-</td><td>1</td><td>-</td><td>-</td><td>20</td><td>-</td><td>5</td><td>14</td><td>1</td><td>41</td></tr><tr><td>4-6</td><td>-</td><td>2</td><td>-</td><td>-</td><td>13</td><td>-</td><td>1</td><td>15</td><td>4</td><td>35</td></tr><tr><td>1-3</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>1</td><td>-</td><td>1</td></tr><tr><td>Total</td><td>3</td><td>9</td><td>3</td><td>1</td><td>396</td><td>1</td><td>72</td><td>92</td><td>14</td><td>591</td></tr></table>
7212a0639acfe6734a8dafaf332ae2bcb0991be2ea80609dfbf11500e605ef9f.png
complex
<table><tr><td></td><td colspan="2">Pain increase at 6-weeks.</td><td colspan="2">Pain increase at 6-months.</td></tr><tr><td></td><td>NRS Points (95% confidence interval)</td><td><i>P</i> value</td><td>NRS Points (95% confidence interval)</td><td><i>P</i> value</td></tr><tr><td>Preoperative anxiety (yes/no)</td><td>&#8722;.30 (&#8722;1.22&#8211;.63)</td><td>.52</td><td>.42 (&#8722;.63&#8211;1.46)</td><td>.43</td></tr><tr><td>Age (years)</td><td>&#8722;.02 (&#8722;.04&#8211;.01)</td><td>.31</td><td>.00 (&#8722;.03&#8211;.03)</td><td>.98</td></tr><tr><td>BMI (points)</td><td>&#8722;.06 (&#8722;.16&#8211;.05)</td><td>.29</td><td>.13 (.01&#8211;.25)</td><td>.04*</td></tr><tr><td>Sex (male)</td><td>&#8722;.22 (&#8722; 1.15&#8211;.71)</td><td>.64</td><td>&#8722;.46 (&#8722; 1.51&#8211;.59)</td><td>.39</td></tr><tr><td>Preoperative pain (points)</td><td>.36 (.18&#8211;.54)</td><td>.00*</td><td>.36 (.16&#8211;.56)</td><td>.00*</td></tr><tr><td>Chronic pain (yes/no <sup>a</sup>)</td><td>.88 (&#8722;.08&#8211;1.85)</td><td>.07</td><td>.55 (&#8722;.54&#8211;1.63)</td><td>.32</td></tr><tr><td>Intercept</td><td>3.04 (&#8722;.56&#8211;6.64)</td><td>.10</td><td>&#8722; 1.96 (&#8722;6.02&#8211;2.10)</td><td>.34</td></tr></table>
8bff07182aeadd56b8bda673f1074d1e9c1032004460fe6969ec0c94c0ed3d1a.png
simple
<table><tr><td>Antibodies</td><td>Species</td><td>Dilution</td><td>Source</td><td>Code no.</td></tr><tr><td>P2X2</td><td>Rabbit</td><td>1:100</td><td>Alomone</td><td>APR-003</td></tr><tr><td>IP<sub>3</sub>R3</td><td>Mouse</td><td>1:100</td><td>Transduction Lab.</td><td>610313</td></tr><tr><td>Syntaxin-1</td><td>Mouse</td><td>1:100</td><td>Sigma</td><td>S0664</td></tr><tr><td>Serotonin</td><td>Mouse</td><td>1:100</td><td>Abcam</td><td>ab16007</td></tr></table>
a3993fcfaa06986b3686217b9afed42c302d0be0328aeb88bd0afaac1fa0fa1f.png
complex
<table><tr><td>No.</td><td>Statement</td><td>Rank</td><td>Z-score</td></tr><tr><td colspan="4">Defining statements</td></tr><tr><td colspan="4">Agrees strongly with the following statements</td></tr><tr><td>12</td><td>I value more time for my personal life</td><td>3</td><td>1.59</td></tr><tr><td>16</td><td>I want to be in a large city</td><td>3</td><td>1.53</td></tr><tr><td>32</td><td>The fact that subspecialists can also be general internists is important to me</td><td>2</td><td>1.20</td></tr><tr><td>20</td><td>I want something that pays well given how long we&#8217;ve trained</td><td>2</td><td>1.13</td></tr><tr><td>25</td><td>I&#8217;d like to do a combination of inpatient and outpatient</td><td>2</td><td>1.12</td></tr><tr><td>13</td><td>Lifestyle and more control over my practice are important</td><td>2</td><td>1.10</td></tr><tr><td>31</td><td>A two-year GIM fellowship is a deterrent</td><td>1</td><td>1.04</td></tr><tr><td>35</td><td>I want to be valued in what I&#8217;m doing</td><td>1</td><td>1.02</td></tr><tr><td>14</td><td>I want to be in a field that is in demand</td><td>1</td><td>1.01</td></tr><tr><td colspan="4">Disagrees strongly with the following statements</td></tr><tr><td>36</td><td>GIM is a dumping ground for patients nobody wants</td><td>-2</td><td>-1.13</td></tr><tr><td>9</td><td>The negative interactions with attendings were important</td><td>-2</td><td>-1.21</td></tr><tr><td>7</td><td>GIM patients are too complex</td><td>-2</td><td>-1.33</td></tr><tr><td>23</td><td>I prefer an outpatient-based practice</td><td>-2</td><td>-1.33</td></tr><tr><td>29</td><td>I am willing to do as many years as it takes to get the job and subspecialty I want</td><td>-3</td><td>-1.94</td></tr><tr><td>17</td><td>I want to work in a smaller community</td><td>-3</td><td>-2.33</td></tr><tr><td colspan="4">Distinguishing statements</td></tr><tr><td colspan="4">Agrees with the following statements more than other factors</td></tr><tr><td>16</td><td>I want to be in a large city</td><td>3</td><td>1.53*</td></tr><tr><td>32</td><td>The fact that subspecialists can also be general internists is important to me.</td><td>2</td><td>1.20*</td></tr><tr><td>31</td><td>A two-year GIM fellowship is a deterrent</td><td>1</td><td>1.04*</td></tr><tr><td>22</td><td>Some specialties are not fairly remunerated and this is an important consideration</td><td>1</td><td>0.76*</td></tr><tr><td colspan="4">Disagrees with the following statements more than other factors</td></tr><tr><td>18</td><td>The resources of a fellowship program are important</td><td>-1</td><td>-0.51</td></tr><tr><td>11</td><td>My decision was predominantly based on experiences as a resident</td><td>-1</td><td>-0.90*</td></tr><tr><td>29</td><td>I am willing to do as many years as it takes to get the job and subspecialty I want</td><td>-3</td><td>-1.93*</td></tr></table>
3954499afae4da97ac79c6943be4602d018d38cf8752edfded186cab584fc740.png
complex
<table><tr><td rowspan="2">Culture days</td><td colspan="2">Control explants</td><td colspan="2">Explants+MNF</td></tr><tr><td>Cultured</td><td>Lost</td><td>Cultured</td><td>Lost</td></tr><tr><td>3</td><td>25</td><td>1</td><td>13</td><td>0</td></tr><tr><td>6</td><td>25</td><td>3</td><td>13</td><td>1</td></tr><tr><td>9</td><td>25</td><td>4</td><td>13</td><td>1</td></tr><tr><td></td><td>75</td><td>8</td><td>39</td><td>2</td></tr><tr><td colspan="5">Total: 114 explants</td></tr></table>
5adc3ca3fa985524560d26e4b7bc754a392748fd90be0240e68198f354869f9b.png
complex
<table><tr><td colspan="9"><i>3rd level ATC Code Prediction using different initializations and comparison to STP</i></td></tr><tr><td><i>Initialization method</i></td><td colspan="2"><i>Supervised learning</i></td><td colspan="2"><i>SuperPred</i></td><td colspan="2"><i>ChEMBL (Perfect 1st level)</i></td><td colspan="2"><i>STP</i></td></tr><tr><td>Prediction method</td><td><i>A(3)</i></td><td><i>CA(3)</i><i>(N(3))</i></td><td><i>A(3)</i></td><td><i>CA(3)</i><i>(N(3))</i></td><td><i>A(3)</i></td><td><i>CA(3)</i><i>(N(3))</i></td><td><i>A(3)</i></td><td><i>CA(3)</i><i>(N(3))</i></td></tr><tr><td>MLP</td><td>63.62%</td><td>68.82%(57.16%)</td><td>63.26%</td><td>70.67%(58.24%)</td><td>72.40%</td><td>83.81%(66.67%)</td><td>72.40%</td><td>73.42%(59.14%)</td></tr><tr><td>Naive Bayes</td><td>56.99%</td><td>50.96%(31.00%)</td><td>66.49%</td><td>68.22%(46.59%)</td><td>69.00%</td><td>78.14%(52.51%)</td><td>57.53%</td><td>60.81%(30.47%)</td></tr><tr><td>Random Forest</td><td>57.35%</td><td>62.60%(48.03%)</td><td>60.93%</td><td>69.06%(54.84%)</td><td>69.00%</td><td>82.20%(62.37%)</td><td>65.23%</td><td>68.46%(50.18%)</td></tr><tr><td>SVM</td><td>64.16%</td><td>67.98%(56.99%)</td><td>67.56%</td><td>72.64%(63.44%)</td><td>76.88%</td><td>86.26%(71.68%)</td><td>64.52%</td><td>70.31%(58.60%)</td></tr></table>
53360da7bad0adaa0de107a2db293e475261d0d9910c6260d31238078bda1cd9.png
complex
<table><tr><td rowspan="2"> </td><td colspan="3">Multivariate</td></tr><tr><td>Odds ratio</td><td>95% CI</td><td>p</td></tr><tr><td>Sm</td><td>0.391</td><td>0.145-1.056</td><td>0.064</td></tr><tr><td>Global longitudinal strain</td><td>1.457</td><td>1.002-2.119</td><td>0.049</td></tr><tr><td>Global circumferential strain</td><td>1.560</td><td>0.912-2.669</td><td>0.105</td></tr><tr><td>Global radial strain</td><td>0.952</td><td>0.818-1.107</td><td>0.533</td></tr></table>
f3821736100300a5aa43536356e1a6b834fb699e9a724d117a8245a093ab1c32.png
complex
<table><tr><td rowspan="3">Body site</td><td colspan="3">Number of pain sites</td></tr><tr><td>1</td><td>2&#8211;3</td><td>&gt;4</td></tr><tr><td>%</td><td>%</td><td>%</td></tr><tr><td>Neck</td><td>9.5</td><td>46.9</td><td>43.6</td></tr><tr><td>Shoulder</td><td>16.8</td><td>38.2</td><td>45.0</td></tr><tr><td>Upper back</td><td>16.6</td><td>39.8</td><td>43.6</td></tr><tr><td>Upper limbs</td><td>23.7</td><td>42.4</td><td>33.9</td></tr><tr><td>Low back</td><td>27.8</td><td>42.0</td><td>30.2</td></tr><tr><td>Upper leg/ knee</td><td>21.2</td><td>39.7</td><td>39.1</td></tr><tr><td>Lower Leg</td><td>16.2</td><td>42.2</td><td>41.6</td></tr><tr><td>Ankle/Feet</td><td>14.4</td><td>34.2</td><td>51.4</td></tr></table>
7571e43d4e4dabfaa6fff2c2f0e716b1011663c5ef0425c0d00c981cf81905f0.png
complex
<table><tr><td rowspan="2">Average computation times [sec]</td><td colspan="2">Fully automatic</td><td colspan="2">Semi-automatic</td></tr><tr><td>CPU</td><td>GPU</td><td>CPU</td><td>GPU</td></tr><tr><td>Linear registration</td><td>112</td><td>109</td><td>140</td><td>130</td></tr><tr><td>Nonlinear registration</td><td>172</td><td>145</td><td>176</td><td>173</td></tr><tr><td>Combining transformations</td><td>42</td><td>42</td><td>42</td><td>42</td></tr><tr><td>Warping of image channels</td><td>79</td><td>78</td><td>76</td><td>75</td></tr><tr><td>Automatic quality assessment</td><td>35</td><td>35</td><td>36</td><td>36</td></tr><tr><td>Sum [sec]</td><td>440</td><td>409</td><td>470</td><td>456</td></tr><tr><td>Sum [min]</td><td>7</td><td>7</td><td>8</td><td>8</td></tr></table>
0e365fb9621fc22646cea8563346aa9ea4f206b8444b4617cec1156460986adc.png
simple
<table><tr><td>1a/2a/STAB ratio (mmol/mmol/mmol)</td><td>Solvent (mL)</td><td>Catalyst</td><td>Reaction time (h)</td><td>Yield<sup>a</sup> (%)</td></tr><tr><td>1/1/1</td><td>THF</td><td>&#8211;</td><td>50</td><td>42</td></tr><tr><td>1/1/1.45</td><td>THF</td><td>&#8211;</td><td>50</td><td>61</td></tr><tr><td>1/1/1</td><td>DCE</td><td>&#8211;</td><td>50</td><td>91</td></tr><tr><td>1/1.5/1.5</td><td>DCE</td><td>&#8211;</td><td>50</td><td>98</td></tr><tr><td>1/1/1.5</td><td>DCE</td><td>&#8211;</td><td>4</td><td>59</td></tr><tr><td>1/1/1.5</td><td>DCE</td><td>&#8211;</td><td>24</td><td>86</td></tr><tr><td>1/1/1.5</td><td>DCE</td><td>Amberlyst-15</td><td>4</td><td>89</td></tr><tr><td>1/1/1.5</td><td>DCE</td><td>AcOH</td><td>4</td><td>98</td></tr></table>
37baa1c47113cd93862e896e96e03477c69a3e438d0b930aae6290b848d3b6f5.png
complex
<table><tr><td><i>Characteristic</i></td><td colspan="2"><i>Healthy weight</i></td><td colspan="2"><i>Overweight</i></td><td colspan="2"><i>Obese</i></td></tr><tr><td> </td><td>n</td><td><i>Mean (s.d.)</i></td><td>n</td><td><i>Mean (s.d.)</i></td><td>n</td><td><i>Mean (s.d.)</i></td></tr><tr><td>Age in months at weight status measurement</td><td>4259</td><td>140.94 (2.80)</td><td>792</td><td>140.98 (3.04)</td><td>914</td><td>141.03 (2.89)</td></tr><tr><td>Birth weight (g)</td><td>3987</td><td>3387.61 (526.66)</td><td>740</td><td>3475.29 (545.34)</td><td>842</td><td>3494.75 (570.38)</td></tr><tr><td>Gestation (weeks)</td><td>4043</td><td>39.45 (1.80)</td><td>746</td><td>39.49 (1.86)</td><td>850</td><td>39.45 (1.75)</td></tr><tr><td>Age of mother in years at delivery</td><td>4043</td><td>29.12 (4.54)</td><td>746</td><td>28.76 (4.54)</td><td>850</td><td>28.82 (4.63)</td></tr><tr><td>Average daily minutes of MVPA</td><td>3611</td><td>24 (16)</td><td>669</td><td>20 (14)</td><td>740</td><td>19 (13)</td></tr><tr><td>Depressive symptoms at 11 years</td><td>3569</td><td>1.99 (2.76)</td><td>651</td><td>2.11 (2.84)</td><td>715</td><td>2.49 (3.36)</td></tr><tr><td>Full-scale IQ at 8 years</td><td>3643</td><td>107.02 (15.34)</td><td>657</td><td>106.36 (15.64)</td><td>746</td><td>103.42 (16.39)</td></tr><tr><td>BMI <i>Z</i>-score at 11 years</td><td>4259</td><td>&#8722;0.25 (0.81)</td><td>792</td><td>1.32 (0.19)</td><td>914</td><td>2.19 (0.42)</td></tr><tr><td>BMI <i>Z</i>-score at 13 years</td><td>1827</td><td>&#8722;0.21 (0.96)</td><td>333</td><td>1.07 (0.56)</td><td>313</td><td>1.89 (0.64)</td></tr><tr><td>BMI <i>Z</i>-score at 16 years</td><td>2533</td><td>&#8722;0.07 (0.84)</td><td>443</td><td>1.00 (0.68)</td><td>463</td><td>1.82 (0.77)</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> </td><td><i>Percentage</i></td><td> </td><td><i>Percentage</i></td><td> </td><td><i>Percentage</i></td></tr><tr><td colspan="7"><i>Proportion of sample</i></td></tr><tr><td>Female</td><td>4260</td><td>71.4</td><td>792</td><td>13.3</td><td>914</td><td>15.3</td></tr><tr><td>Ethnicity</td><td>2325</td><td>54.6</td><td>420</td><td>53.0</td><td>466</td><td>51.0</td></tr><tr><td> White</td><td>3716</td><td>96.4</td><td>672</td><td>95.6</td><td>753</td><td>94.6</td></tr><tr><td> Non-white</td><td>137</td><td>3.6</td><td>31</td><td>4.4</td><td>43</td><td>5.4</td></tr><tr><td colspan="7"><i>Mother's oily fish intake</i></td></tr><tr><td>Never/rarely</td><td>1362</td><td>35.6</td><td>299</td><td>42.1</td><td>347</td><td>44.1</td></tr><tr><td>Once in 2 weeks</td><td>1373</td><td>35.9</td><td>243</td><td>34.2</td><td>253</td><td>32.2</td></tr><tr><td>1&#8211;3 times a week</td><td>1044</td><td>27.3</td><td>161</td><td>22.7</td><td>181</td><td>23.0</td></tr><tr><td>4&#8211;7 times a week</td><td>47</td><td>1.2</td><td>7</td><td>1.0</td><td>4</td><td>0.5</td></tr><tr><td>More than once a day</td><td>1</td><td>0.0</td><td>0</td><td>0.0</td><td>1</td><td>0.1</td></tr><tr><td colspan="7"><i>Mother smoked during pregnancy</i></td></tr><tr><td>Yes</td><td>602</td><td>15.2</td><td>133</td><td>18.2</td><td>177</td><td>21.3</td></tr><tr><td>No</td><td>3369</td><td>84.8</td><td>599</td><td>81.8</td><td>654</td><td>78.7</td></tr><tr><td colspan="7"><i>Mothers education</i></td></tr><tr><td>CBSE</td><td>462</td><td>11.8</td><td>103</td><td>14.3</td><td>142</td><td>17.7</td></tr><tr><td>Vocational</td><td>313</td><td>8.0</td><td>64</td><td>8.9</td><td>81</td><td>10.1</td></tr><tr><td>O level</td><td>1381</td><td>35.3</td><td>270</td><td>37.5</td><td>304</td><td>37.8</td></tr><tr><td>A level</td><td>1051</td><td>26.9</td><td>186</td><td>25.8</td><td>208</td><td>25.9</td></tr><tr><td>Degree</td><td>703</td><td>18.0</td><td>97</td><td>13.5</td><td>69</td><td>8.6</td></tr><tr><td colspan="7"><i>Occupational social class</i></td></tr><tr><td>I (professional)</td><td>280</td><td>8.2</td><td>29</td><td>4.6</td><td>29</td><td>4.4</td></tr><tr><td>II</td><td>1192</td><td>34.9</td><td>207</td><td>33.2</td><td>225</td><td>34.3</td></tr><tr><td>III (non-manual)</td><td>1431</td><td>41.8</td><td>280</td><td>44.9</td><td>293</td><td>44.7</td></tr><tr><td>III (manual)</td><td>214</td><td>6.3</td><td>47</td><td>7.5</td><td>44</td><td>6.7</td></tr><tr><td>IV</td><td>265</td><td>7.7</td><td>53</td><td>8.5</td><td>53</td><td>8.1</td></tr><tr><td>V (unskilled)</td><td>37</td><td>1.1</td><td>8</td><td>1.3</td><td>12</td><td>1.8</td></tr><tr><td>Armed forces</td><td>1</td><td>0.0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td colspan="7"><i>Pubertal status at 11 years</i></td></tr><tr><td>Experienced menarche</td><td>201</td><td>11.3</td><td>78</td><td>25.08</td><td>101</td><td>29.79</td></tr><tr><td>Tanner stage I</td><td>508</td><td>40.7</td><td>69</td><td>30.0</td><td>88</td><td>31.5</td></tr><tr><td>Tanner stage II</td><td>485</td><td>38.9</td><td>100</td><td>43.5</td><td>108</td><td>38.7</td></tr><tr><td>Tanner stage III</td><td>158</td><td>12.7</td><td>40</td><td>17.4</td><td>55</td><td>19.7</td></tr><tr><td>Tanner stage IV</td><td>42</td><td>3.4</td><td>13</td><td>5.7</td><td>13</td><td>4.7</td></tr><tr><td>Tanner stage V</td><td>2</td><td>0.2</td><td>13</td><td>5.7</td><td>1</td><td>0.4</td></tr></table>
579bf68453c8f4c7cd193bdd40aa4c861f1ede5c0a954916bec42e354aa804ca.png
simple
<table><tr><td>Characteristics</td><td>Number</td><td>Percentage (%)</td></tr><tr><td>Gender</td><td></td><td></td></tr><tr><td>Male</td><td>60</td><td>70.6</td></tr><tr><td>Female</td><td>25</td><td>29.4</td></tr><tr><td>Age</td><td></td><td></td></tr><tr><td>&#8804; 60</td><td>53</td><td>62.4</td></tr><tr><td>&gt; 60</td><td>32</td><td>37.6</td></tr><tr><td>Nationality</td><td></td><td></td></tr><tr><td>The Han</td><td>60</td><td>70.6</td></tr><tr><td>The Zhuang</td><td>25</td><td>29.4</td></tr><tr><td>Histology</td><td></td><td></td></tr><tr><td>Squamous carcinoma</td><td>25</td><td>29.4</td></tr><tr><td>Adenocarcinoma</td><td>60</td><td>70.6</td></tr><tr><td>Differentiation</td><td></td><td></td></tr><tr><td>Well and moderate</td><td>58</td><td>68.2</td></tr><tr><td>Poor</td><td>27</td><td>31.8</td></tr><tr><td>Metastasis lymphatics</td><td></td><td></td></tr><tr><td>Yes</td><td>28</td><td>32.9</td></tr><tr><td>No</td><td>57</td><td>67.1</td></tr><tr><td>TNM stage</td><td></td><td></td></tr><tr><td>I + II</td><td>48</td><td>56.5</td></tr><tr><td>III + IV</td><td>37</td><td>43.5</td></tr><tr><td>Surgery status</td><td></td><td></td></tr><tr><td>Lobectomy</td><td>79</td><td>92.9</td></tr><tr><td>Pneumonectomy</td><td>6</td><td>7.1</td></tr><tr><td>Chemotherapy status(74 cases)</td><td></td><td></td></tr><tr><td>GP regimens</td><td>34</td><td>45.9</td></tr><tr><td>NP regimens</td><td>29</td><td>39.2</td></tr><tr><td>TP regimens</td><td>11</td><td>14.9</td></tr><tr><td>ECOG Performance status</td><td></td><td></td></tr><tr><td>0</td><td>22</td><td>25.9</td></tr><tr><td>1</td><td>63</td><td>74.1</td></tr></table>
6c9a68531f00a5fcf41d8bfa2d7d0254131f004afab311903ea1fb25323a08dd.png
complex
<table><tr><td> </td><td rowspan="2" colspan="3">All studies</td><td colspan="6">Level of methodological quality</td></tr><tr><td> </td><td colspan="3">Poor</td><td colspan="3">Fair to good</td></tr><tr><td> </td><td>Acceptable</td><td>Total</td><td>% Acceptable</td><td>Acceptable</td><td>Total</td><td>% Acceptable</td><td>Acceptable</td><td>Total</td><td>% Acceptable</td></tr><tr><td><i>Inter-rater reliability</i></td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Weight-handling and strength</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>ICC</td><td>6</td><td>6</td><td>100.0%</td><td>6</td><td>6</td><td>100.0%</td><td> </td><td> </td><td> </td></tr><tr><td>&#954;</td><td>3</td><td>6</td><td>50.0%</td><td> </td><td> </td><td> </td><td>3</td><td>6</td><td>50.0%</td></tr><tr><td>POA</td><td>16</td><td>16</td><td>100.0%</td><td>12</td><td>12</td><td>100.0%</td><td>4</td><td>4</td><td>100.0%</td></tr><tr><td>Total</td><td>25</td><td>28</td><td>89.3%</td><td>18</td><td>18</td><td>100.0%</td><td>7</td><td>10</td><td>70.0%</td></tr><tr><td><i>Intra-rater reliability</i></td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Weight-handling and strength</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>&#954;</td><td>1</td><td>1</td><td>100.0%</td><td>1</td><td>1</td><td>100.0%</td><td> </td><td> </td><td> </td></tr><tr><td>POA</td><td>7</td><td>7</td><td>100.0%</td><td>7</td><td>7</td><td>100.0%</td><td> </td><td> </td><td> </td></tr><tr><td>Total</td><td>8</td><td>8</td><td>100.0%</td><td>8</td><td>8</td><td>100.0%</td><td> </td><td> </td><td> </td></tr><tr><td><i>Test-retest reliability</i></td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Weight-handling and strength</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>ICC</td><td>42</td><td>44</td><td>95.5%</td><td>33</td><td>34</td><td>97.1%</td><td>9</td><td>10</td><td>90.0%</td></tr><tr><td>POA</td><td>4</td><td>4</td><td>100.0%</td><td>4</td><td>4</td><td>100.0%</td><td> </td><td> </td><td> </td></tr><tr><td>Total</td><td>46</td><td>48</td><td>95.8%</td><td>37</td><td>38</td><td>97.4%</td><td>9</td><td>10</td><td>90.0%</td></tr><tr><td>Posture and mobility</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>ICC</td><td>5</td><td>17</td><td>29.4%</td><td>3</td><td>15</td><td>20.0%</td><td>2</td><td>2</td><td>100.0%</td></tr><tr><td>&#954;</td><td>10</td><td>14</td><td>71.4%</td><td>10</td><td>14</td><td>71.4%</td><td> </td><td> </td><td> </td></tr><tr><td>POA</td><td>22</td><td>24</td><td>91.7%</td><td>22</td><td>24</td><td>91.7%</td><td> </td><td> </td><td> </td></tr><tr><td>Total</td><td>37</td><td>55</td><td>67.3%</td><td>35</td><td>53</td><td>66.0%</td><td>2</td><td>2</td><td>100.0%</td></tr><tr><td>Locomotion</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>ICC</td><td>1</td><td>2</td><td>50.0%</td><td>1</td><td>2</td><td>50.0%</td><td> </td><td> </td><td> </td></tr><tr><td>&#954;</td><td>1</td><td>3</td><td>33.3%</td><td>1</td><td>3</td><td>33.3%</td><td> </td><td> </td><td> </td></tr><tr><td>POA</td><td>3</td><td>4</td><td>75.0%</td><td>3</td><td>4</td><td>75.0%</td><td> </td><td> </td><td> </td></tr><tr><td>Total</td><td>5</td><td>9</td><td>55.6%</td><td>5</td><td>9</td><td>55.6%</td><td> </td><td> </td><td> </td></tr><tr><td><i>Balance</i></td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>POA</td><td>2</td><td>2</td><td>100.0%</td><td>2</td><td>2</td><td>100.0%</td><td> </td><td> </td><td> </td></tr><tr><td>Total</td><td>2</td><td>2</td><td>100.0%</td><td>2</td><td>2</td><td>100.0%</td><td> </td><td> </td><td> </td></tr><tr><td>Total test-retest reliability</td><td>90</td><td>114</td><td>78.9%</td><td>79</td><td>102</td><td>77.5%</td><td>11</td><td>12</td><td>91.7%</td></tr><tr><td><i>Overall reliability statistics</i></td><td>123</td><td>150</td><td>82.0%</td><td>105</td><td>128</td><td>82.0%</td><td>18</td><td>22</td><td>81.8%</td></tr></table>
d8f63de0a5a5a8177b754ec5060ed17906ba9a941892fdb12839267e37155a31.png
complex
<table><tr><td rowspan="3"></td><td colspan="2">BMI &lt;18.5</td><td colspan="2">BMI 18.5&#8211;24.9</td><td colspan="2">BMI 25&#8211;29.9</td><td colspan="2">BMI &#8805; 30</td><td rowspan="3"></td></tr><tr><td colspan="2">Underweight</td><td colspan="2">Normal</td><td colspan="2">Overweight</td><td colspan="2">Obesity</td></tr><tr><td colspan="2"><i>n</i> = 40 (3.3%)</td><td colspan="2"><i>n</i> = 662 (55.3%)</td><td colspan="2"><i>n</i> = 428 (35.7%)</td><td colspan="2"><i>n</i> = 68 (5.7%)</td></tr><tr><td>Single complications</td><td>No.</td><td>%</td><td>No.</td><td>%</td><td>No.</td><td>%</td><td>No.</td><td>%</td><td><i>P</i></td></tr><tr><td>Pleural effusion</td><td>2</td><td>5.0</td><td>50</td><td>7.6</td><td>28</td><td>6.5</td><td>9</td><td>13.2</td><td>0.243</td></tr><tr><td>Arrhythmia</td><td>3</td><td>7.5</td><td>35</td><td>5.3</td><td>18</td><td>4.2</td><td>5</td><td>7.4</td><td>0.735</td></tr><tr><td>Pneumonia</td><td>6*</td><td>15.0</td><td>28</td><td>4.2</td><td>14</td><td>3.3</td><td>2</td><td>2.9</td><td><i>0.029</i></td></tr><tr><td>Prolonged air leaks</td><td>40</td><td>10.0</td><td>19</td><td>2.9</td><td>3**</td><td>1.5</td><td>1</td><td>2.3</td><td><i>0.001</i></td></tr><tr><td>Cardiac insufficiency</td><td>1</td><td>2.5</td><td>11</td><td>1.7</td><td>5</td><td>1.2</td><td>1</td><td>1.5</td><td>0.496</td></tr><tr><td>Heart failure</td><td>0</td><td>0.0</td><td>7</td><td>1.1</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>0.076</td></tr><tr><td>Chylothorax</td><td>10</td><td>2.5</td><td>7</td><td>1.1</td><td>6</td><td>1.4</td><td>4</td><td>5.9</td><td>0.062</td></tr><tr><td>Atelectasis</td><td>00</td><td>0.0</td><td>7</td><td>1.1</td><td>6</td><td>1.4</td><td>2</td><td>2.9</td><td>0.481</td></tr></table>
aa46315b259d50914aee8e870911ce4b1778ae8b86958c714dca0002783e36b2.png
simple
<table><tr><td>Experiment</td><td>Climate<sup>a</sup></td><td>Land cover<sup>b</sup></td><td>Managed grassland area<sup>c</sup></td><td>Atmospheric CO<sub>2</sub> concentration</td><td>Management strategy</td></tr><tr><td><i>E</i><sub><i>hist</i></sub><sup>d</sup></td><td>Varied for 1901&#8211;2010</td><td>Varied for 1901&#8211;2010</td><td>Varied for 1901&#8211;2010</td><td>Varied for 1901&#8211;2010</td><td>Adaptive management change algorithm simulating potential livestock density</td></tr><tr><td><i>E</i><sub><i>control</i></sub></td><td>Varied for 2011&#8211;2100</td><td>Constant as in 2010</td><td>Constant as in 2010</td><td>Varied for 2011&#8211;2100 (A1B scenario)</td><td>Adaptive management change algorithm simulating potential livestock density</td></tr><tr><td><i>E</i><sub><i>noco2</i></sub></td><td>Varied for 2011&#8211;2100</td><td>Constant as in 2010</td><td>Constant as in 2010</td><td>Constant as in 2010</td><td>Adaptive management change algorithm simulating potential livestock density</td></tr><tr><td><i>E</i><sub><i>fixD</i></sub></td><td>Varied for 2011&#8211;2100</td><td>Constant as in 2010</td><td>Constant as in 2010</td><td>Varied for 2011&#8211;2100 (A1B scenario)</td><td>Adaptive management change algorithm with constant livestock density</td></tr></table>
ac3148737eaa2be741bd891cfe33edc374d9540c7f33dbc603fa727b89081030.png
complex
<table><tr><td></td><td></td><td></td><td colspan="3">Log<sub>2</sub>(ratio)</td></tr><tr><td>Accession number</td><td>Gene description</td><td>Localisation</td><td colspan="3">Treatment comparison</td></tr><tr><td></td><td></td><td></td><td>S/M</td><td>MA/M</td><td>SA/M</td></tr><tr><td>At1g57770</td><td>Amine oxidase family</td><td>Chloroplast</td><td>nde</td><td>1.59</td><td>0.80</td></tr><tr><td>At3g14420</td><td>(S)-2-hydroxy-acid oxidase, peroxisomal, putative/glycolate oxidase, putative/short chain alpha-hydroxy acid oxidase, putative Proline oxidase, mitochondrial/osmotic stress-</td><td>Peroxisome</td><td>-1.08</td><td>1.33</td><td>nde</td></tr><tr><td>At3g30775</td><td>responsive proline dehydrogenase (POX) (PRO1) (ERD5)</td><td>Mitochondrion</td><td>nde</td><td>2.51</td><td>1.22</td></tr><tr><td>At3g53950</td><td>Glyoxal oxidase-related</td><td>Endomembrane system</td><td>nde</td><td>1.00</td><td>nde</td></tr><tr><td>At4g16760</td><td>Acyl-CoA oxidase (ACX1)</td><td>Peroxisome</td><td>0,87</td><td>nde</td><td>1.48</td></tr><tr><td>At5g65110</td><td>Acyl-CoA oxidase (ACX2)</td><td>Peroxisome</td><td>0.91</td><td>nde</td><td>1.83</td></tr></table>
c97a565cd943d61e1a695fc6e05e36522fdf6810c6d95f153c5bdc33f0c0c157.png
simple
<table><tr><td>Reference</td><td>No. of case reports</td><td>Patient case conditions</td><td>Prophylaxis used</td><td>Treatment that cleared infection</td><td>Isolate(s) cultured</td><td>Geographic location</td><td>Year published</td></tr><tr><td>Wang et al., 2011</td><td>1</td><td>Mandibulectomy with planned tissue flap reconstruction, infection and necrosis of the flap</td><td>Ciprofloxacin</td><td>Cefepime</td><td><i>A. hydrophila</i></td><td>Missouri, USA</td><td>2011</td></tr><tr><td>Sartor et al., 2013</td><td>1</td><td>Infection of skin flap of hand crush injury</td><td>Ciprofloxacin</td><td>Cotrimoxazole</td><td><i>A. hydrophila</i></td><td>Marseille, France</td><td>2013</td></tr><tr><td>Giltner et al., 2013</td><td>1</td><td>Mandibular osteotomy, necrosis of mandibular flap and wound surrounding the distraction arm device</td><td>Ciprofloxacin</td><td>Vancomycin</td><td><i>A. hydrophila, Morganella morganii</i></td><td>California, USA</td><td>2013</td></tr><tr><td>Wilmer et al., 2013</td><td>1</td><td>Amputation of three digits and necrosis of amputation sites</td><td>Ciprofloxacin</td><td>Co-trimoxazole</td><td><i>A. hydrophila</i></td><td>British Columbia, Canada</td><td>2013</td></tr><tr><td>Patel et al., 2013</td><td>1</td><td>Breast reconstruction, infection of the implant</td><td>Ciprofloxacin, vancomycin</td><td>Aztreonam</td><td><i>A. hydrophila</i></td><td>Washington D.C., USA</td><td>2013</td></tr><tr><td>van Alphen et al., 2014</td><td>2</td><td>Replantation of four fingers resulting in flap necrosis after leech therapy, followed by amputation</td><td>Ertapenem</td><td>Ceftriaxone and co-trimoxazole</td><td><i>A. hydrophila</i></td><td>Minnesota, USA</td><td>2014</td></tr><tr><td></td><td></td><td>Replantation of two fingers failed following leech therapy, amputation</td><td>Ciprofloxacin</td><td>Cefepime, metronidazole, vancomycin; followed by ceftriaxone</td><td><i>A. hydrophila, Proteus vulgaris, Morganella morganii</i></td><td></td><td></td></tr></table>
e0a2acc1fbd61ce400f634059ed3d27d15ece6fcddc0cfb34875aaf292de56d3.png
complex
<table><tr><td>Subscale</td><td>Group</td><td>Baseline score</td><td>One month after the onset of intervention</td><td>Two months after the onset of intervention</td><td>Between groups difference</td></tr><tr><td rowspan="2">Irritability</td><td>N-Acetylcysteine + risperidone</td><td>13.2(5.3)</td><td>10.0(4.1)</td><td>9.7(4.1)</td><td rowspan="2">F1,29= 4.9, P&lt;0.035</td></tr><tr><td>Placebo+Risperidone</td><td>16.7(7.8)</td><td>15.5(7.9)</td><td>15.1(7.8)</td></tr><tr><td rowspan="2">Hyperactivity and Noncompliance</td><td>N-Acetylcysteine + risperidone</td><td>29.3(6.4)</td><td>21.4(7.7)</td><td>18.3(6.9)</td><td rowspan="2">F1,29= 2.4, P=0.12</td></tr><tr><td>Placebo+Risperidone</td><td>31.9(8.9)</td><td>26.8(11.0)</td><td>24.3(12.1)</td></tr><tr><td rowspan="2">Lethargy and Social Withdrawal</td><td>N-Acetylcysteine + risperidone</td><td>11.9(6.5)</td><td>9.0(5.7)</td><td>8.5(6.5)</td><td rowspan="2">F1,28= 0.4, P=0.53</td></tr><tr><td>Placebo+Risperidone</td><td>12.2(8.3)</td><td>11.0(7.8)</td><td>10.9(7.5)6</td></tr><tr><td rowspan="2">Stereotypic Behavior</td><td>N-Acetylcysteine + risperidone</td><td>6.6(4.5)</td><td>4.5(3.6)</td><td>3.9(2.7)</td><td rowspan="2">F1,28= 2.8, P=0.1</td></tr><tr><td>Placebo+Risperidone</td><td>8.5(6.3)</td><td>7.7(6.2)</td><td>7.8(6.6)</td></tr><tr><td rowspan="2">Inappropriate Speech</td><td>N-Acetylcysteine + risperidone</td><td>3.9(3.7)</td><td>3.8(3.7)</td><td>3.2(3.4)</td><td rowspan="2">F1,29= 1.8, P=0.1</td></tr><tr><td>Placebo+Risperidone</td><td>5.7(3.8)</td><td>5.3(3.7)</td><td>5.2(4.0)</td></tr></table>
0565e4af8e09eb7656adf93e37908277f38a5ae9cd46a0352d707ea39d713530.png
simple
<table><tr><td></td><td>Weaned pigs</td><td>Growing pigs</td><td>Gilts</td></tr><tr><td>Number of animals</td><td>9 (6 to 11)</td><td>23 (20 to 25)</td><td>24 (18 to 29)</td></tr><tr><td>Degree</td><td></td><td></td><td></td></tr><tr><td>Binary</td><td>7<sup>a</sup> (0 to 16)</td><td>5<sup>b</sup> (1 to 18)</td><td>5<sup>b</sup> (0 to 22)</td></tr><tr><td>Weighted</td><td>12<sup>a</sup> (0 to 96)</td><td>5<sup>b</sup> (1 to 27)</td><td>5<sup>b</sup> (0 to 36)</td></tr><tr><td>In-degree</td><td></td><td></td><td></td></tr><tr><td>Binary</td><td>4<sup>a</sup> (0 to 8)</td><td>3<sup>b</sup> (0 to 11)</td><td>3<sup>b</sup> (0 to 11)</td></tr><tr><td>Weighted</td><td>7<sup>a</sup> (0 to 51)</td><td>3<sup>b</sup> (0 to 16)</td><td>3<sup>b</sup> (0 to 17)</td></tr><tr><td>Out-degree</td><td></td><td></td><td></td></tr><tr><td>Binary</td><td>3<sup>a</sup> (0 to 9)</td><td>2<sup>b</sup> (0 to 10)</td><td>2<sup>b</sup> (0 to 16)</td></tr><tr><td>Weighted</td><td>5<sup>a</sup> (0 to 73)</td><td>3<sup>b</sup> (0 to 17)</td><td>2<sup>b</sup> (0 to 29)</td></tr><tr><td>Betweenness</td><td></td><td></td><td></td></tr><tr><td>Binary</td><td>0.03<sup>a</sup> (0 to 0.50)</td><td>0.02<sup>a</sup> (0 to 0.26)</td><td>0.02<sup>a</sup> (0 to 0.32)</td></tr><tr><td>Weighted</td><td>0.04<sup>a</sup> (0 to 0.63)</td><td>0.03<sup>a</sup> (0 to 0.32)</td><td>0.02<sup>a</sup> (0 to 0.37)</td></tr><tr><td>Closeness</td><td></td><td></td><td></td></tr><tr><td>Binary</td><td>0.73<sup>a</sup> (0 to 1.00)</td><td>0.43<sup>b</sup> (0.04 to 0.73)</td><td>0.43<sup>b</sup> (0 to 0.94)</td></tr><tr><td>Weighted</td><td>1.15<sup>a</sup> (0 to 6.19)</td><td>0.51<sup>b</sup> (0.04 to 0.93)</td><td>0.49<sup>b</sup> (0 to 1.22)</td></tr><tr><td>Ingoing closeness</td><td></td><td></td><td></td></tr><tr><td>Binary</td><td>0.61<sup>a</sup> (0 to 1.00)</td><td>0.29<sup>b</sup> (0 to 0.55)</td><td>0.32<sup>b</sup> (0 to 0.60)</td></tr><tr><td>Weighted</td><td>0.84<sup>a</sup> (0 to 5.22)</td><td>0.31<sup>b</sup> (0 to 0.66)</td><td>0.32<sup>b</sup> (0 to 0.79)</td></tr><tr><td>Outgoing closeness</td><td></td><td></td><td></td></tr><tr><td>Binary</td><td>0.62<sup>a</sup> (0 to 1.00)</td><td>0.30<sup>b</sup> (0 to 0.60)</td><td>0.32<sup>b</sup> (0 to 0.94)</td></tr><tr><td>Weighted</td><td>0.83<sup>a</sup> (0 to 6.80)</td><td>0.34<sup>b</sup> (0 to 0.89)</td><td>0.32<sup>b</sup> (0 to 1.33)</td></tr></table>
d1d1c3e520d04321119f8969a28d7c44e97f7cf92d18b7092ee158abbde221a7.png
complex
<table><tr><td>Region</td><td>Side</td><td colspan="3">MNI coordinates</td><td><i>T</i> value</td></tr><tr><td>Pre-cuneus</td><td>R</td><td>4</td><td>-70</td><td>36</td><td>32.78</td></tr><tr><td></td><td>L</td><td>-7</td><td>-74</td><td>42</td><td>32.12</td></tr><tr><td>Cuneus</td><td>R</td><td>10</td><td>76</td><td>38</td><td>32.62</td></tr><tr><td></td><td>L</td><td>-10</td><td>-68</td><td>42</td><td>31.25</td></tr><tr><td>Inferior temporal gyrus area (includes fusiform gyrus)</td><td>R</td><td>54</td><td>-34</td><td>-26</td><td>11.18</td></tr><tr><td></td><td>L</td><td>-48</td><td>-56</td><td>-14</td><td>18.78</td></tr><tr><td>Pre-central gyrus</td><td>R</td><td>42</td><td>-14</td><td>48</td><td>15.81</td></tr><tr><td>Post-central gyrus</td><td>R</td><td>44</td><td>-26</td><td>46</td><td>13.96</td></tr><tr><td>Superior temporal gyrus</td><td>R</td><td>50</td><td>-44</td><td>16</td><td>11.18</td></tr><tr><td></td><td>L</td><td>-50</td><td>-44</td><td>18</td><td>16.92</td></tr><tr><td>Basal forebrain</td><td>R</td><td>22</td><td>10</td><td>-18</td><td>12.87</td></tr><tr><td></td><td>L</td><td>-24</td><td>8</td><td>-18</td><td>12.87</td></tr><tr><td>Inferior frontal gyrus</td><td>R</td><td>42</td><td>28</td><td>16</td><td>12.18</td></tr><tr><td></td><td>L</td><td>-42</td><td>24</td><td>18</td><td>12.24</td></tr><tr><td>Inferior frontal orbital</td><td>L</td><td>-34</td><td>40</td><td>-14</td><td>9.71</td></tr><tr><td>Lobe occipital Superior</td><td>R</td><td>22</td><td>-80</td><td>40</td><td>26.90</td></tr><tr><td></td><td>L</td><td>-18</td><td>-80</td><td>34</td><td>25.88</td></tr><tr><td>Superior frontal gyrus</td><td>R</td><td>20</td><td>-8</td><td>64</td><td>6.69</td></tr><tr><td></td><td>L</td><td>-20</td><td>-6</td><td>66</td><td>6.70</td></tr></table>
6b580ef0894dcbe03677d52b6cc29d9134c638ddd0c7cb669ac9296d658ef3bc.png
complex
<table><tr><td rowspan="2">Characteristics</td><td rowspan="2">No. of cases</td><td colspan="2">miR-140 expression</td><td rowspan="2"><i>P</i> value</td></tr><tr><td>Low (median &#8804;0.278)</td><td>High (median &gt;0.278)</td></tr><tr><td colspan="4">Age</td><td>0.667</td></tr><tr><td>&lt; 60 years</td><td>22</td><td>10</td><td>12</td><td></td></tr><tr><td>&#8805; 60 years</td><td>38</td><td>18</td><td>20</td><td></td></tr><tr><td colspan="4">Gender</td><td>0.778</td></tr><tr><td> Male</td><td>33</td><td>16</td><td>17</td><td></td></tr><tr><td> Female</td><td>27</td><td>12</td><td>15</td><td></td></tr><tr><td colspan="4">Tumor size</td><td>0.602</td></tr><tr><td>&lt; 5 cm</td><td>23</td><td>12</td><td>11</td><td></td></tr><tr><td>&#8805; 5 cm</td><td>37</td><td>16</td><td>21</td><td></td></tr><tr><td colspan="4">Stage</td><td>0.045*</td></tr><tr><td> I/II</td><td>28</td><td>1</td><td>27</td><td></td></tr><tr><td> III/IV</td><td>32</td><td>27</td><td>5</td><td></td></tr><tr><td colspan="4">Differentiation</td><td>0.076</td></tr><tr><td> Well/moderate</td><td>24</td><td>13</td><td>11</td><td rowspan="2"></td></tr><tr><td> Poor</td><td>36</td><td>15</td><td>21</td></tr><tr><td colspan="4">Metastasis</td><td>0.031*</td></tr><tr><td> No</td><td>31</td><td>7</td><td>24</td><td></td></tr><tr><td> Yes</td><td>29</td><td>21</td><td>8</td><td></td></tr></table>
ec534edd8cda722785af998365edc865aa498132fa5d55b7487083bad239be50.png
simple
<table><tr><td>Absolute Contraindications</td><td>Relative Contraindications</td></tr><tr><td>Clinical instability or significant pain suggestive of ruptured EP</td><td>Presence of fetal cardiac activity</td></tr><tr><td>Heterotopic pregnancy with viable and desired IUP</td><td>&#946;-hCG level over 5000 mIU/mL</td></tr><tr><td>Liver function tests more than 2 times the upper limit of normal</td><td>An ectopic mass size greater than 4 cm in largest dimension</td></tr><tr><td>White blood cell count of &lt;1500/uL</td><td>Patient refusal of blood transfusion</td></tr><tr><td>Platelet count &lt;100,000/uL</td><td>Patient inability to follow up</td></tr><tr><td>Creatinine &#8805;1.5 mg/dL</td><td></td></tr><tr><td>Current breastfeeding</td><td></td></tr><tr><td>Active pulmonary disease</td><td></td></tr><tr><td>Active peptic ulcer disease</td><td></td></tr><tr><td>Moderate to severe anemia</td><td></td></tr><tr><td>Sensitivity to methotrexate</td><td></td></tr></table>
1c239423b2cd66cc03f230637ad62b1c24cf045849b03f653527c763e125a8b4.png
complex
<table><tr><td>Item</td><td>Details</td><td>Intervention</td></tr><tr><td rowspan="3">1. Acupuncture rationale</td><td>1a) Style of acupuncture</td><td>Traditional needle acupuncture and intradermal acupuncture</td></tr><tr><td>1b) Reasoning for treatment provided based on historical context, literature sources, and/or consensus methods, with references where appropriate</td><td>Selected traditional acupuncture points on the 12 meridian system based on the systematic review by Yeung and clinical experiences</td></tr><tr><td>1c) Extent to which treatment was varied</td><td>No variation</td></tr><tr><td rowspan="8">2. Details of needling</td><td>2a) Number of needle insertions per subject per session (mean and range where relevant)</td><td>Five needle insertions per 1 session</td></tr><tr><td>2b) Names (or location if no standard name) of points used (uni/bilateral)</td><td><i>Neiguan</i> (PC6), <i>Sanyinjiao</i> (SP6), <i>Shenmen</i> (HT7), <i>Zhaohai</i> (KI6), <i>Shenmai</i> (BL62), all unilateral.</td></tr><tr><td>2c) Depth of insertion, based on a specified unit of measurement or on a particular tissue level</td><td>Depth of needle insertion was at least 5 to10 mm and intradermal acupunctured was 1 to 2 mm</td></tr><tr><td>2d) Response sought</td><td><i>De-qi</i> sensation felt by practitioner and subject</td></tr><tr><td>2e) Needle stimulation</td><td>No stimulation and just retention without movement Intradermal acupuncture fixed with skin tape and subjects educated to self finger-press on them at nighttime</td></tr><tr><td>2f) Needle retention time</td><td>Twenty-minute retention for needles, intradermal acupuncture patched 48 to 72 hours until next session</td></tr><tr><td rowspan="2">2 g) Needle type (diameter, length, and manufacturer or material)</td><td>Needles: 0.25 &#215; 40 mm, stainless steel (Dong Bang Medical Co. Ltd, Korea)</td></tr><tr><td>Intradermal acupuncture: 0.18 &#215; 1.3 &#215; 1.5 mm, stainless steel (Dong Bang Medical Co. Ltd, Korea)</td></tr><tr><td rowspan="2">3. Treatment regimen</td><td>3a) Number of treatment sessions</td><td>Three sessions</td></tr><tr><td>3b) Frequency and duration of treatment sessions</td><td>Three times per week, interval of 1 to 4 days between sessions</td></tr><tr><td rowspan="2">4. Other components of treatment</td><td>4a) Details of other interventions administered to the acupuncture group</td><td>Sleep hygiene education</td></tr><tr><td>4b) Setting and context of treatment, including instructions to practitioners, and information and explanations to patients</td><td>Same practitioner treats every subject at every session in the same outpatient clinic</td></tr><tr><td>5. Practitioner background</td><td>5) Description of participating acupuncturists (qualification or professional affiliation, years in acupuncture practice, other relevant experience)</td><td>Licensed traditional Korean medicine doctor at the Kyung Hee East-West Neo Medical Center at Gangdong with more than 10 years of acupuncture treatment experience</td></tr><tr><td rowspan="4">6. Control or comparator interventions</td><td>6a) Rationale for the control or comparator in the context of the research question, with sources that justify this choice</td><td>Sham acupuncture points</td></tr><tr><td rowspan="3">6b) Precise description of the control or comparison group. If sham acupuncture or any other type of acupuncture-like control is used, provide details as for items 1 to 3 above</td><td>Same as intervention group except 2b) and 2d)</td></tr><tr><td>2b) No acupuncture points located away from acupuncture points at least 10 mm</td></tr><tr><td>2d) Without <i>De-qi</i> sensation</td></tr></table>
087e3a3bf156d24dee02216661e52daaf087f681abfa04dbd92b900845a377ad.png
complex
<table><tr><td>Date</td><td>Flight Time</td><td>&#964; (95% Confidence Bounds)</td><td>L<sub>u</sub> (95% Confidence Bounds) W/m<sup>2</sup>/&#956;m/sr</td><td>r<sup>2</sup></td><td>RMSE W/m<sup>2</sup>/&#956;m/sr</td><td>Used Pixels</td></tr><tr><td rowspan="2">8/9/2014</td><td>Early Morning</td><td>0.40 (0.51 0.33)</td><td>&#8722;5.54 (&#8722;9.38&#8211;3.03)</td><td>0.65</td><td>0.37</td><td>48</td></tr><tr><td>Landsat Overpass</td><td>0.69 (0.88 0.57)</td><td>&#8722;2.94 (&#8722;6.75&#8211;0.45)</td><td>0.58</td><td>0.84</td><td>63</td></tr><tr><td rowspan="3">6/2/2015</td><td>Early Morning</td><td>0.35 (0.38 0.33)</td><td>&#8722;4.28 (&#8722;5.10&#8211;3.56)</td><td>0.71</td><td>0.26</td><td>336</td></tr><tr><td>Landsat Overpass</td><td>0.57 (0.62 0.53)</td><td>&#8722;3.61 (&#8722;4.88&#8211;2.53)</td><td>0.62</td><td>0.88</td><td>330</td></tr><tr><td>Mid Afternoon</td><td>0.53 (0.58 0.50)</td><td>&#8722;5.17 (&#8722;6.49&#8211;4.04)</td><td>0.68</td><td>0.97</td><td>330</td></tr><tr><td rowspan="3">7/11/2015</td><td>Early Morning</td><td>0.81 (0.88 0.76)</td><td>&#8722;0.94 (&#8722;1.58&#8211;0.39)</td><td>0.73</td><td>0.12</td><td>283</td></tr><tr><td>Landsat Overpass</td><td>0.49 (0.52 0.47)</td><td>&#8722;5.08 (&#8722;5.86&#8211;4.38)</td><td>0.83</td><td>0.77</td><td>352</td></tr><tr><td>Mid Afternoon</td><td>0.47 (0.48 0.45)</td><td>&#8722;5.21 (&#8722;5.71&#8211;4.74)</td><td>0.94</td><td>0.47</td><td>278</td></tr><tr><td rowspan="3">5/2/2016</td><td>Early Morning</td><td>0.29 (0.33 0.27)</td><td>&#8722;5.23 (&#8722;6.66&#8211;4.05)</td><td>0.53</td><td>0.21</td><td>343</td></tr><tr><td>Landsat Overpass</td><td>0.62 (0.63 0.60)</td><td>&#8722;2.21 (&#8722;2.49&#8211;1.94)</td><td>0.95</td><td>0.46</td><td>299</td></tr><tr><td>Mid Afternoon</td><td>0.65 (0.69 0.62)</td><td>&#8722;2.25 (&#8722;2.94&#8211;1.62)</td><td>0.79</td><td>0.55</td><td>299</td></tr><tr><td rowspan="2">5/3/2016</td><td>Early Morning</td><td>0.43 (0.45 0.41)</td><td>&#8722;4.74 (&#8722;5.49&#8211;4.07)</td><td>0.8</td><td>0.13</td><td>326</td></tr><tr><td>Mid Afternoon</td><td>0.52 (0.55 0.50)</td><td>&#8722;3.38 (&#8722;4.01&#8211;2.82)</td><td>0.83</td><td>0.43</td><td>349</td></tr></table>
8bc66ae2b7089d49a52a34b5bd5fe82939032c3d182332d2540af177a1d525de.png
complex
<table><tr><td rowspan="2">SNP</td><td rowspan="2">Model/Allele</td><td rowspan="2">Genotype</td><td>Control</td><td>ASD</td><td rowspan="2">OR (95% CI)</td><td rowspan="2"><i>p</i></td></tr><tr><td><i>n</i> (%)</td><td><i>n</i> (%)</td></tr><tr><td>rs1801123</td><td>Additive</td><td>AA</td><td>73 (49.7)</td><td>114 (63.3)</td><td>1</td><td></td></tr><tr><td>Ala804Ala</td><td></td><td>AG</td><td>63 (42.9)</td><td>56 (31.1)</td><td></td><td></td></tr><tr><td><i>IRS1</i></td><td></td><td>GG</td><td>11 (7.5)</td><td>10 (5.6)</td><td>0.66 (0.46&#8211;0.95)</td><td>0.022</td></tr><tr><td></td><td>Dominant</td><td>AA</td><td>73 (49.7)</td><td>114 (63.3)</td><td>1</td><td></td></tr><tr><td></td><td></td><td>AG/GG</td><td>74 (50.3)</td><td>66 (36.7)</td><td>0.57 (0.37&#8211;0.89)</td><td>0.013</td></tr><tr><td></td><td>Recessive</td><td>AA/AG</td><td>136 (92.5)</td><td>170 (94.4)</td><td>1</td><td></td></tr><tr><td></td><td></td><td>GG</td><td>11 (7.5)</td><td>10 (5.6)</td><td>0.73 (0.30&#8211;1.76)</td><td>0.48</td></tr><tr><td></td><td>Allele</td><td>A</td><td>209 (71.1)</td><td>284 (78.9)</td><td>1</td><td></td></tr><tr><td></td><td></td><td>G</td><td>85 (28.9)</td><td>76 (21.1)</td><td>0.66 (0.46&#8211;0.94)</td><td>0.022</td></tr><tr><td>rs4773092</td><td>Additive</td><td>AA</td><td>41 (27.9)</td><td>51 (28.3)</td><td>1</td><td></td></tr><tr><td>Cys816Cys</td><td></td><td>AG</td><td>76 (51.7)</td><td>95 (52.8)</td><td></td><td></td></tr><tr><td><i>IRS2</i></td><td></td><td>GG</td><td>30 (20.4)</td><td>34 (18.9)</td><td>0.96 (0.70&#8211;1.32)</td><td>0.8</td></tr><tr><td></td><td>Dominant</td><td>AA</td><td>41 (27.9)</td><td>51 (28.3)</td><td>1</td><td></td></tr><tr><td></td><td></td><td>AG/GG</td><td>106 (72.1)</td><td>129 (71.7)</td><td>0.98 (0.60&#8211;1.59)</td><td>0.93</td></tr><tr><td></td><td>Recessive</td><td>AA/AG</td><td>117 (79.6)</td><td>146 (81.1)</td><td>1</td><td></td></tr><tr><td></td><td></td><td>GG</td><td>30 (20.4)</td><td>34 (18.9)</td><td>0.91 (0.53&#8211;1.57)</td><td>0.73</td></tr><tr><td></td><td>Allele</td><td>A</td><td>158 (53.7)</td><td>197 (54.7)</td><td>1</td><td></td></tr><tr><td></td><td></td><td>G</td><td>136 (46.3)</td><td>163 (45.3)</td><td>0.96 (0.70&#8211;1.31)</td><td>0.8</td></tr></table>
f82d9779f51d27d3601221b3010f3324b4dbee27ee1195a63f819c8c06930344.png
complex
<table><tr><td colspan="7">Content of Hg<sup>2+</sup> added to various samples (<i>n</i> = 7)</td></tr><tr><td colspan="6">PEI-AuNP probe</td><td>DMA</td></tr><tr><td>Sample</td><td>Added amount (<i>&#956;</i>M)</td><td>Detected amount (<i>&#956;</i>M)</td><td>Coefficient of variation (%)</td><td>Recovery (%)</td><td>LOD (nM)</td><td>Detected amount (<i>&#956;</i>M)</td></tr><tr><td rowspan="2">Tap water</td><td>0.150</td><td>0.149 &#177; 1.53 &#215; 10<sup>&#8722;4</sup></td><td>0.102</td><td>99.9 &#177; 0.102</td><td rowspan="2">1.72</td><td>0.153</td></tr><tr><td>0.500</td><td>0.499 &#177; 0.0101</td><td>2.03</td><td>99.9 &#177; 2.03</td><td>0.505</td></tr><tr><td rowspan="2">Pond water</td><td>0.150</td><td>0.150 &#177; 6.92 &#215; 10<sup>&#8722;4</sup></td><td>0.460</td><td>100.2 &#177; 0.461</td><td rowspan="2">1.80</td><td>0.156</td></tr><tr><td>0.500</td><td>0.500 &#177; 3.41 &#215; 10<sup>&#8722;3</sup></td><td>0.682</td><td>100.1 &#177; 0.683</td><td>0.504</td></tr><tr><td rowspan="2">Tuna fish</td><td>0.150</td><td>0.149 &#177; 7.09 &#215; 10<sup>&#8722;4</sup></td><td>0.473</td><td>99.8 &#177; 0.473</td><td rowspan="2">2.00</td><td>0.152</td></tr><tr><td>0.500</td><td>0.503 &#177; 0.0155</td><td>3.08</td><td>100.6 &#177; 3.10</td><td>0.504</td></tr><tr><td rowspan="2">Bovine serum</td><td>0.150</td><td>0.150 &#177; 6.43 &#215; 10<sup>&#8722;4</sup></td><td>0.427</td><td>100.1 &#177; 0.428</td><td rowspan="2">1.95</td><td>0.155</td></tr><tr><td>0.500</td><td>0.503 &#177; 7.68 &#215; 10<sup>&#8722;3</sup></td><td>1.52</td><td>100.7 &#177; 1.53</td><td>0.507</td></tr></table>
a62b09f643871f53831f66ce825f5aacf9c79d8642b87c53e73297e6acdcde36.png
simple
<table><tr><td>Reasons of unwillingness or hesitation</td><td>Will not be vaccinated</td><td>Indecisive</td><td>Total</td></tr><tr><td>Possible side effects</td><td>267 (74.8)</td><td>251 (82.0)</td><td>518 (78.1)</td></tr><tr><td>Lack of comprehensive field evaluation before marketing</td><td>266 (74.5)</td><td>241 (78.8)</td><td>507 (76.5)</td></tr><tr><td>Implementation in our country before wide implementation in other countries</td><td>199 (55.9)</td><td>184 (60.1)</td><td>383 (57.9)</td></tr><tr><td>Vaccines which will be administered here are different than the vaccines in the US</td><td>153 (42.9)</td><td>137 (44.9)</td><td>290 (43.8)</td></tr><tr><td>Do not have trust in the effectiveness of the vaccine</td><td>157 (44.0)</td><td>114 (37.3)</td><td>271 (40.9)</td></tr><tr><td>Do not trust Ministry of Health's practices</td><td>147 (41.2)</td><td>104 (34.0)</td><td>251 (37.9)</td></tr><tr><td>Due to the risk of acquiring H1N1 following vaccination</td><td>71 (19.9)</td><td>66 (21.6)</td><td>137 (20.7)</td></tr><tr><td>The disease is mild</td><td>59 (16.5)</td><td>34 (11.1)</td><td>93 (14.0)</td></tr><tr><td>Contracting the disease is safer</td><td>34 (9.5)</td><td>13 (4.2)</td><td>47 (7.1)</td></tr><tr><td>Other</td><td>30 (8.4)</td><td>15 (4.9)</td><td>45 (6.8)</td></tr></table>
1d8008b17470a6f7dc0bc568951d615eff9b7b88db710caf48c228ff203dcadd.png
complex
<table><tr><td></td><td>Basal</td><td>3 H</td><td>5 H</td><td>24 H</td></tr><tr><td colspan="5">PT, %</td></tr><tr><td>Control</td><td>62.7&#177;7.3</td><td>62.7&#177;3.6</td><td>56.3&#177;3.6</td><td>62.7&#177;3.6</td></tr><tr><td>CM352</td><td>62.7&#177;5.1</td><td>62.0&#177;2.6</td><td>63.7&#177;4.0</td><td>65.1&#177;7.6</td></tr><tr><td colspan="5">aPTT, s</td></tr><tr><td>Control</td><td>19.0&#177;1.0</td><td>19.7&#177;1.5</td><td>19.0&#177;3.5</td><td>19.0&#177;2.6</td></tr><tr><td>CM352</td><td>21.0&#177;4.0</td><td>21.7&#177;4.5</td><td>21.7&#177;4.0</td><td>21.7&#177;2.5</td></tr></table>
f682adf54c63f31a7fbecdcc06ea2a27bb55e42fae36cb092c7fc0cbec60f9ce.png
simple
<table><tr><td>Ionphore of mercury(II) electrodes in FIA system</td><td>LR (M)</td><td>DL (M)</td></tr><tr><td>4,7,13,16-tetrathenoyl-1,10-dioxa-4,7,13, 16-tetraazacyclooctadecane [23]</td><td>3.16 &#215; 10<sup>&#8722;6</sup>&#8211;1 &#215; 10<sup>&#8722;3</sup></td><td>3.16 &#215; 10<sup>&#8722;6</sup></td></tr><tr><td>7,16-dithenyl-l,4,10,13-tetraoxa-7, 16-diazacyclooctadecane [28]</td><td>3.16 &#215; 10<sup>&#8722;6</sup>&#8211;1 &#215; 10<sup>&#8722;3</sup></td><td>3.16 &#215; 10<sup>&#8722;6</sup></td></tr><tr><td>[This study]</td><td>5 &#215; 10<sup>&#8722;6</sup>&#8211;1 &#215; 10<sup>&#8722;1</sup></td><td>5 &#215; 10<sup>&#8722;6</sup></td></tr></table>
36910dcbac8d74bdae9d2bc52436032aa46484cee416a5e8d6b6b7161f96b6e0.png
simple
<table><tr><td></td><td>Magnesium group(<i>n</i> = 30)</td><td>Control group(<i>n</i> = 30)</td><td><i>P</i>-value*</td></tr><tr><td>Age (y)</td><td>25 &#177; 3</td><td>26 &#177; 3</td><td>0.41</td></tr><tr><td>Height (cm)</td><td>162 &#177; 3</td><td>162 &#177; 3</td><td>0.42</td></tr><tr><td>Weight (kg)</td><td>72 &#177; 4</td><td>72 &#177; 4</td><td>0.84</td></tr><tr><td>Gestational age (week)</td><td>39 &#177; 1</td><td>39 &#177; 1</td><td>0.60</td></tr><tr><td>Duration of surgery (min)</td><td>45 &#177; 7</td><td>47 &#177; 7</td><td>0.41</td></tr></table>
a75ec148dcbf023162c6317490184175d24a207e331cd3d41d3889726c9da6dc.png
simple
<table><tr><td>Diagnostic characteristics</td><td>Two parameters</td><td>Three parameters</td><td>Four parameters</td></tr><tr><td>Sensitivity</td><td>96.5%</td><td>89.5%</td><td>63.2%</td></tr><tr><td>Specificity</td><td>66.0%</td><td>87.2%</td><td>95.7%</td></tr><tr><td>Positive predictive value</td><td>77.5%</td><td>89.5%</td><td>94.7%</td></tr><tr><td>Negative predictive value</td><td>93.9%</td><td>87.2%</td><td>68.2%</td></tr><tr><td>Diagnostic accuracy</td><td>82.7%</td><td>88.5%</td><td>77.9%</td></tr><tr><td>Youden index</td><td>62.5%</td><td>76.7%</td><td>58.9%</td></tr><tr><td>Kappa value</td><td>0.641</td><td>0.767</td><td>0.569</td></tr></table>
741a3003c5c4725d49b26f8ddba1506e60574bbfe27fa7d40a74acdf5727cbad.png
complex
<table><tr><td><i>Outcome variables</i></td><td><i>Total</i><i>%</i></td><td colspan="2"><i>Gender (%)</i></td><td></td></tr><tr><td><i>n = 775</i></td><td></td><td>Boys(n = 354)</td><td>Girls(n = 421)</td><td></td></tr><tr><td>Physical activity</td><td></td><td></td><td></td><td>***</td></tr><tr><td>&#8804; 2 hours MVPA/day (low)</td><td>49.4</td><td>37.3</td><td>59.6</td><td></td></tr><tr><td>&#8805; 2 hours MVPA/day (high)</td><td>50.6</td><td>62.7</td><td>40.4</td><td></td></tr><tr><td>Fruit and vegetable consumption</td><td></td><td></td><td></td><td>**</td></tr><tr><td>&#8804; 5 portions/day (low)</td><td>47.6</td><td>53.1</td><td>43.0</td><td></td></tr><tr><td>&#8805; 5 portions/day (high)</td><td>52.4</td><td>46.9</td><td>57.0</td><td></td></tr><tr><td>Groups</td><td></td><td></td><td></td><td></td></tr><tr><td>High PA/High FV</td><td>25.8</td><td>28.2</td><td>23.8</td><td></td></tr><tr><td>High PA/Low FV</td><td>24.8</td><td>34.5</td><td>16.6</td><td>***</td></tr><tr><td>Low PA/High FV</td><td>26.6</td><td>18.6</td><td>33.3</td><td>***</td></tr><tr><td>Low PA/Low FV</td><td>22.8</td><td>18.6</td><td>26.4</td><td>***</td></tr></table>
bb2042306ade498a4847a192d141d98df441fd4e6942bac760eaefc2da9c27cc.png
complex
<table><tr><td> </td><td colspan="3"><i>Leptin</i></td><td colspan="3"><i>Insulin</i></td></tr><tr><td> </td><td><i>Fat adj. height</i></td><td><i>Height adj. fat</i></td><td><i>Height adj. BMI</i></td><td><i>Fat adj. height</i></td><td><i>Height adj. fat</i></td><td><i>Height adj. BMI</i></td></tr><tr><td colspan="7"><i>Boys</i></td></tr><tr><td colspan="7">Visit</td></tr><tr><td> 7</td><td>0.68**</td><td>&#8722;0.20**</td><td>0.05</td><td>0.28**</td><td>&#8722;0.02</td><td>0.05</td></tr><tr><td> 8</td><td>0.61**</td><td>&#8722;0.07</td><td>0.12</td><td>0.41**</td><td>&#8722;0.10</td><td>0.07</td></tr><tr><td> 9</td><td>0.53**</td><td>&#8722;0.02</td><td>0.09</td><td>0.32**</td><td>0.12</td><td>0.21*</td></tr><tr><td> 10</td><td>0.66**</td><td>&#8722;0.04</td><td>0.12</td><td>0.41**</td><td>0.13</td><td>0.23*</td></tr><tr><td> 11</td><td>0.82**</td><td>&#8722;0.36**</td><td>&#8722;0.04</td><td>0.40**</td><td>&#8722;0.07</td><td>0.04</td></tr><tr><td> 12</td><td>0.84**</td><td>&#8722;0.29**</td><td>0.03</td><td>0.41**</td><td>0.04</td><td>0.16</td></tr><tr><td>All adj. age</td><td>0.68**</td><td>&#8722;0.12**</td><td>0.09*</td><td>0.37**</td><td>0.01</td><td>0.11**</td></tr><tr><td colspan="7"> </td></tr><tr><td colspan="7"><i>Girls</i></td></tr><tr><td colspan="7">Visit</td></tr><tr><td> 7</td><td>0.70**</td><td>&#8722;0.02</td><td>0.21*</td><td>0.47**</td><td>&#8722;0.00</td><td>0.14</td></tr><tr><td> 8</td><td>0.79**</td><td>&#8722;0.19 **</td><td>0.10</td><td>0.38**</td><td>0.15</td><td>0.25*</td></tr><tr><td> 9</td><td>0.74**</td><td>&#8722;0.27</td><td>0.08</td><td>0.38**</td><td>0.02</td><td>0.15</td></tr><tr><td> 10</td><td>0.76**</td><td>&#8722;0.06</td><td>0.20*</td><td>0.43**</td><td>0.20*</td><td>0.32**</td></tr><tr><td> 11</td><td>0.88**</td><td>&#8722;0.34**</td><td>0.04</td><td>0.55**</td><td>0.13</td><td>0.22*</td></tr><tr><td> 12</td><td>0.88**</td><td>&#8722;0.07</td><td>0.19</td><td>0.41**</td><td>0.22 *</td><td>0.28**</td></tr><tr><td>All adj. age</td><td>0.78**</td><td>&#8722;0.13**</td><td>0.12*</td><td>0.52**</td><td>0.11*</td><td>0.20**</td></tr></table>
d02e05927ed0260e7074e8c4b299379db6239be40d61c601789d4ca49d8989ba.png
complex
<table><tr><td rowspan="2">Treatment</td><td rowspan="2">Dose(p.o.)</td><td colspan="2">Time (sec) spent in</td><td colspan="2">No. of entry in</td><td colspan="2">% of total time (sec) spent in</td><td colspan="2">% of entries in</td></tr><tr><td>Openarm</td><td>Closearm</td><td>Openarm</td><td>Closearm</td><td>Openarm</td><td>Closearm</td><td>Openarm</td><td>Closearm</td></tr><tr><td>Control</td><td>0.5 ml/mice</td><td>7.6&#177;0.51</td><td>215&#177;1.52</td><td>1.2&#177;0.49</td><td>9.4&#177;0.51</td><td>3.41&#177;0.05</td><td>96.59&#177;0.14</td><td>11.32&#177;0.49</td><td>88.68&#177;0.51</td></tr><tr><td>Diazepama</td><td>1 mg/kg</td><td>6.8&#177;0.58</td><td>260&#177;1.87***</td><td>1.6&#177;0.81</td><td>12.0&#177;0.55*</td><td>2.55&#177;0.04*</td><td>97.45&#177;0.14</td><td>11.76&#177;0.81</td><td>88.24&#177;0.55</td></tr><tr><td>SSL200</td><td>200 mg/kg</td><td>2.8&#177;0.20***</td><td>209&#177;1.44</td><td>0.8&#177;0.37</td><td>15.4&#177;0.75***</td><td>1.32&#177;0.02***</td><td>98.68&#177;0.14</td><td>4.94&#177;0.37</td><td>95.06&#177;0.75</td></tr><tr><td>SSL400</td><td>400 mg/kg</td><td>16.6&#177;0.51***</td><td>237&#177;1.95***</td><td>0.8&#177;0.37</td><td>9.0&#177;0.45</td><td>6.55&#177;0.04***</td><td>93.45&#177;0.15</td><td>8.16&#177;0.37</td><td>91.84&#177;0.45</td></tr></table>
a2dbecb286a5e3cc6520eecd6faaf6745574b89c9d6406628bed2a31dd264164.png
complex
<table><tr><td>Items</td><td>Inpatients</td><td>Outpatients</td><td colspan="3">Cost per patient (&#8364;), mean (SD)</td></tr><tr><td></td><td>One-day stay</td><td>One visit</td><td>Inpatients<sup>a</sup></td><td>Outpatients<sup>b</sup></td><td><i>P</i> value</td></tr><tr><td>Staff salary<sup>c</sup></td><td>228.17<sup>d</sup></td><td>80.52</td><td>2806.49 (174.00)</td><td>262.50 (22.92)</td><td>&lt;.001</td></tr><tr><td>QDU (1) and (2) visits<sup>e</sup></td><td>na</td><td>127.24</td><td>na</td><td>414.80 (0.11)</td><td></td></tr><tr><td>Diagnostic tests<sup>f</sup></td><td>83.48</td><td>218.77</td><td>1026.80 (76.00)</td><td>713.19 (38.85)</td><td>&lt;.001</td></tr><tr><td>Therapeutic procedures<sup>g</sup></td><td>1.67</td><td>0.54</td><td>20.54 (3.53)</td><td>1.76 (0.23)</td><td>&lt;.001</td></tr><tr><td>Pharmaceuticals and consumables</td><td>9.95</td><td>0.87</td><td>122.39 (20.44)</td><td>2.84 (0.59)</td><td>&lt;.001</td></tr><tr><td>Consultations<sup>h</sup></td><td>2.47</td><td>0.32</td><td>30.38 (9.57)</td><td>1.04 (0.37)</td><td>&lt;.001</td></tr><tr><td>Adverse events</td><td>0.50</td><td>0.09</td><td>6.15 (2.37)</td><td>0.29 (0.10)</td><td>&lt;.001</td></tr><tr><td>Depreciation</td><td>2.18</td><td>3.70</td><td>26.81 (2.44)</td><td>12.06 (0.90)</td><td>&lt;.001</td></tr><tr><td>Total costs</td><td>328.42</td><td>432.05</td><td>4039.56 (513.02)</td><td>1408.48 (197.32)</td><td>&lt;.001</td></tr></table>
782dedd996409febe6c96925f423a15766df1b7449bac34b959ec23b5a5ec4b7.png
simple
<table><tr><td>Haplogroup</td><td>n</td><td>Frequency (%)</td></tr><tr><td>B4*</td><td>4</td><td>1.2</td></tr><tr><td>B4a1*</td><td>18</td><td>5.6</td></tr><tr><td>B4a1a1</td><td>16</td><td>4.9</td></tr><tr><td>B4a1a3a</td><td>5</td><td>1.5</td></tr><tr><td>B4b1</td><td>8</td><td>2.5</td></tr><tr><td>B4c1b2a2</td><td>9</td><td>2.8</td></tr><tr><td>B4c2</td><td>2</td><td>0.6</td></tr><tr><td>B5b*</td><td>4</td><td>1.2</td></tr><tr><td>B5b1c</td><td>8</td><td>2.5</td></tr><tr><td>D5b1c1</td><td>5</td><td>1.5</td></tr><tr><td>D6a</td><td>1<sup>#</sup></td><td>0.3</td></tr><tr><td>E1a1a</td><td>39</td><td>12.0</td></tr><tr><td>E1a2</td><td>5</td><td>1.5</td></tr><tr><td>E1b</td><td>7</td><td>2.2</td></tr><tr><td>E2</td><td>7</td><td>2.2</td></tr><tr><td>F1a1a</td><td>1</td><td>0.3</td></tr><tr><td>F1a2</td><td>1</td><td>0.3</td></tr><tr><td>F1a3a</td><td>16</td><td>4.9</td></tr><tr><td>F1a4a1</td><td>29</td><td>9.0</td></tr><tr><td>F3b1a</td><td>1</td><td>0.3</td></tr><tr><td>M*</td><td>2</td><td>0.6</td></tr><tr><td>M7c1</td><td>45</td><td>13.9</td></tr><tr><td>M10</td><td>1</td><td>0.3</td></tr><tr><td>M21b</td><td>1<sup>#</sup></td><td>0.3</td></tr><tr><td>M71a2</td><td>1</td><td>0.3</td></tr><tr><td>M73a</td><td>2</td><td>0.6</td></tr><tr><td>N21a</td><td>2</td><td>0.6</td></tr><tr><td>P1*</td><td>2</td><td>0.6</td></tr><tr><td>P1d</td><td>7<sup>#</sup></td><td>2.2</td></tr><tr><td>&#8220;P1e&#8221;<sup>&#167;</sup></td><td>5<sup>#</sup></td><td>1.5</td></tr><tr><td>Q1</td><td>46</td><td>14.2</td></tr><tr><td>Q3</td><td>1<sup>#</sup></td><td>0.3</td></tr><tr><td>R*</td><td>2</td><td>0.6</td></tr><tr><td>R9c1*</td><td>3</td><td>0.9</td></tr><tr><td>R9c1a</td><td>15</td><td>4.6</td></tr><tr><td>R9c1b2</td><td>1</td><td>0.3</td></tr><tr><td>R14</td><td>2</td><td>0.6</td></tr><tr><td>Total</td><td>324</td><td>100</td></tr></table>
80da3b2ab37f3ea3f6232d9824c61d7ab90e450f8deba96723bd7ea60302b7c2.png
simple
<table><tr><td>Characteristics</td><td></td><td>Sweden (%)</td><td>Italy (%)</td><td>p*</td></tr><tr><td>Number of respondents</td><td></td><td>272</td><td>149</td><td></td></tr><tr><td>Gender</td><td>Male</td><td>166 (61.0)</td><td>113 (75.8)</td><td></td></tr><tr><td></td><td>Female</td><td>106 (39.0)</td><td>36 (24.2)</td><td>.002</td></tr><tr><td></td><td>Missing data</td><td>0</td><td>0</td><td></td></tr><tr><td>Age</td><td>&lt;40 y</td><td>28 (10.3)</td><td>18 (12.2)</td><td>ns</td></tr><tr><td></td><td>40- &lt; 54 y</td><td>170 (62.7)</td><td>87 (58.8)</td><td></td></tr><tr><td></td><td>&#8805;55 y</td><td>73 (26.9)</td><td>43 (29.1)</td><td></td></tr><tr><td></td><td>Missing data</td><td>0</td><td>0</td><td></td></tr><tr><td>Living with partner</td><td>Yes</td><td>235 (88.8)</td><td>121 (81.2)</td><td>ns</td></tr><tr><td></td><td>No</td><td>37 (11.2)</td><td>28 (18.8)</td><td></td></tr><tr><td></td><td>Missing data</td><td>0</td><td>0</td><td></td></tr><tr><td>Number of children</td><td>0</td><td>39 (14.6)</td><td>40 (27.2)</td><td>.000</td></tr><tr><td></td><td>1-2</td><td>131 (49.1)</td><td>86 (58.5)</td><td></td></tr><tr><td></td><td>3 or more</td><td>97 (36.3)</td><td>21 (14.3)</td><td></td></tr><tr><td></td><td>Missing data</td><td>5</td><td>2</td><td></td></tr><tr><td>Work-related factors</td><td></td><td></td><td></td><td></td></tr><tr><td>Recent degrading experiences/harassment at work</td><td>Yes</td><td>49 (18.0)</td><td>45 (30.2)</td><td>ns</td></tr><tr><td></td><td>No</td><td>212 (77.9)</td><td>102 (68.5)</td><td></td></tr><tr><td></td><td>Missing data</td><td>11</td><td>2</td><td></td></tr><tr><td>Perpetrator, superior</td><td>Yes</td><td>27 (9.9)</td><td>38 (25.5)</td><td>.000</td></tr><tr><td></td><td>No</td><td>245 (90.1)</td><td>111 (74.5)</td><td></td></tr><tr><td></td><td>Missing data</td><td>0</td><td>0</td><td></td></tr><tr><td>Perpetrator, colleague</td><td>Yes</td><td>23 (8.5)</td><td>17 (11.4)</td><td>ns</td></tr><tr><td></td><td>No</td><td>249 (91.5)</td><td>132 (88.6)</td><td></td></tr><tr><td></td><td>Missing data</td><td>0</td><td>0</td><td></td></tr><tr><td>Hours on night call, mean (SD)</td><td></td><td>8.82 (13.1)</td><td>5.93 (4.57)</td><td>.028</td></tr><tr><td>Taken care of in the organisation, mean (SD)</td><td></td><td>2.49 (1.03)</td><td>1.60 (0.93)</td><td>.000</td></tr><tr><td>Regular meetings to discuss situations at work, mean (SD)</td><td></td><td>2.92 (0.88)</td><td>2.66 (0.90)</td><td>.005</td></tr><tr><td>Role conflict, mean (SD)</td><td></td><td>2.93 (0.88)</td><td>3.04 (0.95)</td><td>ns</td></tr><tr><td>Empowering leadership, mean (SD)</td><td></td><td>2.92 (1.13)</td><td>2.57 (1.23)</td><td>.004</td></tr><tr><td>Work/home interface and behavioural factors</td><td></td><td></td><td></td><td></td></tr><tr><td>Work demands interfere with family life, mean (SD)</td><td></td><td>3.71 (0.95)</td><td>3.77 (1.01)</td><td>ns</td></tr><tr><td>Family life interferes with work, mean (SD)</td><td></td><td>2.66 (1.13)</td><td>2.50 (1.03)</td><td>ns</td></tr><tr><td>Sickness presenteeism, mean (SD)</td><td></td><td>3.19 (1.16)</td><td>3.34 (1.09)</td><td>ns</td></tr><tr><td>Compensatory leave, mean (SD)</td><td></td><td>1.33 (0.77)</td><td>1.25 (0.68)</td><td>ns</td></tr><tr><td>Psychological distress</td><td></td><td></td><td></td><td></td></tr><tr><td>Suicidal ideation in last 12 months, number (%)</td><td>Yes</td><td>32 (11.8)</td><td>26 (17.4)</td><td>ns</td></tr><tr><td></td><td>No</td><td>235 (86.4)</td><td>120 (80.5)</td><td></td></tr><tr><td></td><td>Missing data</td><td>5</td><td>3</td><td></td></tr><tr><td>Depression, mean (SD)</td><td></td><td>2.09 (0.47)</td><td>2.01 (0.44)</td><td>ns</td></tr><tr><td>Burnout exhaustion, mean (SD)</td><td></td><td>2.57 (0.51)</td><td>2.49 (0.58)</td><td>ns</td></tr><tr><td>Burnout disengagement, mean (SD)</td><td></td><td>2.28 (0.52)</td><td>2.17 (0.57)</td><td>ns</td></tr></table>
593fdc0b25a1b98f1062f8b7c75230c4a08df6629d4944fbb0d1e0340390d8de.png
complex
<table><tr><td>Question</td><td>Domain</td><td colspan="2">Unadjusted odds ratios</td><td colspan="2">Adjusted odds ratios on age and sex</td><td colspan="2">Adjusted odds ratios on age, sex and number of years of residence in France</td></tr><tr><td> </td><td> </td><td>Value</td><td>CI</td><td>Value</td><td>CI</td><td>Value</td><td>CI</td></tr><tr><td>1*</td><td>I</td><td>1.41</td><td>1.01 1.97</td><td>1.43</td><td>1.02 2.00</td><td>1.43</td><td>1.02&#8211;2.00</td></tr><tr><td>2*</td><td>I</td><td>1.58</td><td>1.15&#8211; 2.18</td><td>1.61</td><td>1.17&#8211; 2.23</td><td>1.61</td><td>1.17&#8211;2.23</td></tr><tr><td>3</td><td>I</td><td>1.11</td><td>0.82&#8211; 1.51</td><td>1.13</td><td>0.83 &#8211; 1.54</td><td>1.13</td><td>0.83&#8211;1.54</td></tr><tr><td>4</td><td>I</td><td>1.23</td><td>0.90&#8211; 1.66</td><td>1.25</td><td>0.91&#8211; 1.71</td><td>1.26</td><td>0.92&#8211;1.72</td></tr><tr><td>5*</td><td>I</td><td>1.48</td><td>1.08&#8211; 2.02</td><td>1.49</td><td>1.09&#8211; 2.04</td><td>1.50</td><td>1.09&#8211;2.05</td></tr><tr><td>6*</td><td>I</td><td>1.45</td><td>1.03&#8211; 2.04</td><td>1.48</td><td>1.05 &#8211; 2.08</td><td>1.48</td><td>1.05 &#8211; 2.09</td></tr><tr><td>7</td><td>II</td><td>1.27</td><td>0.93&#8211; 1.74</td><td>1.28</td><td>0.93&#8211; 1.75</td><td>1.27</td><td>0.93&#8211;1.75</td></tr><tr><td>8</td><td>II</td><td>1.27</td><td>0.93&#8211; 1.73</td><td>1.28</td><td>0.93&#8211; 1.75</td><td>1.28</td><td>0.93&#8211;1.75</td></tr><tr><td>9</td><td>II</td><td>1.26</td><td>0.93&#8211; 1.71</td><td>1.28</td><td>0.94&#8211; 1.74</td><td>1.28</td><td>0.94 &#8211; 1.75</td></tr><tr><td>10*</td><td>II</td><td>1.37</td><td>1.00&#8211; 1.88</td><td>1.39</td><td>1.02 &#8211; 1.90</td><td>1.39</td><td>1.02&#8211;1.91</td></tr><tr><td>11*</td><td>II</td><td>1.46</td><td>1.06&#8211; 2.02</td><td>1.47</td><td>1.06&#8211; 2.03</td><td>1.47</td><td>1.06&#8211;2.03</td></tr><tr><td>12*</td><td>III</td><td>1.43</td><td>1.04&#8211; 1.96</td><td>1.43</td><td>1.05&#8211; 1.96</td><td>1.44</td><td>1.05&#8211; 1.97</td></tr><tr><td>13</td><td>III</td><td>1.35</td><td>0.99&#8211; 1.85</td><td>1.36</td><td>1.00&#8211; 1.86</td><td>1.37</td><td>1.01&#8211;1.88</td></tr><tr><td>14*</td><td>III</td><td>1.51</td><td>1.05&#8211; 2.17</td><td>1.52</td><td>1.06&#8211; 2.19</td><td>1.53</td><td>1.06&#8211;2.20</td></tr><tr><td>15</td><td>III</td><td>1.29</td><td>0.93&#8211; 1.79</td><td>1.30</td><td>0.93&#8211; 1.81</td><td>1.31</td><td>0.94&#8211;1.82</td></tr><tr><td>16*</td><td>IV</td><td>1.39</td><td>1.00&#8211; 1.93</td><td>1.41</td><td>1.02&#8211; 1.97</td><td>1.42</td><td>1.02&#8211;1.98</td></tr><tr><td>17</td><td>IV</td><td>1.13</td><td>0.79&#8211; 1.60</td><td>1.14</td><td>0.80 &#8211; 1.62</td><td>1.14</td><td>0.80&#8211;1.62</td></tr><tr><td>18</td><td>IV</td><td>1.30</td><td>0.91 &#8211; 1.86</td><td>1.29</td><td>0.90&#8211; 1.86</td><td>1.29</td><td>0.90&#8211;1.85</td></tr><tr><td>19</td><td>IV</td><td>1.30</td><td>0.95 &#8211; 1.77</td><td>1.33</td><td>0.98&#8211; 1.8</td><td>1.33</td><td>0.98&#8211;1.82</td></tr><tr><td>20</td><td>IV</td><td>1.1</td><td>0.80&#8211; 1.51</td><td>1.10</td><td>0.80&#8211; 1.51</td><td>1.10</td><td>0.80&#8211;1.51</td></tr><tr><td>21</td><td>IV</td><td>1.39</td><td>0.96&#8211; 2.00</td><td>1.38</td><td>0.95&#8211; 1.99</td><td>1.38</td><td>0.95&#8211;1.99</td></tr><tr><td>22*</td><td>IV</td><td>1.53</td><td>1.03&#8211; 2.26</td><td>1.59</td><td>1.07&#8211; 2.36</td><td>1.60</td><td>1.08&#8211;2.38</td></tr><tr><td>23*</td><td>IV</td><td>1.53</td><td>1.08&#8211; 2.15</td><td>1.51</td><td>1.07&#8211; 2.13</td><td>1.52</td><td>1.07&#8211;2.14</td></tr></table>
db808cd1c458e4f697d65aabfad9b45f70d14ebe8e0e27f7296f79fa04c65e32.png
complex
<table><tr><td>Study population</td><td>Survey no.</td><td>Time of survey</td><td>Survey population</td><td>No. examined (%)</td><td>No. positive for mf (%)</td><td>Mf GMI* for all examined</td><td>Mf GMI* for positives</td></tr><tr><td rowspan="7">Kirare</td><td>1</td><td>Sep-04</td><td>530</td><td>471 (88.9)</td><td>123 (26.1)</td><td>4.83</td><td>851.1</td></tr><tr><td>2</td><td>Jan-06</td><td>530</td><td>461 (87.0)</td><td>96 (20.8)</td><td>2.46</td><td>385.7</td></tr><tr><td>3</td><td>Jan-07</td><td>530</td><td>438 (82.6)</td><td>69 (15.8)</td><td>1.08</td><td>101.5</td></tr><tr><td>4</td><td>Oct-07</td><td>530</td><td>351 (66.2)</td><td>35 (10.0)</td><td>0.70</td><td>200.3</td></tr><tr><td>5</td><td>Oct-08</td><td>530</td><td>302 (57.0)</td><td>39 (12.9)</td><td>0.90</td><td>142.4</td></tr><tr><td>6</td><td>Oct-09</td><td>512</td><td>259 (53.5)</td><td>13 (5.0)</td><td>0.30</td><td>194.7</td></tr><tr><td>7</td><td>Nov-10</td><td>690</td><td>400 (58.0)<sup>#</sup></td><td>17<sup>&#167;</sup> (4.4)</td><td>0.25<sup>&#164;</sup></td><td>178.9</td></tr><tr><td> </td><td>8</td><td>Nov-11</td><td>690</td><td>393 (57.0)<sup>#</sup></td><td>11<sup>&#167;</sup> (2.7)</td><td>0.15<sup>&#164;</sup></td><td>180.8</td></tr><tr><td>Kiomoni</td><td>7</td><td>Nov-10</td><td>504</td><td>386 (76.6)<sup>#</sup></td><td>18<sup>&#167;</sup> (4.7)</td><td>0.34<sup>&#164;</sup></td><td>423.1</td></tr><tr><td> </td><td>8</td><td>Nov-11</td><td>504</td><td>312 (61.9)<sup>#</sup></td><td>7<sup>&#167;</sup> (2.2)</td><td>0.16<sup>&#164;</sup></td><td>487.3</td></tr><tr><td>Kisimatui</td><td>7</td><td>Nov-10</td><td>651</td><td>389 (59.8)<sup>#</sup></td><td>34<sup>&#167;</sup> (8.7)</td><td>0.55<sup>&#164;</sup></td><td>159.1</td></tr><tr><td> </td><td>8</td><td>Nov-11</td><td>651</td><td>367 (56.4)<sup>#</sup></td><td>24<sup>&#167;</sup> (6.5)</td><td>0.33<sup>&#164;</sup></td><td>77.2</td></tr></table>
c95b6eedb215f7c9f0c5da50f05f51551d2edbd27a065fb18077f7b5e02ae24e.png
complex
<table><tr><td></td><td></td><td colspan="2">Composite SES measure</td><td colspan="2">Adults in poverty measure</td></tr><tr><td></td><td>Individual</td><td>Group</td><td>Multilevel</td><td>Group</td><td>Multilevel</td></tr><tr><td colspan="6">Individual-level education</td></tr><tr><td> Low</td><td>1.00 (reference)</td><td></td><td>1.00 (reference)</td><td></td><td>1.00 (reference)</td></tr><tr><td> Medium</td><td>1.30 (0.82&#8211;2.07)</td><td></td><td>1.32 (0.84&#8211;2.06)</td><td></td><td>1.28 (0.83&#8211;1.98)</td></tr><tr><td> High</td><td>1.19 (0.76&#8211;1.88)</td><td></td><td>1.19 (0.74&#8211;1.94)</td><td></td><td>1.17 (0.75&#8211;1.83)</td></tr><tr><td colspan="6">Community-level SESb</td></tr><tr><td> 1 (low)</td><td></td><td>1.00 (reference)</td><td>1.00 (reference)</td><td></td><td></td></tr><tr><td> 2</td><td></td><td>1.34 (0.83&#8211;2.15)</td><td>1.34 (0.80&#8211;2.24)</td><td></td><td></td></tr><tr><td> 3</td><td></td><td>1.21 (0.78&#8211;1.88)</td><td>1.22 (0.82&#8211;1.81)</td><td></td><td></td></tr><tr><td> 4</td><td></td><td>1.14 (0.72&#8211;1.82)</td><td>1.13 (0.72&#8211;1.77)</td><td></td><td></td></tr><tr><td> 5 (high)</td><td></td><td>1.31 (0.86&#8211;2.00)</td><td>1.30 (0.86&#8211;1.96)</td><td></td><td></td></tr><tr><td colspan="6">Community-level poverty</td></tr><tr><td> High</td><td></td><td></td><td></td><td>1.00 (reference)</td><td>1.00 (reference)</td></tr><tr><td> Medium</td><td></td><td></td><td></td><td>1.16 (0.81&#8211;1.66)</td><td>1.13 (0.83&#8211;1.54)</td></tr><tr><td> Low</td><td></td><td></td><td></td><td>1.30 (0.85&#8211;1.99)</td><td>1.27 (0.85&#8211;1.92)</td></tr></table>
5e848d206a7032766e8475e807b67fcafc71b11f23759f027cd3b0f8314b3e7a.png
simple
<table><tr><td>Gene</td><td>Gene position (chromosome - bp)*</td><td>SNP location (chromosome - bp)</td><td>NCBI SNP number</td><td>Variation (5&#8217;orientation)</td><td>Position in CDS</td><td>Position in protein</td><td>Aminoacid substitution</td></tr><tr><td><i>TEKT4</i></td><td>25: 871,130..877,122</td><td>874,677</td><td>rs109315777</td><td>T/A</td><td>584</td><td>195</td><td>M/K</td></tr><tr><td><i>LOC100138021</i></td><td>X:49,737,023..49,737,868</td><td>49,737,296</td><td>rs461402021</td><td>G/C</td><td>573</td><td>191</td><td>I/M</td></tr><tr><td><i>CENPI</i></td><td>X:54,969,324..55,038,297</td><td>54,971,267</td><td>rs134782295</td><td>G/A</td><td>143</td><td>48</td><td>S/N</td></tr><tr><td><i>TAF7L**</i></td><td>X:55,127,019..55,144,665</td><td>55,133,975</td><td>rs445729496</td><td>C/T</td><td>829/535</td><td>277/179</td><td>A/T</td></tr><tr><td><i>NXF2</i></td><td>X:55,592,336..55,604,610</td><td>55,602,546</td><td>ss1026566625</td><td>T/C</td><td>661</td><td>221</td><td>N/D</td></tr><tr><td><i>CYLC1</i></td><td>X:69,903,617..69,933,552</td><td>69,914,225</td><td>rs477320469</td><td>T/A</td><td>818</td><td>273</td><td>Y/F</td></tr><tr><td><i>UXT</i></td><td>X:91,468,065..91,474,474</td><td>91,472,521</td><td>rs132821996</td><td>C/T</td><td>344</td><td>115</td><td>S/N</td></tr><tr><td><i>SPACA5</i></td><td>X:92,799,368..92,801,705</td><td>92,801,539</td><td>rs211186307</td><td>C/T</td><td>109</td><td>37</td><td>G/S</td></tr></table>
0173683f20a495c8b8bf089a244d7fa2456b3b5ecb9ec8a6a72e694cfe00d4b5.png
complex
<table><tr><td> </td><td colspan="2">Global</td><td colspan="2">Septal</td><td colspan="2">Regional</td></tr><tr><td> </td><td>MBF</td><td>PN</td><td>MBF</td><td>PN</td><td>MBF</td><td>PN</td></tr><tr><td>Reference method</td><td>1.20 &#177; 0.44</td><td>0.20 &#177; 0.08</td><td>1.23 &#177; 0.56*</td><td>0.28 &#177; 0.11*</td><td>1.22 &#177; 0.68</td><td>0.34 &#177; 0.21</td></tr><tr><td>Accelerated method</td><td>1.24 &#177; 0.25</td><td>0.08 &#177; 0.05</td><td>1.28 &#177; 0.44</td><td>0.17 &#177; 0.06</td><td>1.28 &#177; 0.46</td><td>0.21 &#177; 0.11</td></tr><tr><td>p-value</td><td>0.7297</td><td>0.0059</td><td>0.6806</td><td>0.0002</td><td>0.5353</td><td>0.0001</td></tr></table>
c908a38802912e22d2c32da26c73b99c40168e2ff1ba4d2b8b6fdef139f3cb86.png
complex
<table><tr><td>Scenario</td><td>Intervention</td><td>Baseline</td><td>2020 coverage targets</td><td>2025 coverage targets</td><td>2030 coverage targets</td></tr><tr><td>1. Sustain</td><td>All</td><td colspan="4">Maintain coverage of all interventions at 2011&#8211;2013 levels</td></tr><tr><td>2. Accelerate</td><td>Vector controlLLINIRS</td><td>Means of 2011&#8211;2013 country-specific coverage</td><td>80% with LLIN replaced every 3 years</td><td>90% with LLIN replaced every 2 years</td><td>Maintain coverage</td></tr><tr><td></td><td>Other measures</td><td colspan="4">10% additional coverage with complementary control measures for resistance management</td></tr><tr><td></td><td>SMC</td><td>0%</td><td>80%</td><td>95%</td><td>Maintain</td></tr><tr><td></td><td>IPTp</td><td>0%</td><td>80%</td><td>90%</td><td>Maintain</td></tr><tr><td></td><td>Blood tests, using RDTs or microscopy</td><td>20%</td><td colspan="2"></td><td>90%</td></tr><tr><td></td><td></td><td>10% G6PD testing</td><td colspan="2"></td><td>90%</td></tr><tr><td></td><td>Treatment of uncomplicated cases</td><td>2013 country-specific coverage</td><td>90% at public facilities, 50% in communities</td><td>.</td><td>75% community based treatment</td></tr><tr><td></td><td>Treatment of severe cases</td><td>100% hospitalised cases treated with quinine</td><td>100% hospitalised cases treated with injectable artesunate</td><td>50% severe cases with rectal artesunate in communities</td><td>75% severe cases with rectal artesunate in communities</td></tr></table>
637f39ae0a49de21507a64c2aaea192600b0440bdebbed29c74e4ae84b84f726.png
simple
<table><tr><td>Dataset</td><td># Total genes (<i>T</i>)</td><td># Instances (<i>n</i>)</td><td># Classes (<i>C</i>)</td></tr><tr><td>Colon tumor</td><td>2000</td><td>62</td><td>2</td></tr><tr><td>Central nervous system </td><td>7129</td><td>60</td><td>2</td></tr><tr><td>Leukaemia</td><td>6817</td><td>72</td><td>2</td></tr><tr><td>Breast cancer</td><td>24481</td><td>97</td><td>2</td></tr><tr><td>Ovarian cancer</td><td>15154</td><td>253</td><td>2</td></tr><tr><td>MLL</td><td>12582</td><td>72</td><td>3</td></tr><tr><td>SRBCT</td><td>2308</td><td>83</td><td>4</td></tr><tr><td>Lung cancer</td><td>12533</td><td>181</td><td>5</td></tr></table>
40390bec323b878e3877d4bf6808ec8693b4db95ae9a0c1ca8b4a640370e7dc3.png
simple
<table><tr><td> </td><td>Regression coefficient</td><td>S.E</td><td>Odds ratio</td><td>95% C.I</td><td>P value</td></tr><tr><td>Retrovirus status</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>(positive vs negative)</td><td>1.67</td><td>0.70</td><td>5.68</td><td>1.35 - 21.20</td><td>0.02</td></tr><tr><td>Gender (male vs female)</td><td>0.85</td><td>0.47</td><td>2.30</td><td>0.96 - 6.00</td><td>0.07</td></tr><tr><td>Age (years)</td><td>0.12</td><td>0.05</td><td>1.10 <sup>1</sup></td><td>1.01 - 1.25</td><td>0.02</td></tr><tr><td>Constant</td><td>&#8722;1.34</td><td>0.40</td><td> </td><td> </td><td>&lt;0.02</td></tr></table>
888803b6f4d0bbd2fb2337f8f136556a7e2bb85cc4d5792aa9d1708f8a66740d.png
complex
<table><tr><td></td><td>Number</td><td colspan="2">pAkt</td><td><i>P </i>value</td></tr><tr><td></td><td></td><td>Median</td><td>Range</td><td></td></tr><tr><td>Total</td><td>141</td><td>36.0</td><td>0&#8211;255.0</td><td></td></tr><tr><td>Ethnicity</td><td></td><td></td><td></td><td></td></tr><tr><td> African-American</td><td>72</td><td>35.7</td><td>0&#8211;174.0</td><td></td></tr><tr><td> Latina</td><td>69</td><td>36.6</td><td>0&#8211;255.0</td><td>0.992</td></tr><tr><td>Age at diagnosis</td><td></td><td></td><td></td><td></td></tr><tr><td> &lt;50 years</td><td>73</td><td>31.0</td><td>0&#8211;255.0</td><td></td></tr><tr><td> &#8805; 50 years</td><td>68</td><td>39.0</td><td>0&#8211;174.0</td><td>0.678</td></tr><tr><td>Tumor size</td><td></td><td></td><td></td><td></td></tr><tr><td> &lt;5 cm</td><td>90</td><td>32.2</td><td>0&#8211;174.0</td><td></td></tr><tr><td> &#8805; 5 cm</td><td>51</td><td>36.6</td><td>0&#8211;255.0</td><td>0.117</td></tr><tr><td>Lymph node status</td><td></td><td></td><td></td><td></td></tr><tr><td> Positive</td><td>89</td><td>45.0</td><td>0&#8211;255.0</td><td></td></tr><tr><td> Negative</td><td>52</td><td>27.5</td><td>0&#8211;135.0</td><td>0.001</td></tr><tr><td>AJCC stage</td><td></td><td></td><td></td><td></td></tr><tr><td> 0&#8211;II</td><td>88</td><td>33.3</td><td>0&#8211;174.0</td><td></td></tr><tr><td> III&#8211;IV</td><td>53</td><td>42.0</td><td>0&#8211;255.0</td><td>0.160</td></tr><tr><td>Histological grade</td><td></td><td></td><td></td><td></td></tr><tr><td> Well to moderately differentiated</td><td>44</td><td>30.0</td><td>0&#8211;174.0</td><td></td></tr><tr><td> Poorly differentiated</td><td>97</td><td>40.8</td><td>0&#8211;255.0</td><td>0.094</td></tr><tr><td>ER/PR status</td><td></td><td></td><td></td><td></td></tr><tr><td> ER/PR<sup>+</sup></td><td>81</td><td>30.0</td><td>0&#8211;255.0</td><td></td></tr><tr><td> ER/PR<sup>-</sup></td><td>60</td><td>47.3</td><td>0&#8211;170.0</td><td>0.164</td></tr><tr><td>HER2/neu status (IHC)</td><td></td><td></td><td></td><td></td></tr><tr><td> Positive</td><td>46</td><td>44.5</td><td>0&#8211;255.0</td><td></td></tr><tr><td> Negative</td><td>95</td><td>30.0</td><td>0&#8211;168.9</td><td>0.009</td></tr></table>
c7199ed308cf028217391a435426a1eaa3a5f4288b63c66b7e47a5f98694bc5b.png
simple
<table><tr><td>Plant</td><td>Tissue</td><td>InsP<sub>6</sub> (&#956;M)</td><td>Ins(1,2,4,5,6)P<sub>5</sub> (&#956;M)</td></tr><tr><td><i>Zea mays</i></td><td>leaves</td><td>101&#8211;198 (3)</td><td>nd</td></tr><tr><td><i>Oryza sativa</i></td><td>leaves</td><td>9&#8211;49 (6)</td><td>nd</td></tr><tr><td><i>Arabidopsis thaliana</i></td><td>leaves</td><td>29&#8211;89 (9)</td><td>2&#8211;22 (5)</td></tr><tr><td><i>Arabidopsis thaliana</i></td><td>seedlings</td><td>47&#8211;110 (4)</td><td>nd</td></tr><tr><td><i>Nicotiana tabacum</i></td><td>leaves</td><td>11&#8211;24 (3)</td><td>nd</td></tr><tr><td><i>Solanum lycopersicum</i></td><td>leaves</td><td>39&#8211;65 (3)</td><td>nd</td></tr><tr><td><i>Trifolium repens</i></td><td>leaves</td><td>21 (1)</td><td>6 (1)</td></tr><tr><td><i>Acer rubrum</i></td><td>leaves</td><td>35 (1)</td><td>2 (1)</td></tr><tr><td><i>Ginkgo biloba</i></td><td>leaves</td><td>61 (1)</td><td>nd</td></tr><tr><td><i>Camelina sativa</i></td><td>leaves</td><td>70 (1)</td><td>6 (1)</td></tr><tr><td><i>Glycine max</i></td><td>leaves</td><td>nd (1)</td><td>nd</td></tr><tr><td><i>Pueraria labata</i></td><td>leaves</td><td>nd (1)</td><td>nd</td></tr></table>
b13263a3400b158e5e44f54736ac39d811258cefa5b0bc3fbb8d4e6df309c34d.png
simple
<table><tr><td>Gene Symbol</td><td>Gene name</td></tr><tr><td>MBD2</td><td>Methyl-CpG binding domain protein 2</td></tr><tr><td>FMO3</td><td>Flavin containing monooxygenase 3</td></tr><tr><td>RORC</td><td>RAR-related orphan receptor C</td></tr><tr><td>SGCG</td><td>Sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein)</td></tr><tr><td>PNKD</td><td>Paroxysmal nonkinesigenic dyskinesia</td></tr><tr><td>RNASE1</td><td>Ribonuclease, RNase A family, 1 (pancreatic)</td></tr><tr><td>NKRF</td><td>NFKB repressing factor</td></tr><tr><td>PFKM</td><td>Phosphofructokinase, muscle</td></tr><tr><td>MOCS1</td><td>Molybdenum cofactor synthesis 1</td></tr><tr><td>TRA2A</td><td>Transformer 2 alpha homolog</td></tr></table>
bb0aaf026d772141d33e005f5cb31d531cb0c777c8e8717e42f65132a0a69ee8.png
complex
<table><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">Genetic effect</td><td colspan="2">Genotype-by-age effect</td><td colspan="2">Genetic + genotype-by-age effects</td></tr><tr><td>SNP<sup>a</sup></td><td>Chr<sup>b</sup></td><td>Position</td><td>Alleles</td><td>MAF</td><td>LRT1</td><td>-log(<i>p</i>)</td><td>LRT2</td><td>-log(<i>p</i>)</td><td>LRT3</td><td>-log(<i>p</i>)</td></tr><tr><td>rs17631940</td><td>17</td><td>30842243</td><td>A/G</td><td>0.49</td><td>23.99</td><td>6.01</td><td>1.02</td><td>0.50</td><td>25.00</td><td>5.43</td></tr><tr><td>rs1476112</td><td>18</td><td>170690</td><td>T/G</td><td>0.08</td><td>14.40</td><td>3.83</td><td>13.43</td><td>3.61</td><td>27.83</td><td>6.04</td></tr><tr><td>rs8102150</td><td>19</td><td>922139</td><td>G/C</td><td>0.03</td><td>7.05</td><td>2.10</td><td>23.09</td><td>5.81</td><td>30.14</td><td>6.55</td></tr></table>
b0d64d606f4e6ad13f925d01b6f2434b912cbf33c6a9a6e0baafb5e459dbd968.png
complex
<table><tr><td rowspan="2">Variable</td><td> </td><td>Normal (<i>n</i> = 2,537)</td><td> </td><td>VSD (<i>n</i> = 124)</td><td rowspan="2"><i>P </i>value</td></tr><tr><td>Mean &#177; SD</td><td>10 to 90%</td><td>Mean &#177; SD</td><td>10 to 90%</td></tr><tr><td>NBL (mm)</td><td>6.74 &#177; 0.87</td><td>5.60 to 7.90</td><td>6.40 &#177; 0.79</td><td>5.30 to 7.40</td><td>&lt;0.0001</td></tr><tr><td>BPD (mm)</td><td>54.33 &#177; 9.10</td><td>48.00 to 60.00</td><td>52.65 &#177; 4.87</td><td>47.12 to 59.70</td><td>0.041</td></tr><tr><td>HC (mm)</td><td>197.34 &#177; 15.57</td><td>177.00 to 218.00</td><td>193.94 &#177; 14.66</td><td>175.00 to 213.40</td><td>0.017</td></tr><tr><td>AC (mm)</td><td>177.08 &#177; 16.15</td><td>156.00 to 198.00</td><td>171.36 &#177; 16.12</td><td>150.82 to 194.45</td><td>&lt;0.0001</td></tr><tr><td>Femur length (mm)</td><td>37.33 &#177; 3.86</td><td>32.50 to 42.40</td><td>35.93 &#177; 3.78</td><td>30.72 to 41.10</td><td>&lt;0.0001</td></tr><tr><td>Tibia length (mm)</td><td>32.92 &#177; 3.42</td><td>28.30 to 37.30</td><td>31.90 &#177; 3.53</td><td>27.12 to 36.92</td><td>0.001</td></tr><tr><td>Fibula length (mm)</td><td>32.76 &#177; 3.33</td><td>28.35 to 37.00</td><td>31.71 &#177; 3.27</td><td>26.88 to 36.00</td><td>0.001</td></tr><tr><td>Humerus length (mm)</td><td>35.39 &#177; 3.34</td><td>31.00 to 39.70</td><td>34.40 &#177; 3.24</td><td>29.94 to 38.70</td><td>0.001</td></tr><tr><td>Radius length (mm)</td><td>30.34 &#177; 2.94</td><td>26.70 to 34.00</td><td>29.38 &#177; 2.70</td><td>25.70 to 32.46</td><td>&lt;0.0001</td></tr><tr><td>Ulna length (mm)</td><td>32.92 &#177; 3.21</td><td>28.80 to 37.00</td><td>32.07 &#177; 3.14</td><td>28.00 to 36.30</td><td>0.004</td></tr><tr><td>Estimated FBW (g)</td><td>508.75 &#177; 116.48</td><td>364.00 to 666.00</td><td>470.74 &#177; 107.31</td><td>343.60 to 608.20</td><td>&lt;0.0001</td></tr><tr><td>CTAR</td><td>0.22 &#177; 0.12</td><td>0.18 to 0.25</td><td>0.21 &#177; 0.03</td><td>0.18 to 0.25</td><td>0.753</td></tr><tr><td>CTCR</td><td>0.46 &#177; 0.06</td><td>0.42 to 0.50</td><td>0.46 &#177; 0.03</td><td>0.43 to 0.50</td><td>0.131</td></tr><tr><td>UA PI</td><td>1.16 &#177; 0.22</td><td>0.93 to 1.40</td><td>1.33 &#177; 0.34</td><td>0.99 to 1.91</td><td>&lt;0.0001</td></tr><tr><td>UA RI</td><td>0.69 &#177; 0.08</td><td>0.60 to 0.78</td><td>0.74 &#177; 0.09</td><td>0.64 to 0.86</td><td>&lt;0.0001</td></tr><tr><td>MCA PI</td><td>1.59 &#177; 0.27</td><td>1.26 to 1.90</td><td>1.48 &#177; 0.24</td><td>1.18 to 1.82</td><td>&lt;0.0001</td></tr><tr><td>MCA RI</td><td>0.81 &#177; 0.08</td><td>0.72 to 0.91</td><td>0.79 &#177; 0.65</td><td>0.71 to 0.87</td><td>0.008</td></tr><tr><td>MCA/UA PI ratio</td><td>1.41 &#177; 0.34</td><td>1.02 to 1.79</td><td>1.19 &#177; 0.38</td><td>0.66 to 1.67</td><td>&lt;0.0001</td></tr><tr><td>MCA/UA RI ratio</td><td>1.19 &#177; 0.18</td><td>0.99 to 1.40</td><td>1.09 &#177; 0.18</td><td>0.85 to 1.30</td><td>&lt;0.0001</td></tr></table>
bc5153abdc510450944f4d5ef9b7aaa9e8e501ee51d2aadb25746af095c0f303.png
simple
<table><tr><td>Variables</td><td>Cases(n=73)</td><td>Controls(n=146)</td></tr><tr><td>Having ANC visit</td><td></td><td></td></tr><tr><td> Yes</td><td>56(76.7%)</td><td>121(82.9%)</td></tr><tr><td> No</td><td>17(23.3%)</td><td>25(17.1%)</td></tr><tr><td>Gestational Age at first ANC</td><td></td><td></td></tr><tr><td> First trimester</td><td>11(24.4%)</td><td>18(17.1%)</td></tr><tr><td> Second trimester</td><td>23(51.1%)</td><td>59(56.2%)</td></tr><tr><td> Third trimester</td><td>11(24.4%)</td><td>28(26.7%)</td></tr><tr><td>TT vaccination</td><td></td><td></td></tr><tr><td> Yes</td><td>47(64.4%)</td><td>105(71.9%)</td></tr><tr><td> No</td><td>26(35.6%)</td><td>41(28.1%)</td></tr><tr><td>Dose of TT vaccination</td><td></td><td></td></tr><tr><td> Single dose</td><td>6(12.8%)</td><td>20(19.0%)</td></tr><tr><td> Two to Three doses</td><td>35(74.5%)</td><td>73(69.5%)</td></tr><tr><td> Four to Five doses</td><td>6(12.8%)</td><td>12(11.4%)</td></tr><tr><td>Postnatal visit within 7 days</td><td></td><td></td></tr><tr><td> Yes</td><td>34(46.6%)</td><td>72(49.3%)</td></tr><tr><td> No</td><td>39(53.4%)</td><td>74(50.7%)</td></tr><tr><td>Previous birth intervals</td><td></td><td></td></tr><tr><td> Less than two years</td><td>15(20.5%)</td><td>18(12.3%)</td></tr><tr><td> Two years</td><td>7(9.6%)</td><td>9(6.2%)</td></tr><tr><td> More than two years</td><td>51(69.9%)</td><td>119(81.5%)</td></tr><tr><td>Walking distance from the nearest health facility</td><td></td><td></td></tr><tr><td> &lt; 1 hour</td><td>24(32.9%)</td><td>51(34.9%)</td></tr><tr><td> 1-2 hours</td><td>42(57.5%)</td><td>91(62.3%)</td></tr><tr><td> &gt; 2 hours</td><td>7(9.6%)</td><td>4(2.7%)</td></tr><tr><td>Place of delivery</td><td></td><td></td></tr><tr><td> Home</td><td>56(76.7%)</td><td>136(93.2%)</td></tr><tr><td> Health Facility</td><td>17(23.3%)</td><td>10(6.8%)</td></tr></table>
4112c6adc673e9766fde86c55b0e5b32ee11b307dfa25a8c31e37f984c7a6b2f.png
simple
<table><tr><td>First author</td><td>Year</td><td>Country</td><td>Patient (M/F)</td><td>Age (year)</td><td>Technology</td><td>Lgr5 positive threshold</td><td>HR (95 % CI) of OS</td><td>HR (95 % CI) of DFS</td><td>Quality score</td></tr><tr><td>Liu</td><td>2014</td><td>China</td><td>363 (200/166)</td><td>59mean</td><td>IHC</td><td>NA</td><td>2.604 (1.894&#8211;3.584)</td><td>NA</td><td>7</td></tr><tr><td>He</td><td>2014</td><td>China</td><td>53 (29/24)</td><td>NA</td><td>IHC</td><td>NA</td><td>2.482 (1.52&#8211;4.283)</td><td>NA</td><td>7</td></tr><tr><td>Gao</td><td>2014</td><td>China</td><td>44 (22/20)</td><td>59median</td><td>IHC</td><td>The percentage of stained cells &#8805; 10 %</td><td>2.299 (0.922&#8211;5.714)</td><td>NA</td><td>6</td></tr><tr><td>Wu</td><td>2012</td><td>China</td><td>192 (120/72)</td><td>62median</td><td>IHC</td><td>Multiplying the intensity and the quantity score &gt; 5</td><td>2.768 (1.619&#8211;4.732)</td><td>NA</td><td>8</td></tr><tr><td>Hsu</td><td>2013</td><td>China</td><td>296 (169/127)</td><td>63.5mean</td><td>IHC</td><td>The percentage of stained cells multiplied by the intensity scores &#8805;180</td><td>NA</td><td>2.21 (1.11&#8211;4.37)</td><td>7</td></tr><tr><td>Saiqusa</td><td>2012</td><td>Japan</td><td>52 (41/11)</td><td>64.5median</td><td>IHC</td><td>The percentage of stained cells &#8805; 50 %</td><td>1.061 (0.299&#8211;3.771)</td><td>4.942 (1.39&#8211;17.577)</td><td>6</td></tr><tr><td>Ziskin</td><td>2012</td><td>America</td><td>891 (467/424)</td><td>71.4mean</td><td>ISH</td><td>Intensity score &gt;1</td><td>1.15 (0.95&#8211;1.4)</td><td>NA</td><td>7</td></tr><tr><td>Valladares-Ayerbes</td><td>2012</td><td>Spain</td><td>54 (33/21)</td><td>62.7mean</td><td>QRT-PCR</td><td>11.6</td><td>2.517 (0.924&#8211;6.858)</td><td>2.995 (1.192&#8211;7.527)</td><td>8</td></tr><tr><td>Takahashi</td><td>2011</td><td>Japan</td><td>180 (105/75)</td><td>NA</td><td>QRT-PCR</td><td>Median value</td><td>0.909 (0.535&#8211;1.543)</td><td>3.3 (1.49&#8211;7.33)</td><td>6</td></tr><tr><td>Bao</td><td>2012</td><td>China</td><td>246 (131/115)</td><td>63mean</td><td>IHC</td><td>The percentage of stained cells &#8805; 5 %</td><td>1.122 (0.866&#8211;1.448)</td><td>NA</td><td>4</td></tr><tr><td>Peng</td><td>2010</td><td>China</td><td>169 (101/68)</td><td>57mean</td><td>IHC</td><td>The percentage of stained cells &#8805; 10 %</td><td>2.16 (1.35&#8211;3.45)</td><td>NA</td><td>7</td></tr><tr><td>Takeda</td><td>2010</td><td>Japan</td><td>60 (32/28)</td><td>65.7mean</td><td>IHC</td><td>The percentage of stained cells &#8805; 5 %</td><td>NA</td><td>NA</td><td>7</td></tr></table>
33fed5e5299823482179d871a44f2a8af609df44820ffa57d8d113cee317e29f.png
simple
<table><tr><td>Probe set</td><td>Gene symbol</td><td>Locus</td><td>Description</td><td>Fold difference</td><td>q-value</td></tr><tr><td>209735_at</td><td>ABCG2</td><td>4q22</td><td>ATP-binding cassette, sub-family G (WHITE), member 2</td><td>&#8722;1.29</td><td>0.031</td></tr><tr><td>208868_s_at</td><td>GABARAPL1</td><td>12p13.2</td><td>GABA(A) receptor-associated protein like 1</td><td>&#8722;1.17</td><td>0.043</td></tr><tr><td>208813_at</td><td>GOT1</td><td>19q24.1-q25.1</td><td>glutamic-oxaloacetic transaminase 1, soluble (aspartate aminotransferase 1)</td><td>&#8722;1.17</td><td>0.043</td></tr><tr><td>212878_s_at</td><td>KLC1</td><td>14q32.3</td><td>kinesin light chain 1</td><td>&#8722;1.14</td><td>0.044</td></tr><tr><td>208002_s_at</td><td>ACOT7</td><td>1p36</td><td>acyl-CoA thioesterase 7</td><td>&#8722;1.14</td><td>0.033</td></tr><tr><td>213897_s_at</td><td>MRPL23</td><td>11p15.5</td><td>mitochondrial ribosomal protein L23</td><td>&#8722;1.10</td><td>0.043</td></tr><tr><td>211382_s_at</td><td>TACC2</td><td>10q26</td><td>transforming, acidic coiled-coil containing protein 2</td><td>&#8722;1.10</td><td>0.033</td></tr><tr><td>214365_at</td><td>TPM3</td><td>1q21.2</td><td>tropomyosin 3</td><td>&#8722;1.10</td><td>0.037</td></tr><tr><td>213738_s_at</td><td>ATP5A1</td><td>18q21</td><td>ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle</td><td>&#8722;1.10</td><td>0.031</td></tr><tr><td>221909_at</td><td>RNFT2</td><td>12q24.22</td><td>ring finger protein, transmembrane 2</td><td>&#8722;1.10</td><td>0.033</td></tr><tr><td>201322_at</td><td>ATP5B</td><td>12q13.13</td><td>ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide</td><td>&#8722;1.10</td><td>0.049</td></tr><tr><td>203272_s_at</td><td>TUSC2</td><td>3p21.3</td><td>tumor suppressor candidate 2</td><td>&#8722;1.09</td><td>0.049</td></tr><tr><td>218332_at</td><td>BEX1</td><td>Xq22.1</td><td>brain expressed, X-linked 1</td><td>&#8722;1.09</td><td>0.033</td></tr><tr><td>201077_s_at</td><td>NHP2L1</td><td>NA</td><td>NHP2 non-histone chromosome protein 2-like 1 (S. cerevisiae)</td><td>&#8722;1.09</td><td>0.041</td></tr><tr><td>201410_at</td><td>PLEKHB2</td><td>2q21.1</td><td>pleckstrin homology domain containing, family B (evectins) member 2</td><td>&#8722;1.08</td><td>0.033</td></tr><tr><td>219760_at</td><td>LIN7B</td><td>19q13.3</td><td>lin-7 homolog B (C. elegans)</td><td>&#8722;1.08</td><td>0.049</td></tr><tr><td>221315_s_at</td><td>FGF22</td><td>19p13.3</td><td>fibroblast growth factor 22</td><td>&#8722;1.08</td><td>0.042</td></tr><tr><td>221706_s_at</td><td>USE1</td><td>19p13.11</td><td>unconventional SNARE in the ER 1 homolog (S. cerevisiae)</td><td>&#8722;1.07</td><td>0.042</td></tr><tr><td>202967_at</td><td>GSTA4</td><td>6p12.1</td><td>glutathione S-transferase alpha 4</td><td>&#8722;1.07</td><td>0.049</td></tr><tr><td>207839_s_at</td><td>TMEM8B</td><td>9p13.3</td><td>transmembrane protein 8B</td><td>&#8722;1.07</td><td>0.042</td></tr><tr><td>221746_at</td><td>UBL4A</td><td>Xq28</td><td>ubiquitin-like 4A</td><td>&#8722;1.07</td><td>0.033</td></tr><tr><td>208971_at</td><td>UROD</td><td>1p34</td><td>uroporphyrinogen decarboxylase</td><td>&#8722;1.07</td><td>0.043</td></tr><tr><td>202486_at</td><td>AFG3L2</td><td>18p11</td><td>AFG3 ATPase family gene 3-like 2 (S. cerevisiae)</td><td>&#8722;1.06</td><td>0.044</td></tr></table>
6c8f20f15bdf1a48489ab8b2d4a29238b7ef36bf46958261325cec1c74be3d5f.png
complex
<table><tr><td colspan="2">Characteristics</td><td>Hospitalized</td><td>%</td><td>Non-Hospitalized</td><td>%</td></tr><tr><td> </td><td> </td><td>N=8681</td><td> </td><td>N=8681</td><td> </td></tr><tr><td colspan="2">Sex</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td>Male</td><td>3588</td><td>41.3</td><td>3588</td><td>41.3</td></tr><tr><td> </td><td>Female</td><td>5093</td><td>58.7</td><td>5093</td><td>58.7</td></tr><tr><td colspan="6">Age (years at index date)</td></tr><tr><td> </td><td>0 - &#8805; 18</td><td>574</td><td>6.6</td><td>574</td><td>6.6</td></tr><tr><td> </td><td>&gt;18 - &#8805; 45</td><td>2737</td><td>31.5</td><td>2737</td><td>31.5</td></tr><tr><td> </td><td>&gt; 45 - &#8805; 65</td><td>2246</td><td>25.9</td><td>2246</td><td>25.9</td></tr><tr><td> </td><td>&gt; 65 - &#8805; 79</td><td>2218</td><td>25.6</td><td>2218</td><td>25.6</td></tr><tr><td> </td><td>&gt; 79</td><td>906</td><td>10.4</td><td>906</td><td>10.4</td></tr><tr><td colspan="6">Number of medications</td></tr><tr><td> </td><td>0</td><td>3416</td><td>39.4</td><td>4534</td><td>52.2</td></tr><tr><td> </td><td>1</td><td>1794</td><td>20.7</td><td>2121</td><td>24.4</td></tr><tr><td> </td><td>2</td><td>985</td><td>11.3</td><td>872</td><td>10.0</td></tr><tr><td> </td><td>3</td><td>767</td><td>8.8</td><td>535</td><td>6.2</td></tr><tr><td> </td><td>4</td><td>544</td><td>6.3</td><td>302</td><td>3.5</td></tr><tr><td> </td><td>&#8805;5</td><td>1175</td><td>13.5</td><td>317</td><td>3.7</td></tr><tr><td colspan="6">CDS category</td></tr><tr><td> </td><td>CDS score 0</td><td>3671</td><td>42.3</td><td>5206</td><td>60.0</td></tr><tr><td> </td><td>CDS score 1-2</td><td>1331</td><td>15.3</td><td>1287</td><td>14.3</td></tr><tr><td> </td><td>CDS score 3-4</td><td>1731</td><td>19.9</td><td>1415</td><td>16.3</td></tr><tr><td> </td><td>CDS score &#8805;5</td><td>1948</td><td>22.4</td><td>773</td><td>8.9</td></tr><tr><td colspan="6">Duration of hospitalization</td></tr><tr><td> </td><td>1 day</td><td>417</td><td>4.8</td><td> </td><td> </td></tr><tr><td> </td><td>2-5 days</td><td>4374</td><td>50.4</td><td> </td><td> </td></tr><tr><td> </td><td>&gt; 5days</td><td>3890</td><td>44.8</td><td> </td><td> </td></tr><tr><td colspan="6">Admission type</td></tr><tr><td> </td><td>Emergency</td><td>3966</td><td>45.7</td><td> </td><td> </td></tr><tr><td> </td><td>Planned</td><td>4715</td><td>54.3</td><td> </td><td> </td></tr><tr><td colspan="6">Admission for surgery</td></tr><tr><td> </td><td>Yes</td><td>4360</td><td>50.2</td><td> </td><td> </td></tr><tr><td> </td><td>No</td><td>4321</td><td>49.8</td><td> </td><td> </td></tr></table>
a2dcad5991a0f4253c7d85e2cd8cca5443b5a6036c1728d70b0a0729f85a08ad.png
simple
<table><tr><td> </td><td>No antibody</td><td>Erbitux &#174; (anti-ErB1)</td><td>Herceptin &#174; (anti-ErB2)</td></tr><tr><td>U87Ctrl</td><td>130.1&#177;4.4</td><td>98.3&#177;8.6(*)</td><td>125.6&#177;7.9 (ns)</td></tr><tr><td>U87dn</td><td>144.3&#177;3.3</td><td>104.3&#177;3.9(*)</td><td>131.6&#177;8.8 (ns)</td></tr></table>
2f91af3f8f518a46ba2bcb0746d5d2ec3b0b726c71e783f7a7237d8adc3993ba.png
complex
<table><tr><td></td><td>(1)</td><td>(2)</td><td>(3)</td><td>(4)</td><td>(5)</td><td>(6)</td></tr><tr><td>Outcome variable:</td><td colspan="3">Distance (km) from nearest clinic</td><td colspan="3">At least 2 km from nearest clinic</td></tr><tr><td>Black African</td><td>0.735**</td><td>&#8722;0.180</td><td>&#8722;0.185</td><td>0.041</td><td>&#8722;0.108</td><td>&#8722;0.115</td></tr><tr><td></td><td>(0.310)</td><td>(0.311)</td><td>(0.323)</td><td>(0.087)</td><td>(0.072)</td><td>(0.074)</td></tr><tr><td>Coloured</td><td>&#8722;0.078</td><td>&#8722;0.613*</td><td>&#8722;0.601*</td><td>&#8722;0.206**</td><td>&#8722;0.284***</td><td>&#8722;0.292***</td></tr><tr><td></td><td>(0.360)</td><td>(0.337)</td><td>(0.356)</td><td>(0.085)</td><td>(0.072)</td><td>(0.073)</td></tr><tr><td>Primary schooling</td><td></td><td>&#8722;0.161***</td><td>&#8722;0.156***</td><td></td><td>&#8722;0.026***</td><td>&#8722;0.024***</td></tr><tr><td></td><td></td><td>(0.033)</td><td>(0.034)</td><td></td><td>(0.004)</td><td>(0.004)</td></tr><tr><td>Secondary schooling</td><td></td><td>&#8722;0.158***</td><td>&#8722;0.195***</td><td></td><td>&#8722;0.020***</td><td>&#8722;0.024***</td></tr><tr><td></td><td></td><td>(0.051)</td><td>(0.056)</td><td></td><td>(0.007)</td><td>(0.007)</td></tr><tr><td>Completed high school</td><td></td><td>&#8722;0.028</td><td>&#8722;0.071</td><td></td><td>0.029</td><td>0.021</td></tr><tr><td></td><td></td><td>(0.158)</td><td>(0.180)</td><td></td><td>(0.021)</td><td>(0.021)</td></tr><tr><td>Tertiary schooling</td><td></td><td>0.565**</td><td>0.630***</td><td></td><td>0.147*</td><td>0.171*</td></tr><tr><td></td><td></td><td>(0.219)</td><td>(0.243)</td><td></td><td>(0.078)</td><td>(0.087)</td></tr><tr><td>2nd per capita income quintile</td><td></td><td>&#8722;0.484**</td><td>&#8722;0.376*</td><td></td><td>&#8722;0.085***</td><td>&#8722;0.065**</td></tr><tr><td></td><td></td><td>(0.217)</td><td>(0.223)</td><td></td><td>(0.032)</td><td>(0.031)</td></tr><tr><td>3rd per capita income quintile</td><td></td><td>&#8722;0.582**</td><td>&#8722;0.480</td><td></td><td>&#8722;0.141***</td><td>&#8722;0.129***</td></tr><tr><td></td><td></td><td>(0.295)</td><td>(0.315)</td><td></td><td>(0.039)</td><td>(0.040)</td></tr><tr><td>4th per capita income quintile</td><td></td><td>&#8722;0.755**</td><td>&#8722;0.710**</td><td></td><td>&#8722;0.193***</td><td>&#8722;0.193***</td></tr><tr><td></td><td></td><td>(0.326)</td><td>(0.350)</td><td></td><td>(0.042)</td><td>(0.042)</td></tr><tr><td>5th per capita income quintile</td><td></td><td>&#8722;0.497</td><td>&#8722;0.499</td><td></td><td>&#8722;0.138***</td><td>&#8722;0.147***</td></tr><tr><td></td><td></td><td>(0.341)</td><td>(0.370)</td><td></td><td>(0.050)</td><td>(0.051)</td></tr><tr><td>Number of children (&lt;15) in household</td><td></td><td>0.186***</td><td>0.192***</td><td></td><td>0.030***</td><td>0.029***</td></tr><tr><td></td><td></td><td>(0.052)</td><td>(0.057)</td><td></td><td>(0.008)</td><td>(0.008)</td></tr><tr><td>Number of individuals age 15 and older in household</td><td></td><td>&#8722;0.125**</td><td>&#8722;0.121**</td><td></td><td>&#8722;0.005</td><td>&#8722;0.005</td></tr><tr><td></td><td></td><td>(0.056)</td><td>(0.054)</td><td></td><td>(0.011)</td><td>(0.010)</td></tr><tr><td>Number of pensioners in household</td><td></td><td>0.389**</td><td>0.408**</td><td></td><td>0.043</td><td>0.058**</td></tr><tr><td></td><td></td><td>(0.164)</td><td>(0.177)</td><td></td><td>(0.028)</td><td>(0.029)</td></tr><tr><td>Self-reports poor or fair health</td><td></td><td></td><td>&#8722;0.441***</td><td></td><td></td><td>&#8722;0.055***</td></tr><tr><td></td><td></td><td></td><td>(0.163)</td><td></td><td></td><td>(0.020)</td></tr><tr><td>Observations</td><td>14,968</td><td>14,843</td><td>12,400</td><td>14,968</td><td>14,843</td><td>12,400</td></tr></table>
5668b2bd6d00c5e2bd24372f31abc031edfd504f0cebcf0ddbeaf14520eb4a3b.png
complex
<table><tr><td rowspan="2">Purchase status</td><td colspan="2">Condition</td></tr><tr><td>Loss</td><td>Near-miss</td></tr><tr><td>Non-purchasers</td><td>20.18 (20.41)</td><td>34.74 (25.15)</td></tr><tr><td>Purchasers</td><td>19.43 (9.64)</td><td>61.00 (17.94)*</td></tr></table>
5d45e25b0a011765a8262021f6ab1c9ab56345c73b82a6e9daa213149f75fcee.png
complex
<table><tr><td colspan="2"></td><td>HSFD</td><td>HUFD</td><td>HDSD</td><td>HRSD</td></tr><tr><td colspan="2"></td><td>g/Kg</td><td>g/Kg</td><td>g/Kg</td><td>g/Kg</td></tr><tr><td colspan="2">Protein</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Casein</td><td>254.1</td><td>254.1</td><td>212.9</td><td>212.9</td></tr><tr><td colspan="2">Lipid</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Corn oil</td><td></td><td></td><td>11.1</td><td>11.1</td></tr><tr><td></td><td>Olive oil</td><td></td><td>364.5</td><td></td><td></td></tr><tr><td></td><td>Lard</td><td>364.5</td><td></td><td></td><td></td></tr><tr><td colspan="2">Carbohydrates</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Corn starch</td><td>305</td><td>305</td><td>675</td><td></td></tr><tr><td></td><td>Banana starch</td><td></td><td></td><td></td><td>675</td></tr><tr><td></td><td>Sucrose</td><td>33.8</td><td>33.8</td><td>67</td><td>67</td></tr><tr><td colspan="2">Vit. &amp; Min.</td><td>15</td><td>15</td><td>15</td><td>15</td></tr><tr><td colspan="2">Caloric value (Kcal/g)</td><td>5.6</td><td>5.6</td><td>3.9</td><td>3.9</td></tr></table>
6af0f70ec607a87d6f7521fc8d1de9e62f8974fc89396cdb1e6abb707a20460f.png
complex
<table><tr><td>Normal endothelial cells</td><td>Vasculogenic mimicry cells</td></tr><tr><td colspan="2">Similarities</td></tr><tr><td colspan="2">VE-cadherin positive</td></tr><tr><td colspan="2">E-selectin positive</td></tr><tr><td colspan="2">CD34 positive</td></tr><tr><td colspan="2">Differences</td></tr><tr><td>TIE-2 positive</td><td>TIE-2 negative</td></tr><tr><td>VEGFR-1, 2 positive</td><td>VEGFR-1, 2 negative</td></tr><tr><td>P-selectin positive</td><td>P-selectin negative</td></tr><tr><td>VCAM-1/CD106 positive</td><td>VCAM-1/CD106 negative</td></tr><tr><td>CD31/PECAM-1 positive</td><td>CD31/PECAM-1 negative *13 (Subpopulations PECAM-1 positive melanoma cells)</td></tr><tr><td>TIE-1 negative</td><td>TIE-1 positive</td></tr><tr><td>VEGF-C negative</td><td>VEGF-C positive</td></tr><tr><td>Neuropilin 1 negative</td><td>Neuropilin 1 positive</td></tr><tr><td>Endoglin negative</td><td>Endoglin positive</td></tr><tr><td>Tissue factor pathway inhibitor 1 (TFPI1) negative</td><td>Tissue factor pathway inhibitor 1 (TFPI1) positive</td></tr><tr><td>Laminin 5 gamma 2 chain (LAMC2) negative</td><td>Laminin 5 gamma 2 chain (LAMC2) positive</td></tr><tr><td>EphA-2 negative</td><td>EphA-2 positive</td></tr></table>
77e3b4036f3f6da45e7f562ef33f1ff74cf1a21a3f63603f6e1143653a146e3a.png
simple
<table><tr><td>Agent</td><td>Normal dose</td><td>Estimated GFR (creatinine clearance: CrCl)</td></tr><tr><td>Zidovudine</td><td>300 mg twice a day orally</td><td>100 mg thrice a day orally</td></tr><tr><td>Lamivudine</td><td>150 mg twice a day orally</td><td>30&#8211;49 mL/min = 150 mg once a day orally15&#8211;29 mL/min = 100 mg once a day orally5&#8211;14 mL/min = 50 mg once a day orally&lt;5 mL/min = 25 mg once a day orally</td></tr><tr><td>Stavudine</td><td>30 mg twice a day orally</td><td>26&#8211;50 mL/min = 15 mg twice a day orally&lt;26 mL/min = 15 mg once a day orally</td></tr><tr><td>Didanosine</td><td>&gt;60 kg: 200 mg twice a day orally &lt;60 kg, 125 mg twice a day orally</td><td>30&#8211;59 mL/min = 200 mg once a day orally10&#8211;29 mL/min = 150 mg once a day orally&lt;10 mL/min = 100 mg once a day orally30&#8211;59 mL/min = 150 mg once a day orally10&#8211;29 mL/min = 100 mg once a day orally&lt;10 mL/min = 75 mg once a day orally</td></tr><tr><td>Tenofovir</td><td>300 mg once a day orally</td><td>30&#8211;49 mL/min = 300 mg every second day10&#8211;29 mL/min = 300 mg every third day&lt;10 mL/min = 300 mg once weekly</td></tr></table>
641fa993ad75ad731c3915550288023267958aed98800a6f3a2d7110afba4ce6.png
simple
<table><tr><td>ASIC channel type</td><td>pH sensitivity (pH<sub>50</sub>) [21]</td><td>Predominant localization</td><td>Likely cellular localization</td><td>Potential function</td><td>References</td></tr><tr><td>ASIC1A</td><td>5.8&#8211;6.8</td><td>Central and peripheral nervous systems</td><td>Axons, cell bodies, dendrites</td><td>Cell death following injury, epilepsy, pain signaling, neuroinflammation, neurodegeneration, fear behavior</td><td>[21&#8211;35]</td></tr><tr><td>ASIC1B</td><td>6.1&#8211;6.2</td><td>Peripheral nervous system</td><td>Axons, cell bodies</td><td></td><td>[21, 36]</td></tr><tr><td>ASIC2A</td><td>4.5&#8211;4.9</td><td>Central and peripheral nervous systems</td><td>Axons, cell bodies, dendrites</td><td>Modulate ASIC1, ASIC2b, and ASIC3 function, autonomic circulatory control</td><td>[21, 37&#8211;40]</td></tr><tr><td>ASIC2B</td><td>Associates with other channels to have pH sensitivity</td><td>Central and peripheral nervous systems</td><td>Axons, axons terminals, cell bodies</td><td>Modulate ASIC1 function, autonomic circulatory control, acidosis-induced neuronal death</td><td>[37, 38, 41]</td></tr><tr><td>ASIC3</td><td>6.4&#8211;6.6</td><td>Peripheral and central nervous systems</td><td>Axons, axons terminals, cell bodies</td><td>Pain signaling, fear conditioning with exogenous expression, anxiety and aggression</td><td>[21, 42&#8211;50]</td></tr><tr><td>ASIC4</td><td>Not pH sensitive</td><td>Central nervous system</td><td></td><td>Fear and anxiety through ASIC1a antagonism</td><td>[51]</td></tr></table>
1393b2f5151b50bdceda7aa7cdb4d698624f35d717106ae3e2b048bf3469d6b3.png
complex
<table><tr><td> </td><td>Total female participants n(%)</td><td>Female with DNA methylation data, n(%)</td><td><i>P </i>value</td></tr><tr><td>Factors</td><td>n = 750</td><td>n = 245</td><td> </td></tr><tr><td colspan="4">Maternal history of asthma</td></tr><tr><td>Yes</td><td>80 (10.8)</td><td>30 (12.3)</td><td>0.50</td></tr><tr><td>No</td><td>662 (89.2)</td><td>213 (87.7)</td><td> </td></tr><tr><td>Missing</td><td>8</td><td>2</td><td> </td></tr><tr><td colspan="4">Maternal smoking during pregnancy</td></tr><tr><td>Yes</td><td>188 (25.3)</td><td>47 (19.3)</td><td>0.05</td></tr><tr><td>No</td><td>555 (74.7)</td><td>197 (80.7)</td><td> </td></tr><tr><td>Missing</td><td>7</td><td>1</td><td> </td></tr><tr><td colspan="4">Maternal body mass index (kg/m<sup>2</sup>)</td></tr><tr><td>Underweight (&lt;18.5)</td><td>10 (1.7)</td><td>4 (2.2)</td><td>0.82</td></tr><tr><td>Normal (18.5- &lt;25)</td><td>355 (61.5)</td><td>109 (59.2)</td><td> </td></tr><tr><td>Overweight (&#8805;25.00)</td><td>212 (36.7)</td><td>71 (38.6)</td><td> </td></tr><tr><td>Missing</td><td>173</td><td>61</td><td> </td></tr><tr><td colspan="4">Low birth weight</td></tr><tr><td>Yes</td><td>35 (4.8)</td><td>9 (3.8)</td><td>0.53</td></tr><tr><td>No</td><td>699 (95.2)</td><td>228 (96.2)</td><td> </td></tr><tr><td>Missing</td><td>16</td><td>8</td><td> </td></tr><tr><td colspan="4">Asthma at age 18 years</td></tr><tr><td>Yes</td><td>128 (19.4)</td><td>35 (14.3)</td><td>0.07</td></tr><tr><td>No</td><td>531 (80.6)</td><td>210 (85.7)</td><td> </td></tr><tr><td>Missing</td><td>91</td><td>0</td><td> </td></tr><tr><td colspan="4">Median (5%, 95% value); n</td></tr><tr><td>Breastfeeding duration (weeks)</td><td>8.0 (0, 40); 664</td><td>10.5 (0, 40); 222</td><td>0.16</td></tr><tr><td>Missing</td><td>86</td><td>20</td><td> </td></tr><tr><td>Body mass index at age 18 (kg/m<sup>2</sup>)</td><td>22.2 (18, 32); 499</td><td>22.9 (19.05, 32.93); 240</td><td>0.56</td></tr><tr><td>Missing</td><td>251</td><td>5</td><td> </td></tr></table>
9367c6298eb1c813621f411915f88b83c820717527951ea665f163fedc4e5009.png
complex
<table><tr><td>Patient No.</td><td>Age</td><td>Gender</td><td>FEV<sub>1</sub> (% pred.)</td><td>COPD</td><td colspan="2">DP (cmH<sub>2</sub>O)</td><td colspan="2">PIF (L/min)</td><td colspan="2">IV (L)</td><td colspan="2">IT (s)</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>GD</td><td>TD</td><td>GD</td><td>TD</td><td>GD</td><td>TD</td><td>GD</td><td>TD</td></tr><tr><td>1</td><td>74</td><td>Male</td><td>69</td><td>Mod.</td><td>24</td><td>31</td><td>80</td><td>34</td><td>2.2</td><td>1.9</td><td>2.5</td><td>6.3</td></tr><tr><td>2</td><td>69</td><td>Male</td><td>39</td><td>Sev.</td><td>35</td><td>58</td><td>97</td><td>47</td><td>2.1</td><td>1.6</td><td>1.9</td><td>3.0</td></tr><tr><td>3</td><td>79</td><td>Male</td><td>58</td><td>Mod.</td><td>8</td><td>14</td><td>47</td><td>23</td><td>1.3</td><td>1.5</td><td>3.0</td><td>6.1</td></tr><tr><td>4</td><td>70</td><td>Female</td><td>74</td><td>Mod.</td><td>9</td><td>15</td><td>48</td><td>24</td><td>1.7</td><td>1.4</td><td>3.2</td><td>5.0</td></tr><tr><td>5</td><td>52</td><td>Female</td><td>68</td><td>Mod.</td><td>37</td><td>44</td><td>99</td><td>41</td><td>2.0</td><td>1.8</td><td>1.7</td><td>3.8</td></tr><tr><td>6</td><td>76</td><td>Female</td><td>66</td><td>Mod.</td><td>15</td><td>34</td><td>64</td><td>36</td><td>1.0</td><td>1.3</td><td>1.3</td><td>3.1</td></tr><tr><td>7</td><td>71</td><td>Female</td><td>49</td><td>Sev.</td><td>19</td><td>61</td><td>72</td><td>48</td><td>1.8</td><td>1.5</td><td>2.0</td><td>2.3</td></tr><tr><td>Average</td><td>70</td><td></td><td>60</td><td></td><td>21</td><td>37</td><td>72</td><td>36</td><td>1.7</td><td>1.6</td><td>2.2</td><td>4.2</td></tr></table>
7f86582189207386cbc5f620172dae13cf91e9bae6c2cb4091dedc68ed62d9ed.png
simple
<table><tr><td>Component </td><td>Slices </td><td>LUTs </td><td>FFs </td><td>Freq.</td></tr><tr><td> Network stack </td><td>1788 </td><td> 1380 </td><td> 2790 </td><td>127.6 MHz </td></tr><tr><td> Adapters </td><td> 624</td><td> 643 </td><td> 981 </td><td> 186.4 MHz </td></tr><tr><td> Bus </td><td> 284 </td><td>210 </td><td>335 </td><td> 220 MHz </td></tr></table>
afc2be7935ad310696205dcac2ed8fdda4a886c73822ac5f86f941c29ee75e8f.png
simple
<table><tr><td>Gene name</td><td>Protein description</td><td>Cellular component</td><td>Biological process</td><td>Predominant normal tissue expression</td><td>Spectral counts</td><td>Position in B596 NAS fraction (sorted by spectral counts)</td></tr><tr><td>CCDC86</td><td>Cytokine-induced protein with coiled-coil domain</td><td>Nucleus</td><td>Unknown</td><td>Testis</td><td>106</td><td>22/236</td></tr><tr><td>H2AFY</td><td>Core histone macro-H2A.1</td><td>Nucleus</td><td>Chromatine Structure</td><td>Lung</td><td>42</td><td>44/236</td></tr><tr><td>MECP2</td><td>Methyl-CpG-binding protein 2</td><td>Nucleus</td><td>Chromatine Structure</td><td>Brain</td><td>16</td><td>85/236</td></tr><tr><td>NUMA1</td><td>Nuclear mitotic apparatus protein 1</td><td>Nucleus</td><td>Cell cycle</td><td>Lung</td><td>14</td><td>90/236</td></tr><tr><td>LYAR</td><td>Cell growth-regulating nucleolar protein</td><td>Nucleus</td><td>Cell cycle</td><td>Testis</td><td>10</td><td>106/236</td></tr><tr><td>STMN2</td><td>Stathmin-2</td><td>Cytoskeleton</td><td>Microtubule polymerization</td><td>Brain</td><td>1</td><td>219/236</td></tr></table>
78cda7c6eb6f93bcdef8e2cc4cd4cd16d0dc2af3a1f8fdb241d7867b2126ef19.png
simple
<table><tr><td>Sequence</td><td>Length (aa)</td><td>Position(s) in HXB2 (aa)</td><td>Positions in HIVconsv (aa)</td><td>Presence of exact match in LANL-HSD</td><td>NetMHC binding affinity (nM)</td><td>HLA allele</td><td>PEAKS score (&#8722;10logP)</td><td>Sample collection time(s) (h)</td></tr><tr><td>YKRWIILGLNK</td><td>11</td><td>Gag 262&#8211;272</td><td>58&#8211;68</td><td>No</td><td>11,608</td><td>A*03:01</td><td>15.30</td><td>1.5</td></tr><tr><td>KRWIILGLNK</td><td>10</td><td>Gag 263&#8211;272</td><td>59&#8211;68</td><td>Yes</td><td>6,379</td><td>A*03:01</td><td>16.35</td><td>2.5</td></tr><tr><td>IYKRWIILGLNK</td><td>12</td><td>Gag 261&#8211;272</td><td>57&#8211;68</td><td>No</td><td>1,472</td><td>A*03:01</td><td>15.32</td><td>3.5</td></tr><tr><td>IILGLNK</td><td>7</td><td>Gag 266&#8211;272</td><td>62&#8211;68</td><td>No</td><td>NA</td><td>A*03:01</td><td>14.82</td><td>2.5, 3.5</td></tr><tr><td>FPISPIETVPVKL</td><td>13</td><td>Pol 155&#8211;167</td><td>194&#8211;206</td><td>No</td><td>163 (WB)</td><td>B*07:02</td><td>56.52</td><td>3.5, 6</td></tr><tr><td>SPIETVPVKL</td><td>10</td><td>Pol 158&#8211;167</td><td>197&#8211;206</td><td>Yes</td><td>191 (WB)</td><td>B*07:02</td><td>41.33</td><td>2.5, 3.5, 6</td></tr><tr><td>AIFQSSMTK</td><td>9</td><td>Pol 313&#8211;321</td><td>351&#8211;360</td><td>Yes</td><td>20 (SB)</td><td>A*03:01</td><td>47.95</td><td>2.5, 3.5, 6</td></tr><tr><td>RKGGIGGYSAG</td><td>11</td><td>Pol 902&#8211;912</td><td>663&#8211;673</td><td>Yes</td><td>20,750</td><td>B*07:02</td><td>14.82</td><td>6</td></tr><tr><td>RTWKSLVK</td><td>8</td><td>Vif 19&#8211;26</td><td>412&#8211;419</td><td>No</td><td>39 (SB)</td><td>A*03:01</td><td>28.89</td><td>6</td></tr><tr><td>KIWPS-RWKPK<sup><i>a</i></sup></td><td>10</td><td>Gag/Pol</td><td>131&#8211;140</td><td>NA</td><td>71 (WB)</td><td>A*03:01</td><td>19.25</td><td>6</td></tr><tr><td>KLTP-WVPAHK<sup><i>a</i></sup></td><td>10</td><td>Env/Pol</td><td>518&#8211;527</td><td>NA</td><td>19 (SB)</td><td>A*03:01</td><td>40.52</td><td>6</td></tr></table>
4b453830e6aac92d62808d40c5f0fe60785d3ddb46616ec34f6e079c736291ee.png
simple
<table><tr><td>No. of embryos (repeat)</td><td>Cleavage (%)</td><td>Blastocyst (%)</td><td>No. of cells in blastocysts</td></tr><tr><td>1356 (6)</td><td>846 (76.3 &#177; 4.0)</td><td>367 (26.7 &#177; 3.9)</td><td>54.6 &#177; 13.6</td></tr></table>
baa84bad908220c86674711b5651f65231bf81c0d5e96f5381c71f690706f21f.png
simple
<table><tr><td></td><td></td><td>RHY+ORD+</td><td>RHY&#8722;ORD+</td><td>RHY+ORD-</td><td>RHY&#8722;ORD&#8722;</td></tr><tr><td>Region 1</td><td>GD</td><td>365 (8.38)</td><td>304 (7.19)</td><td>391 (8.69)</td><td>410 (9.41)</td></tr><tr><td></td><td>RPD</td><td>412 (9.20)</td><td>333 (7.90)</td><td>462 (10.18)</td><td>448 (10.35)</td></tr><tr><td></td><td>REG</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td></tr><tr><td>Region 2</td><td>GD</td><td>394 (8.49)</td><td>439 (10.01)</td><td>360 (8.44)</td><td>333 (7.85)</td></tr><tr><td></td><td>RPD</td><td>476 (13.31)</td><td>709 (23.13)</td><td>429 (11.68)</td><td>443 (14.86)</td></tr><tr><td></td><td>REG</td><td>0.10 (0.01)</td><td>0.24 (0.02)</td><td>0.12 (0.01)</td><td>0.21 (0.02)</td></tr><tr><td>Region 3</td><td>GD</td><td>331 (7.21)</td><td>353 (8.48)</td><td>337 (6.87)</td><td>397 (8.97)</td></tr><tr><td></td><td>RPD</td><td>400 (12.97)</td><td>527 (21.01)</td><td>412 (13.59)</td><td>627 (21.41)</td></tr><tr><td></td><td>REG</td><td>0.10 (0.01)</td><td>0.18 (0.02)</td><td>0.11 (0.01)</td><td>0.24 (0.02)</td></tr><tr><td>Region 4</td><td>GD</td><td>396 (9.43)</td><td>403 (11.07)</td><td>400 (10.32)</td><td>401 (10.57)</td></tr><tr><td></td><td>RPD</td><td>537 (20.22)</td><td>581 (22.34)</td><td>574 (20.99)</td><td>642 (24.91)</td></tr><tr><td></td><td>REG</td><td>0.11 (0.01)</td><td>0.14 (0.02)</td><td>0.17 (0.02)</td><td>0.19 (0.02)</td></tr><tr><td>Region 5</td><td>GD</td><td>548 (17.03)</td><td>531 (17.39)</td><td>537 (19.09)</td><td>517 (18.01)</td></tr><tr><td></td><td>RPD</td><td>1113 (36.11)</td><td>1056 (34.84)</td><td>1155 (36.50)</td><td>1062 (37.47)</td></tr><tr><td></td><td>REG</td><td>0.49 (0.02)</td><td>0.46 (0.02)</td><td>0.51 (0.02)</td><td>0.43 (0.02)</td></tr></table>
0653f96496c5124b6c6d6c930f30c79b33cdd9ed1840e2fe2f57875d43527ac5.png
complex
<table><tr><td></td><td></td><td></td><td colspan="3">Males</td><td colspan="3">Females</td></tr><tr><td></td><td></td><td></td><td>Adjusted Odds Ratio(95%CI): reference time, 1995</td><td></td><td><sup>&#167;</sup>MH &#967;<sup>2 </sup>for Linear trend, 1995&#8211;2003:</td><td>Adjusted Odds Ratio(95%CI): reference time, 1995</td><td></td><td><sup>&#167;</sup>MH &#967;<sup>2 </sup>for Linear trend, 1995&#8211;2003:</td></tr><tr><td></td><td></td><td></td><td>1999</td><td>2003</td><td>P value</td><td>1999</td><td>2003</td><td>P value</td></tr><tr><td>R</td><td>Education (~age)&#8225;</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>0&#8211;7 years</td><td>0.93(0.62&#8211;1.34)</td><td>0.72(0.47&#8211;1.09)</td><td>0.227</td><td>1.07(0.57&#8211;2.01)</td><td>1.03(0.62&#8211;1.72)</td><td>0.838</td></tr><tr><td>U</td><td></td><td>8&#8211;9 years</td><td>0.74(0.29&#8211;1.88)</td><td>0.84(0.28&#8211;2.46)</td><td>0.731</td><td>0.52(0.24&#8211;1.13)</td><td>0.50(0.22&#8211;1.14)</td><td>0.104</td></tr><tr><td></td><td></td><td>&#8805;10 years</td><td>0.38(0.15&#8211;0.98)</td><td>0.44(0.22&#8211;0.87)</td><td>0.223</td><td>0.33(0.17&#8211;0.65)</td><td>0.29(0.08&#8211;0.96)</td><td>0.043</td></tr><tr><td>R</td><td>Marital status</td><td>Single</td><td>1.48(0.76&#8211;2.86)</td><td>0.50(0.22&#8211;1.12)</td><td>0.188</td><td>0.74(0.23&#8211;2.4)</td><td>0.31(0.06&#8211;1.49)</td><td>0.021</td></tr><tr><td></td><td></td><td>Married</td><td>0.66(0.38&#8211;1.15)</td><td>0.63(0.42&#8211;0.96)</td><td>0.096</td><td>0.91(0.53&#8211;1.57)</td><td>0.82(0.49&#8211;1.37)</td><td>0.112</td></tr><tr><td>A</td><td>Employed</td><td>Yes</td><td>0.66(0.42&#8211;1.03</td><td>0.76(0.48&#8211;1.21</td><td>0.914</td><td>0.81(0.21&#8211;3.15)</td><td>0.73(0.22&#8211;2.42)</td><td>0.479</td></tr><tr><td></td><td></td><td>No</td><td>1.03(0.57&#8211;1.84)</td><td>0.55(0.34&#8211;0.89)</td><td>0.026</td><td>0.82(0.48&#8211;1.38)</td><td>0.78(0.47&#8211;1.31)</td><td>0.055</td></tr><tr><td></td><td>Travels</td><td>Never</td><td>0.99(0.52&#8211;1.91)</td><td>1.36(0.86&#8211;2.16)</td><td>0.180</td><td>0.93(0.54&#8211;1.60</td><td>1.09(0.70&#8211;1.71)</td><td>0.644</td></tr><tr><td>L</td><td></td><td>Sometimes</td><td>0.66(0.44&#8211;0.98)</td><td>0.43(0.27&#8211;0.70)</td><td>0.019</td><td>0.76(0.33&#8211;1.71)</td><td>0.59(0.31&#8211;1.10)</td><td>0.024</td></tr><tr><td></td><td></td><td>Often</td><td>0.76(0.21&#8211;2.75)</td><td>0.62(0.19&#8211;1.94)</td><td>0.563</td><td>0.92(0.23&#8211;3.67)</td><td>0.44(0.07&#8211;2.89)</td><td>0.051</td></tr><tr><td></td><td>Duration lived</td><td>&lt;1 year</td><td>0.25(.10&#8211;0.63)</td><td>0.63(0.22&#8211;1.81</td><td>0.733</td><td>0.57(0.33&#8211;0.99)</td><td>0.79(0.35&#8211;1.82)</td><td>0.199</td></tr><tr><td></td><td>(In current residence)</td><td>1&#8211;5 yrs</td><td>0.74(0.36&#8211;1.52)</td><td>0.57(0.26&#8211;1.28)</td><td>0.069</td><td>1.79(0.88&#8211;3.62)</td><td>1.41(0.74&#8211;2.69)</td><td>0.234</td></tr><tr><td></td><td></td><td>&#8805;6 yrs</td><td>1.24(0.76&#8211;2.03)</td><td>0.95(0.60&#8211;1.51)</td><td>0.937</td><td>0.45(0.23&#8211;0.89)</td><td>0.48(0.26&#8211;0.88)</td><td>0.011</td></tr><tr><td></td><td>Migration</td><td>Village</td><td>0.72(0.43&#8211;1.22)</td><td>0.99(0.51&#8211;1.94)</td><td>0.922</td><td>1.12(0.58&#8211;2.16)</td><td>1.04(0.55&#8211;1.97)</td><td>0.840</td></tr><tr><td></td><td>(origin 5 years)</td><td>Town</td><td>0.48(0.22&#8211;0.98)</td><td>0.30(0.13&#8211;0.72)</td><td>0.041</td><td>1.75(0.99&#8211;3.01)</td><td>1.31(0.75&#8211;2.32)</td><td>0.586</td></tr><tr><td></td><td>Given birth</td><td>Yes</td><td>--</td><td>--</td><td></td><td>0.75(0.42&#8211;1.34)</td><td>0.58(0.30&#8211;1.11)</td><td>0.019</td></tr><tr><td></td><td>(ever): age, 15&#8211;29</td><td>No</td><td>--</td><td>--</td><td></td><td>0.56(0.23&#8211;1.33)</td><td>0.27(0.07&#8211;0.99)</td><td>0.012</td></tr><tr><td>U</td><td>Education (~age)&#8225;</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>0&#8211;7 years</td><td>1.66(0.80&#8211;3.42)</td><td>1.34(0.72&#8211;2.49)</td><td>0.398</td><td>0.83(0.59&#8211;1.16)</td><td>1.11(0.71&#8211;1.76)</td><td>0.498</td></tr><tr><td>R</td><td></td><td>8&#8211;9 years</td><td>0.42(0.14&#8211;1.26)</td><td>0.52(0.26&#8211;1.06)</td><td>0.305</td><td>1.10(0.76&#8211;1.61)</td><td>0.66(0.39&#8211;1.08)</td><td>0.179</td></tr><tr><td></td><td></td><td>&#8805;10 years</td><td>1.03(0.72&#8211;1.49)</td><td>0.55(0.40&#8211;0.74)</td><td>0.001*</td><td>0.91(0.61&#8211;1.34)</td><td>0.53(0.39&#8211;0.72)</td><td>0.001*</td></tr><tr><td>B</td><td>Marital status</td><td>Single</td><td>0.95(0.62&#8211;1.46)</td><td>0.51(0.33&#8211;0.79)</td><td>0.001*</td><td>1.05(0.69&#8211;1.58)</td><td>0.49(0.35&#8211;0.69)</td><td>0.001*</td></tr><tr><td></td><td></td><td>Married</td><td>1.04(0.72&#8211;1.52)</td><td>0.71(0.47&#8211;0.98)</td><td>0.035</td><td>0.92(0.74&#8211;1.14)</td><td>0.73(0.57&#8211;0.94)</td><td>0.002</td></tr><tr><td>A</td><td>Employed</td><td>Yes</td><td>0.97(0.69&#8211;1.36)</td><td>0.64(0.44&#8211;0.95)</td><td>0.001</td><td>0.98(0.67&#8211;1.41)</td><td>0.69(0.51&#8211;0.95)</td><td>0.018</td></tr><tr><td></td><td></td><td>No</td><td>0.99(0.60&#8211;1.64)</td><td>0.52(0.37&#8211;0.74)</td><td>0.001*</td><td>0.93(0.76&#8211;1.15)</td><td>0.63(0.47&#8211;0.85)</td><td>0.001*</td></tr><tr><td>N</td><td>Travels</td><td>Never</td><td>0.81(0.57&#8211;1.16)</td><td>0.57(0.32&#8211;1.02)</td><td>0.001</td><td>0.88(0.70&#8211;1.11)</td><td>0.64(0.49&#8211;0.83)</td><td>0.003</td></tr><tr><td></td><td></td><td>Sometimes</td><td>1.14(0.86&#8211;1.49)</td><td>0.52(0.34&#8211;0.81)</td><td>0.001*</td><td>1.06(0.84&#8211;1.35)</td><td>0.71(0.52&#8211;0.97)</td><td>0.008</td></tr><tr><td></td><td></td><td>Often</td><td>1.11(0.55&#8211;2.21)</td><td>0.80(0.38&#8211;1.70)</td><td>0.189</td><td>0.77(0.23&#8211;2.59)</td><td>0.44(0.23&#8211;0.82)</td><td>0.002</td></tr><tr><td></td><td>Duration lived</td><td>&lt;1 year</td><td>1.62(0.83&#8211;3.19)</td><td>0.47(0.28&#8211;0.76)</td><td>0.052</td><td>0.83(0.54&#8211;1.27)</td><td>0.66(0.45&#8211;0.97)</td><td>0.196</td></tr><tr><td></td><td>(In current residence)</td><td>1&#8211;5 yrs</td><td>0.85(0.54&#8211;1.35)</td><td>0.71(0.47&#8211;1.09)</td><td>0.007</td><td>0.83(0.59&#8211;1.16)</td><td>0.56(0.40&#8211;0.79)</td><td>0.001*</td></tr><tr><td></td><td></td><td>&#8805;6 yrs</td><td>0.90(0.56&#8211;1.46)</td><td>0.53(0.29&#8211;0.99)</td><td>0.001*</td><td>1.31(0.95&#8211;1.81)</td><td>0.86(0.57&#8211;1.33)</td><td>0.129</td></tr><tr><td></td><td>Migration</td><td>Village</td><td>1.01(0.39&#8211;2.59)</td><td>0.39(0.09&#8211;1.54)</td><td>0.314</td><td>0.98(0.42&#8211;2.32)</td><td>0.93(0.42&#8211;2.09)</td><td>0.651</td></tr><tr><td></td><td>(origin 5 years)</td><td>Town</td><td>1.03(0.63&#8211;1.68)</td><td>0.69(0.49&#8211;0.96)</td><td>0.001</td><td>0.83(0.64&#8211;1.06)</td><td>0.58(0.45&#8211;0.74)</td><td>0.001*</td></tr><tr><td></td><td>Given birth</td><td>Yes</td><td>--</td><td>--</td><td></td><td>0.73(0.63&#8211;0.35)</td><td>0.51(0.38&#8211;0.67)</td><td>0.001*</td></tr><tr><td></td><td>(ever): age, 15&#8211;29</td><td>No</td><td>--</td><td>--</td><td></td><td>0.87(0.64&#8211;1.19)</td><td>0.52(0.35&#8211;0.75)</td><td>0.042</td></tr></table>
b3ca8bf8439908eae2c8a8ec533babdaa6893de502c8bb642a22f194acd3ede4.png
simple
<table><tr><td>Serum biochemical factors</td><td>Malignant cholestasis</td><td>Stone induced cholestasis</td><td>P value</td></tr><tr><td>AST(IU/L)</td><td>87.00&#177;23.06</td><td>167.67&#177;36.15</td><td>0.169</td></tr><tr><td>ALT(IU/L)</td><td>91.87&#177;32.23</td><td>242.00&#177;46.01</td><td>0.050</td></tr><tr><td>AlkPhos (IU/L)</td><td>1269.88&#177;335.91</td><td>852.50&#177;204.53</td><td>0.282</td></tr><tr><td>T Bili (mg/dl)</td><td>11.60&#177;2.72</td><td>5.47&#177;1.63</td><td>0.054</td></tr><tr><td>D Bili (mg/dl)</td><td>5.91&#177;1.58</td><td>2.27&#177;0.85</td><td>0.006</td></tr></table>
1462213a2ffc64d56c60f41005c89f54a4bf9f5e852fcf06e0650d3e63afd851.png
simple
<table><tr><td>Cycle Rate(Hz)</td><td>AveragePhase 0%Displacement(mm)</td><td>SD ofPhase 0%Displacement(mm)</td><td>AveragePhase 50%Displacement(mm)</td><td>SD ofPhase 50%Displacement(mm)</td></tr><tr><td>0.2</td><td>20.01</td><td>0.04</td><td>&#8722;19.65</td><td>0.08</td></tr><tr><td>0.33</td><td>19.96</td><td>0.05</td><td>&#8722;19.64</td><td>0.11</td></tr><tr><td>1</td><td>20.73</td><td>.08</td><td>&#8722;18.87</td><td>0.59</td></tr></table>